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Abstract 
 
 
The impact of fluorine in medicinal chemistry is reviewed in the first chapter of 
this work and the fluorine gauche effect, which has not been fully exploited in 
medicinal chemistry, is also discussed. GABAA and GABAB receptors are then 
presented and the synthesis of neurosteroid antagonists acting at GABAA receptors is 
reported. The synthesis of such compounds was motivated to explore the mode of action 
of neurosteroids at GABA receptors.  
The observation that the C-F bond has a strong preference to align gauche to the 
C-N+ bond in protonated β-fluoroamines stimulated the enantioselective synthesis of 3-
fluoro-GABA enantiomers. This was achieved from L- and D- phenylalanine in six steps 
and in an overall yield of 31%. The preferred conformations of 3-fluoro-GABA in 
solution are then explored by NMR analysis and ab initio calculations. The biological 
evaluation of 3-fluoro-GABA enantiomers on GABA aminotransferase was then 
investigated and showed that the (R)-enantiomer undergoes HF elimination ten times 
more rapidly than the (S)-enantiomer, suggesting a preferred binding conformation of 
GABA on GABA aminotransferase. This study demonstrates that the C-F bond can be 
used as a chemical probe to reveal the binding conformation of a bioactive amine and 
this offers exciting prospects for future research.  
The synthesis of 3-fluoro-GABA from phenylalanine indicated that amino acids 
are practical starting materials for the preparation of β-fluoroamines. This methodology 
is applied to L-lysine to generate (2R)-fluorohexane-1,6-diamine. The formation of a 
diamine of potential interest for catalysis is also observed in this synthesis. 
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Chapter 1: Fluorine in bioactive molecules 
 
1.1 Introduction 
 
"Independent scientific evidence repeatedly showing up over the past 50 years 
reveals that fluoride allegedly shortens our life span, promotes cancer and various mental 
disturbances, accelerates osteoporosis and broken hips in old folks, and makes us stupid, 
docile, and subservient, all in one package." 
This quote from an article which has spread over the net can be found on many web 
sites, e.g. http://www.tuberose.com/Fluoride.html. Although not always based on scientific 
facts, this article reflects the public concerns about water fluorination in the USA. 
Certainly, the industrial applications of fluorine chemistry have boomed over the last 60 
years and have today a visible impact on everybody’s life, not only with fluorinated 
toothpastes, but also with TeflonTM and GoreTexTM which are made of perfluorinated 
polymers. Fluorine chemistry now plays an important role in a wide range of advanced 
technologies extending from medicinal chemistry to liquid crystals. A quick search on 
Scifinder shows that hits on “fluorine” have steadily increased over the last 35 years, as 
illustrated in Graph 1.1.  
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Graph 1.1: Evolution of the number of hits on “bromine” and “fluorine” between 1970 and 2005 
on SciFinder. 
 
 
Fluorine was first isolated in 1886 by French chemist Henri Moissan, a discovery 
for which he received the Nobel Prize just a century ago, in 1906. In the first part of the 
20th century, fluorine had a significant impact on material science with the discovery of 
chlorofluorocarbons (CFCs) as refrigerants and the discovery of fluoropolymers. 
The first application of fluorinated compounds in biology occurred in the early 
1950s with the introduction of fluorinated anaesthetics as alternatives for diethyl ether. 
Halothane (1) has long been used as an anaesthetic because of its low blood-gas partition 
coefficient which shortens the recovery time of patients. In the 1990s, sevoflurane (2) and 
desflurane (3) have been found to have lower levels of metabolism and lower blood-gas 
partition coefficient. They are currently used in anaesthesia.1  
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It was with the synthesis of 9α-fluorohydrocortisone acetate (4) reported by Fried2 
in 1954 that the potential of fluorine to enhance the pharmacological properties of 
bioactive molecules was first demonstrated. This work has initiated the development of 
fluorine first in corticosteroid chemistry but then more widely in the pharmaceutical 
industry and it is estimated at present that about 20-25% of drugs contain at least one 
fluorine atom.3 This is remarkable as fluorine was present in only 5% of pharmaceutical 
compounds in 1970. 
 
 
 
 
 
The physicochemical properties of the fluorine atom are presented first in Chapter 1 
and the particular reactivity of fluorinated compounds is discussed. The different strategies 
in which fluorinated compounds are employed in medicinal chemistry are then reviewed. 
Finally, the ability of fluorine to influence the conformation of molecules and in particular 
of β-fluoroamines is examined. This conformational influence, often called “fluorine 
gauche effect” is well recognised but its potential in organic or medicinal chemistry has 
not been fully exploited.  
 
 
O
HO
H
O
OAc
OH
F H
4
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1.2 The significance of fluorine in bioactive molecules 
1.2.1 Physicochemical properties of fluorine 
 
Fluorine is located at the top right hand side of the periodic table and is therefore 
the most electronegative element (3.98 on the Pauling scale). This high electronegativity is 
due to the positive charge of the nucleus (+9) which strongly attracts the electrons of the 
outer shell. The two main consequences of this are that the fluorine atom has a high 
ionization potential and a low polarisability. As fluorine is much more electronegative than 
carbon (2.55 on the Pauling scale), the C-F bond presents a significant polar character 
which contributes to making the C-F bond the strongest bond that carbon can form with 
any other element. These atomic properties of fluorine account for the thermal and 
chemical stability of highly fluorinated compounds and their weak intermolecular 
interactions. 
Due to its high electronegativity, fluorine is always a strong electron withdrawing 
group by the inductive effect. However, it can donate electrons by the mesomeric effect 
and the three lone pairs on fluorine have to be considered to explain the specific stability of 
carbocations and carbanions α or β to a fluorine atom. While α fluorine stabilises a 
carbocation by the mesomeric effect, β fluorine destabilises a carbocation by the inductive 
effect (Figure 1.1).  
 
 
 
Figure 1.1: Fluorine stabilises α carbocations and destabilises β carbocations. 
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While α fluorine destabilises a carbanion due to n-pi interaction, β fluorine 
stabilises a carbanion by the inductive effect and also by negative hyperconjugation. 
(Figure 1.2) 
 
 
 
Figure 1.2: Fluorine destabilises α carbanions , but stabilises β carbanions. 
 
Fluorination induces considerable changes in the electronic distribution of a 
molecule, again a consequence of fluorine’s high electronegativity. Additional to the 
strength of the C-F bond, fluorine also strengthens C-O, C-C and other C-F bonds when α 
to fluorine. This for example accounts for the very good chemical and enzymatic stability 
of a CF3 group.  
Changes in electronic distribution imply obvious changes in reactivity. For 
instance, when fluorine is α, β or even γ to the site of a nucleophilic substitution, SN1 and 
SN2 reactions are generally disfavoured, because of the inductive effect of fluorine which 
strengthens the bond to be broken. Thus, fluorine chemists quickly realise that many 
reaction conditions that work with non fluorinated compounds are not immediately 
transposable to fluorinated substrates because of the specific reactivity of fluorine, leading 
often to surprises or disappointments. One example among others is the hydrolysis of a 
tosylate α to a CF3 group which occurs on the O-S bond and not as expected on the C-O 
bond4 (Figure 1.3). 
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Figure 1.3: Fluorine effect on the hydrolysis of tosylate with CF3 group in the α position 
 
The presence of a fluorine atom in a molecule also affects the properties of nearby 
functional groups. Because of its electron withdrawing effect, fluorine causes carboxylic 
acids, amines and alcohols to be more acidic, an effect which can be dramatic and change 
the nature, the solubility and the reactivity of a molecule. Table 1.1 and Table 1.2 show the 
effect of fluorination (mono, di and tri-fluorination) on the pKa of acetic acid and on 
protonated ethylamine. This effect will be discussed in more detail later but it demonstrates 
here that the pKa of bioactive molecules can be modulated by the introduction of fluorine.  
 
 
Compound CH3CO2H FCH2CO2H F2CHCO2H F3CCO2H 
pKa 4.76 2.59 1.24 0.23 
 
Table 1.1: pKa of acetic acid and its α-fluorinated analogues in water at 25 °C.5 
 
 
Compound CH3CH2NH2 FCH2CH2NH2 F2CHCH2NH2 F3CCH2NH2 
pKa 10.7 8.97 7.52 5.7 
 
Table 1.2: pKa of ethylamine and its β-fluorinated analogues in water.6 
R CF3
O
SO2 Tol
R CF3
OH
H2SO4
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Fluorine can be used by medicinal chemists as a tool to tune the pKa of amines or 
acids in order to improve for example the solubility, the oral absorption or the 
bioavailability of a drug. Numerous examples exist in the literature where the introduction 
of a single fluorine atom has been beneficial on the in vivo activity of a bioactive molecule 
because the pKa has changed.7-9 Modulation of pKa can also affect the binding of a drug to 
its target macromolecule, in a positive or negative way. 
 
A key property of fluorine in medicinal chemistry is its small size. With a van der 
Waals radius of 1.47 Å, fluorine is the smallest substituent (other than hydrogen’s 
isotopes) that can be used to replace a hydrogen atom (van der Waals radius 1.20 Å). 
Therefore, the substitution of a hydrogen atom for fluorine doesn’t induce much steric or 
geometrical perturbation and it is well established that enzymes will generally bind the 
fluorinated analogue of a natural substrate. Thus, fluorine is a good hydrogen mimic and 
has been widely used in medicinal chemistry in this respect. Counter examples have been 
published recently where the size of a fluorine atom does induce geometrical changes in 
sterically hindered systems. Substitution of a hydrogen atom by a fluorine atom prevents 
for example a β-heptapeptide from folding,10 but in general such steric effects are small. 
Fluorine is actually more isosteric with an oxygen atom, whose van der Waals 
radius is 1.52 Å.11 The van der Waals volume (Vw) of a hydroxyl group has been 
calculated to be around 8.04 cm3.mol-1, but 1.05 cm3.mol-1 is subtracted from this value for 
each hydrogen bond formed (Table 1.3). The C-F bond for secondary or tertiary fluorine 
has a Vw of 6.2 cm3.mol-1 and in the case of aromatic fluorine, this value is 5.8 cm3.mol-1.11 
Moreover, the lengths of typical C-F and C-O bonds (1.39 vs 1.43 Å) and their comparable 
electronegativities (oxygen is the next most electronegative element after fluorine) suggest 
Chapter 1 
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 8 
that fluorine can be regarded also as an isosteric and isopolar replacement for the hydroxyl 
group. 
 
 
 
 
 
 
 
 
 
Table 1.3: van der Waals molar volume Vw (cm3 mol-1) for various non-fluorinated and fluorinated 
functional groups.11, 12 
 
 
The major difference between fluorine and the hydroxyl group is the ability of the 
latter to form strong hydrogen bonds which are indispensable features in biological 
processes, such as molecular recognition, binding and folding. In contrast, and despite its 
three lone pairs, fluorine is a weak hydrogen bond acceptor. This is mainly due to its low 
polarisability: the three lone pairs of electrons are tightly held by the nucleus. 
It is clear that fluorine cannot directly replace the role of the acidic hydrogen in a 
hydrogen bond, but it can indirectly act as a hydrogen bond donor by enhancing the acidity 
of a geminal proton. This property has been shown for CF2H groups where the acidic 
proton can interact with O=C groups.13 Curiously, this property has not been discussed 
much in the literature. It is the ability of fluorine to act as a hydrogen bond acceptor which 
has been the subject of debate over the last decade. 
 
A hydrogen bond is defined by a C-F····H-X contact shorter than 2.35 Å where X is 
an electronegative atom such as N or O. Dunitz writes that “organic fluorine hardly ever 
Atom or group Vw (cm3 mol-1) 
C(primary)-F 5.72 
C(secondary)-F 6.20 
OH (without hydrogen bond) 8.04 
>CF2 15.3 
>C=O 11.70 
CH3 
 
13.67 
CF3 21.3 
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 9 
accepts hydrogen bonds, that is, it does so only in the absence of a better acceptor”.14 
O’Hagan et al15 have calculated that the strength of a C(sp3)-F····H-O bond is 
2.38 kcal.mol-1, which represents less than half the strength of a C-O····H-O bond (5-10 
kcal.mol-1). The conclusion is that fluorine is only a weak hydrogen bond acceptor. 
Furthermore, analysis of the Cambridge Structural Database reveals that short contacts 
consistent with a true F····H bond are extremely rare.16 According to Diederich and Müller, 
they should rather be described as dipolar interactions.17 
However, it is now recognised that although those interactions are much weaker 
than C=O····H-X (X= N or O), they do influence molecular packing in crystals.18 In 
addition, numerous intermolecular O-H····F-C and N-H····F-C hydrogen bridges have been 
reported to stabilise the binding of fluorinated compounds to enzyme active sites.19, 20  
This leads us to a newly recognised interaction described as a C-F orthogonal 
dipole-dipole interaction21 between intrinsically polar C-F and C=O bonds. It has being 
discovered by examination of the Cambridge Structural Database that the C-F bond often 
points approximately perpendicular to the partially positively charged electrophilic carbon 
of a C=O or a C≡N bond as shown in Figure 1.4. 
 
 
 
Figure 1.4: Schematic representation of C-F interaction with carboxyl and nitrile group. 
 
 
These interactions have been found in small molecules and in protein-ligand 
complexes.17 Initial measurements of these stabilising interactions on a model system gave 
a relatively low value of about 0.19 to 0.36 kcal.mol-1 in nonpolar solvents such as 
chloroform or benzene.21 By comparison, the average stabilising effect of dipole-dipole 
OR
R
F
C
NR
F
C
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orthogonal C=O····C=O interactions have been estimated to be about 1.9 kcal.mol-1.22 
H····F bonding in crystal structures have been recently scrutinised in order to discover new 
motifs which are prone to form stabilising interactions with fluorine and which can render 
a specific binding site fluorophilic.17  
There is no doubt that further discussions will arise in the near future on the ability 
of fluorine to form noncovalent interactions with polar bonds as this is of great interest in 
medicinal chemistry for understanding the specific binding abilities of fluorinated 
substrates to macromolecules.  
The C-F bond has proved to be a good substitute for C-H or C-OH bonds. In some 
instances, other fluorinated motifs have been used or suggested to mimic other functional 
groups of natural substrates. In particular, fluoro olefins are considered good bioisosteres 
of peptide bonds. When incorporated into a peptide, the geometry, the charge distribution 
and the dipolar moment of the fluoro olefin are all close enough to those of the peptide 
bond to be recognised by enzymes.  The trans double bond maps sterically the length and 
the angle of the peptide bond and the fluorine introduces the polarity in the olefin unit in a 
direction similar to the effect of the oxygen in the peptide unit23 (Figure 1.5). This strategy 
has been used with success to make peptidase inhibitors.24 Calculations on dipole moments 
have shown that trifluoromethylalkene isosteres (8) are even better electrostatic mimic of 
the amide bond.25 
 
 
 
 
 
Figure 1.5: Comparison of the charge distribution in dipeptide and dipeptide analogues.26  
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Lipophilicity is another physical property which can be greatly affected by the 
introduction of one or more fluorine atoms into a molecule. There is no simple relationship 
between fluorination and lipophilicity, however general rules have been established. 
Fluorination always increases lipophilicity in the case of aromatic compounds. In the case 
of aliphatic molecules like alkanes, fluorination usually decreases the lipophilicity but 
increases the hydrophobicity, such that highly fluorinated or perfluoro compounds are not 
soluble in organic solvents nor in water but rather form a third phase, a fluorous phase. It is 
important here to distinguish between lipophilicity and hydrophobicity which reflect the 
same idea in the case of non fluorinated compounds but which are different with molecules 
containing several fluorine atoms. This is due to the definition of lipophilicity as the 
logarithmic coefficient of a compound’s distribution between octanol and water at a given 
pH, usually 7.4. As the solubility of fluorinated compounds usually decreases more in 
water than in octanol, it seems sometimes than fluorination increases lipophilicity but it 
just reflects the lack of affinity for both solvents.26 In any case, it is very difficult to predict 
the effect of fluorination on the lipophilicity of aliphatic compounds.  
This is illustrated by a study conducted by H.J. Böhm on a large number of pairs of 
molecules, in which one hydrogen atom was substituted by one fluorine atom. Log D was 
measured for each compound and the difference in log D for each pair was calculated. The 
results presented in Graph 1.2 indicate that fluorination has indeed various effects on 
lipophilicity. Although this study has been conducted on a structurally limited database of 
fluorinated compounds, it shows that on average, substitution of one hydrogen atom by a 
fluorine atom increases lipophilicity slightly, by roughly 0.25 log unit.8  
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Graph 1.2: Histogram of change in log D observed upon substitution of a hydrogen atom by a 
fluorine atom.8 
 
 
Lipophilicity is a key parameter in medicinal chemistry. Indeed, a good drug must 
be lipophilic enough to be able to cross numerous biological membranes, typically lipid 
bilayer membranes on the way to its target. Then on its target, usually a protein, it partially 
desolvates to bind on the specific binding site of the macromolecule. Lipophilic 
interactions are of particular importance for obtaining a good binding affinity and this 
explains why drugs often possess lipophilic groups such as aromatics or CF3. However, a 
drug must not be too lipophilic because this reduces its water solubility and its 
bioavailability. Therefore a balance is required between good lipophilicity and sufficient 
overall polarity. This can be brought about by fluorine, which can simultaneously increase 
lipophilicity and dipolar interactions, an interesting intrinsic property of fluorine which is 
called “the polar hydrophobicity of fluorinated compounds”.27  
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1.2.2 Fluorine in medicinal chemistry 
 
We have seen that the introduction of fluorine can change the electron distribution 
and therefore the biological properties of a molecule. Also, fluorine usually has beneficial 
effects on lipophilicity and on the pKa of drugs, two crucial factors for their transport and 
their bioavailability. A third important factor for the biological activity of a drug is its 
metabolism and here too fluorine can play an important role.  
Before reaching its target, the drug needs to resist acidic or basic media and 
numerous adventitious enzymes. For example, rapid oxidative metabolism of lipophilic 
compounds by liver enzymes, particularly the P450 cytochromes, often reduces the half-life 
of the drug. P450 cytochromes are oxidative enzymes containing a heme group at the active 
site and they transform a hydrophobic substrate into a more hydrophilic one by 
introduction of a hydroxyl group. P450 cytochromes require for reaction one molecule of 
oxygen, two protons and two electrons. Most aromatic oxidations involve P450 
cytochromes with radical-cation intermediates and it seems that the electronic deficiency in 
the complex C····H····O-FeIV is disfavoured by the electron withdrawing effect of a fluorine 
atom or a fluoroalkyl group. As a result, substituting a C-H by a C-F bond in a molecule 
can block or reduce its oxidative metabolism by P450 enzymes. This accounts for the 
plethora of drugs bearing a fluorinated substituent on an aromatic ring, especially in the 
para position. This is the most widely used method to prevent oxidative metabolism of 
aromatic rings. Figure 1.6 illustrates this idea.28 
Chapter 1 
_______________________________ 
 14 
 
 
 
 
 
Figure 1.6: Development of Ezetimibe (10) as a potent inhibitor of cholesterol absorption.28 
 
 
The ability of fluorine to block oxidative metabolism can also be a problem in some 
cases when it makes the drug metabolically too stable. Thus, fluorinated compound (11) 
had a half-life of 220 h which was not acceptable for a drug, but substitution of the fluorine 
by a metabolically labile methyl group shortened the half-life of compound (12) to 3.5 h. 
Celecoxib29 (12) is a cyclooxygenase 2 (COX 2) inhibitor (Figure 1.7).  
 
 
 
 
t1/2 (rat) up to 220 h    t1/2 (rat)=3.5 h 
 
Figure 1.7: Development of Celecoxib (12): effect of methyl substitution for fluorine on the half-
life of (11) and (12).29 
 
 
Also, significant levels of non-metabolised fluorinated drugs can be found in 
wastewater, representing a hazard for the environment and health. ‘The Scotsman’ 
newspaper reported on 9th August 2004 that British drinking water contains fluoxetine 
(Prozac) (13), one of the most prescribed anti-depressant drugs in the world. Fluoxetine is 
present in wastewater because of the large quantities prescribed but also because it is only 
partially metabolised in the body before being excreted.  
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Fluorine is often used to slow down the oxidative metabolism of a drug but in some 
cases, fluorine can also accelerate such metabolism.30 Therefore, the introduction of 
fluorine can not be regarded as a general method to reduce metabolism and it remains a 
trial and error process in medicinal chemistry development. 
 
Due to the specific electronic effects mentioned previously, fluorine can be used in 
many ways to design analogues of natural compounds or of natural intermediates, for the 
purpose of inhibiting enzymes or disclosing enzymatic mechanisms. An example among 
others is the stabilisation of hemiketals by the inductive effect of fluorine (Figure 1.8), 
which has been applied to design compounds that mimic the tetrahedral intermediate 
during the enzymatic cleavage of esters or peptides bonds.  
 
 
 
Figure 1.8: Stabilisation of hemiketals by fluorine. 
 
 
Scheme 1.1 shows the cleavage of a peptide bond by a serine protease and its 
inhibition by an α-difluoro-ketomethylene peptide analogue. The application of this 
strategy is extremely broad. A large number of difluoro- and enantiopure monofluoro-
ketomethylene peptides isosteres has been synthesised for this purpose.31-33 Many of these 
have been used for the study and the inhibition of different kind of proteases.26 This 
inhibition of proteases comes from the propensity of difluoro ketones to form hemiketals. 
NHMe
O
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Consequently, the intermediate (14) is stable enough to remain covalently bound in 
the active site of the enzyme as a more or less irreversible inhibitor which can still be 
displaced by the natural substrate. 
 
 
 
 
 
 
 
Scheme 1.1: Inhibition of serine protease by a difluoromethylene peptide isostere. 
 
 
Chapter 1 
_______________________________ 
 17 
 
Fluorine can play many roles in the rational design of fluorinated substrate 
inhibitors of enzymes. One of particular interest in this context, is the concept of suicide 
substrates for the inhibition of pyridoxal-5’-phosphate (PLP) dependent enzymes. PLP 
dependent enzymes form a large family which includes amino acid racemases, 
decarboxylases and amino transferases. Their biological role is crucial in the control of 
amino acid and neuroamine metabolism. Scheme 1.2 outlines the general transformation of 
amino acids into amines or α-keto acids by PLP dependent enzymes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.2: Mechanisms of PLP dependent enzymes. 
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A suicide substrate is usually a compound which by the action of an enzyme can 
generate a Michael type acceptor species. This species then reacts quickly and irreversibly 
with a nucleophile located in the active site of the enzyme. In the case of PLP dependent 
enzymes, suicide substrate inhibitors typically possess at least one fluorine atom β to the 
amino group linked to the PLP co-factor. This illustrates the biological importance of β-
fluoro amines and β-fluoro amino acids. The fluorine can be placed either on the side chain 
of the amino acid or on a CFX2 group in the α-position, depending on the enzyme 
(Scheme 1.3). The formation of the Schiff base is facilitated by the electron withdrawing 
effect of the fluorine which renders the α proton more acidic. Loss of fluoride generates 
the active Michael type acceptor which reacts readily with a nucleophilic residue on the 
enzyme.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.3: Inhibition of PLP dependent enzymes by β-fluoro amino acids. 
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Scheme 1.3 presents the general mode of action of fluorinated suicide substrates on 
PLP dependent enzymes. In some cases however, the real mechanism is more complex. 
The inhibition of PLP dependent enzymes by fluorinated amino acids will be discussed 
later on the particular case of the GABA transaminase. 
 
Given the physiological importance of those transformations, significant efforts 
have been made towards the design of fluorinated inhibitors. This has led to some 
successes in the 1980s. For example, α-difluoromethylornithine (15) was found to be a 
good irreversible inhibitor of ornithine decarboxylase34 and it is still used for the treatment 
of trypanosomiasis also called sleeping sickness. (S)-(+)-α-(Fluoromethyl)histidine (16) 
and β-fluoroalanine (17) were found to be irreversible inhibitors of histidine 
decarboxylase35 and alanine racemase36, 37 respectively. 
 
 
 
 
The inhibition of PLP enzymes stimulated an early interest in fluorinated amino 
acids. Recently, they have gained a renewed interest, and this is reflected by an increase in 
publications in this area. Most of current research on fluorinated amino acids is now 
focused on their incorporation into enzymes, fluorinated polypeptides and fluorinated β-
peptides (peptides made of α-fluoro-β-amino acids). One of the reasons for this interest is 
that fluorinated amino acids have a significant influence on the conformation, stability and 
folding of such compounds. 
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One fluorinated amino acid that has attracted recent interest is 4-fluoroproline. 
Raines et al. have discovered that its substitution for proline or 4-hydroxyproline in the 
collagen structure produces a thermally more stable helical peptide (Figure 1.9).38  
 
 
 
 
 
 
 
Figure 1.9: Thermal denaturation of collagen-related triple helices.38 
(Proline-Proline-Glycine)10    (blue):  Tm(°C)= 41 1 
(Proline-(4R)-Hydroxyproline-Glycine)10  (red) :  Tm(°C)= 69 1 
(Proline-(4R)-Fluoroproline-Glycine)10              (black):   Tm(°C)= 91 1. 
Tm(°C) is the temperature at the midpoint of the thermal transition curve. 
 
 
Collagen is the most abundant protein in animals, representing 75% of the weight 
of human skin for example. In connective tissue, collagen consists of three individual 
peptide strands folded into a right-handed triple helix. Each strand comprises about 300 
tripeptide repeats of the sequence (X-Y-Gly), where proline (Pro) and (4R)-hydroxyproline 
(Hyp) are most prevalent in the X- and Y-positions respectively. The substitution of (4R)-
hydroxyproline for (4R)-fluoroproline confers the greater thermal stability to the 
decatripeptide, with Tm rising from 69 °C to 91°C. This striking increase results from 
stereoelectronic effects.  
Molecular modeling of the triple helical (Proline-Proline-Glycine)10 strands has 
shown that the pyrrolidine ring of proline adopts preferably a Cγ-endo ring puckered 
conformation in the X-position whereas it adopts preferably a Cγ-exo ring puckered 
Chapter 1 
_______________________________ 
 21 
conformation in the Y-position. Both ring conformations are populated at room 
temperature in the case of proline, increasing the entropy of the system. But in the case of 
(4R)-fluoroproline, the Cγ-exo ring puckered conformation is greatly favoured. The 
predisposition of (4R)-fluoroproline towards this  ring conformation leads in the Y-position 
to stabilisation of the triple helix.39 This specific fluorine effect comes from the propensity 
of the C-F bond to align gauche to the C-N bond (Figure 1.10), which will be discussed in 
section 1.3. 
 
 
 
         Cγ-endo                  Cγ-exo 
Figure 1.10: Stabilisation of the Cγ-exo ring conformation in the case of (4R)-fluoroproline. 
 
 
The discovery of thermally stable collagen-related peptides is of great interest and 
opens the way to the production of new biomaterials. To date, the tripeptide unit (Pro-Flp-
Gly) offers the greatest thermal stability.40 
Other recent studies have illustrated the pivotal role that fluorine can have in 
protein engineering and in influencing peptide conformation. Recently, the St Andrews lab 
has demonstrated that the incorporation of threo- and erythro difluorosuccinic acid into 
small peptides has a strong influence on the peptide conformation.41, 42 Also, β-peptides 
have been the subject of many conformational studies since it was shown that they adopt 
secondary structures similar to their α-peptidic analogues. As they are metabolically more 
stable than α-peptides, this class of compounds has potential as drugs or non-natural 
polymers. Interesting discoveries have been made in this field, such as the observation that 
a single stereogenic C-F inversion forces a β-heptapeptide to adopt two totally different 
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secondary structures.10 However, despite interesting and often quite dramatic observations, 
the field of fluorinated β-amino acids and β-polypeptides remains largely unexplored. 
 
Fluorinated amino acids have also been incorporated into proteins with the major 
advantage that the chemical environment of the fluorinated residue and therefore the 
folding of the protein can be monitored by 19F NMR, a technique which is extremely 
sensitive to the spatial environment. 19F NMR analysis can then be used to investigate 
conformational changes in a protein which occur for example when a substrate binds. 
Moreover, no background fluorine signal is observed from natural proteins. Also, the 
introduction of fluorine into proteins can induce increased thermal stability43 or a change in 
lipophilicity, but the general consequences of the presence of fluorinated amino acids in 
proteins remain not very well understood. Nevertheless, the early observations obtained 
from incorporating fluorinated amino acids into peptides and proteins have raised their 
level of interest and have stimulated the development of new methods of syntheses for 
fluorinated amino acids. 
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1.3 The fluorine gauche effect 
1.3.1 Origin of the gauche effect 
 
Most often, the effects of fluorine on the conformation of large molecules such as 
peptides cannot be explained by its size, but rather by the stereoelectronic effects induced 
by the presence of the fluorine atom. Although these effects can be dramatic, they are often 
omitted in discussions of fluorine in medicinal or organic chemistry, perhaps because such 
stereoelectronic effects have largely been of academic interest only. People have recently 
understood how they can be applied advantageously in the design of fluorinated molecules. 
 
The most widely discussed stereoelectronic effect associated with fluorine is 
undoubtedly the so-called gauche effect which recognised that the lowest energy 
conformation for two vicinal C-F bonds has the two fluorine atoms gauche to each other 
rather than anti as one might expect intuitively for steric reasons and dipole repulsion 
between the electronegative atoms (Figure 1.11). 
The simplest and most studied system where the fluorine gauche effect is observed 
is 1,2-difluoroethane (18). In 1960, Klaboe44 showed by analysis of infrared absorption 
spectra that the gauche conformer is more stable than the anti conformer. Since this time, 
many more studies have been carried on the conformational behaviour of this system and 
NMR data,45 ab initio calculations,46-48 and X-ray diffraction49 have all concluded that the 
gauche conformer is more stable than the anti conformer by ~1 kcal.mol-1, an unusual 
observation which is not seen with 1,2-dichloroethane or 1,2-dibromoethane. 
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Figure 1.11: Newman projections of the rotamers of 1,2-difluoroethane. The gauche conformer 
(18a) is stabilised by ~1 kcal.mol-1 over the anti conformer (18b) in the gas phase.50 
 
 
This effect is not limited to 1,2-difluoroethane. Similar observations have been 
reported on erythro- and threo-2,3-difluorobutane (19) and (20): the gauche conformers 
(19a) and (19c) are more stable in organic solvents as well as in the gas phase. The energy 
required to bring the two methyl groups into close proximity is overcome by favourable 
fluorine gauche stabilisation.51 In the case of threo-2,3-difluorobutane, the fluorine gauche 
effect and steric interactions reinforce the conformation (20b) (Figure 1.12). 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Newman projections of the rotamers of erythro- and threo- 
2,3-difluorobutane (19) and (20). 
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Different explanations have been proposed to rationalise the “gauche effect”. The 
most widely accepted theory comes from the general idea that the preferred conformation 
places the best σ-donor bond or lone pair, antiperiplanar to the best σ-acceptor bond. This 
is to conform with the hyperconjugation of the electron-rich bonding σ C-H orbital to the 
electron-deficient antibonding σ* C-F orbital, which requires the C-H bond to align 
antiperiplanar to the C-F bond (Figure 1.13). C-H bonds are generally better σ-donor bonds 
than C-C bonds.52 
 
 
 
Figure 1.13: Hyperconjugation σC-H → σ*C-F. 
 
A so-called “bent-bond” theory has also been advanced by Wiberg47 to account for 
the lower energy of the gauche conformer. X-ray analyses and ab initio calculations have 
shown that the bond which is defined as the path of maximum charge density between two 
atoms does not always follow a straight line as it is conventionally represented.53 In the 
case of 1,2-difluoroethane, Wiberg explained54 that the energy difference between the 
gauche and anti conformers does not come from stabilisation of the gauche but from 
destabilisation of the anti conformer. The strong electronegativity of the fluorine atom 
induces a distortion of the C-C orbitals to give a C-C bond bent towards the fluorine 
(Figure 1.14). In the anti conformer, the C-C orbitals are bent in opposite direction, leading 
to decreased overlap and poorer bonding, whereas in the gauche conformer, orbitals are 
bent roughly in the same direction. The concept of bent orbitals has been widely proposed 
to explain the stability of small rings such as cyclopropanes. 
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Figure 1.14: Bent bond analysis: The anti conformer is destabilised due to a poor sp3 overlap. The 
gauche conformer overlaps in a better bond. 
 
 
Likewise, the C=C bond in 1,2-difluoroethene is shown by calculated charge 
density maps to be distorted in the case of the trans-1,2-difluoroethene and bent in the case 
of the cis-1,2-difluoroethene, which accounts for the better stability of the cis over the 
trans isomer (Figure 1.15).54 
 
 
 
 
 
 
 
 
Figure 1.15: Wiberg electron density maps of cis-1,2-difluoroethene (left)  and trans-1,2-
difluoroethene (right) calculated using 6-31+G* basis set.54 
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However a recent study has showed that energy difference “due to bond bending is 
too small to account for a significant portion of the ~ 1 kcal.mol-1 preferential stabilisation 
of the gauche conformer”.48 It has also been pointed that not only antiperiplanar σC-H 
→σ*C-F should be considered in the hyperconjugation theory (see figure 1.13), but also cis 
σC-H →σ*C-F  as it appears that hyperconjugation from cis σC-H accounts for around 25 % of 
the antiperiplanar σC-H hyperconjugation stabilisation (Figure 1.16).48 This is an important 
statement and it could explain why the F-C-C-F dihedral angle in X-ray structures49 of 1,2-
difluoroethane is 68° and not 60° as it should be in theory.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16: Anti σC-H →σ*C-F  and cis σC-H →σ*C-F  orbital overlaps, showing the greater overlap of 
the main lobe of the anti orbital C-H bond with the back lobe of the C-F* antibond. The orbital 
contours are shown in the C-C-F plane.48 
F
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The gauche preference is not only observed in vicinal C-F bonds systems. In fact, it 
is general for any electronegative substituents such as fluorine, oxygen or nitrogen. For 
example, one C-F bond can be substituted by a C-OH bond, since the electronegativity of 
the hydroxyl group is only slightly less than that of the fluorine atom. Thus, gauche 
preferences have also been described in β-fluoroalcohols.55 2-Fluoroethanol is the simplest 
β-fluoroalcohol and has been used as a model to study the conformational behaviour of 
vicinal C-F and C-O bonds. It appears that the molecule adopts clearly a gauche 
conformation (21a), stabilised by 2.0 kcal.mol-1 over the anti conformation (21b). 
However, this stabilisation does not originate only from through-bond stereoelectronic 
effects but rather from an intramolecular O-H····F bond. Indeed, the calculated gauche 
structure (21c) which lacks intramolecular O-H···F bond is lower in energy than its anti 
structure (21d), but only by 0.1 kcal.mol-1. In conclusion, stereoelectronic effects in β-
fluoroalcohols contribute only to a very small part in the stabilisation of the gauche 
conformation (Figure 1.17).55, 56 
 
 
 
 
 
 
 
 
Figure 1.17: Calculated minimum conformations of 2-fluoroethanol: the gauche conformer (21a) is 
stabilised by ~2 kcal.mol-1 due to intramolecular O-H···F bonding. 
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The gauche preference in 2-fluoroethanol arises almost exclusively from 
intramolecular O-H····F bonding. Therefore it was interesting to investigate the situation 
when the hydroxyl group becomes protonated. Two factors should reinforce the gauche 
preference: firstly, the positive charge on the oxygen increases the polarisation of the C-O 
bond which should result in a stronger stereoelectronic effect and a lower σ* energy. 
Secondly, the protonated oxygen is a better hydrogen bond donor.  
Calculations have shown indeed that the most stable conformation of protonated 2-
fluoroethanol (22a) is 7.2 kcal.mol-1 more stable than its anti structure (22b) and includes 
an intramolecular O-H····F bond. The calculated gauche structure (22c) which lacks 
intramolecular O-H····F bonding is still 4.4 kcal.mol-1 lower in energy than its 
corresponding anti structure (22d) (Figure 1.18). This value represents more than four 
times the stereoelectronic gauche stabilisation in 1,2-difluoroethane and suggests that 
intramolecular hydrogen bonding accounts for around 2.6 kcal.mol-1 in the stabilisation, 
which is close to the value found for the intramolecular O-H····F bonding in the non-
protonated species (~2 kcal.mol-1).  
 
 
 
 
 
 
 
 
 
Figure 1.18: Calculated conformations of protonated 2-fluoroethanol: the gauche conformer (22a) 
is stabilised by 7.2 kcal.mol-1 over the anti conformer (22b) due most probably to stereoelectronic 
effects and intramolecular O-H····F bonding. 
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In a similar manner to β-fluoroalcohols, β-fluoroamines exhibit a small gauche 
preference, although this effect is less pronounced as nitrogen is less electronegative. In the 
case of 2-fluoroethylamine, the gauche conformers are stabilised over the anti conformer 
by around 1 kcal.mol-1. It seems that this stabilisation, similar to that found in 2-
fluoroethanol, arises from intramolecular H····F bonding.56  
The situation changes dramatically when the nitrogen becomes protonated and a 
large gauche preference is then observed. The gauche conformer (23a) of 2-
fluoroethylammonium is stabilised by 5.8 kcal.mol-1 over the anti conformer (23b) as 
evaluated by density functional theory (DFT) calculations (Figure 1.19).56 This observation 
is potentially of some utility as amines are protonated at physiological pH and such an 
effect will be observed in vivo for β-fluoroamines. The large value of 5.8 kcal.mol-1 
indicates that the fluorinated amine is fully populated in the gauche conformation in 
solution. 
 
 
 
 
Figure 1.19: The gauche conformation of 2-fluoroethylammonium is stabilised by 5.8 kcal.mol-1 
over the anti conformation. 
 
 
Other systems such as 3-fluoropiperidinium (24), N-methyl-3-fluoropiperidinium 
(25) and N,N-dimethyl-3-fluoropiperidinium (26) salts have been studied by NMR, ab 
initio calculations and X-ray crystallography. Consistent with the observations described 
above, a strong preference for gauche alignments of the C-F and C-N+ bonds was observed 
when the nitrogen is positively charged (Figure 1.20).57 
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Figure 1.20: Stabilisation of the gauche (axial) F-C-C-N+ conformation over the anti (equatorial) 
conformation in 3-fluoropiperidinium systems.57 
 
 
As the anti conformers (24b), (25b) and (26b) were never detected in solution, the 
gauche conformers (24a), (25a) and (26a) were estimated to be at least 2.5 kcal.mol-1 
lower in energy. It is predicted that the stabilising effect lies around 4-5 kcal.mol-1. 
Different parameters could be evoked to explain this effect. Intramolecular C-F···H-N+ 
bonding can help stabilise the gauche conformation, but it has been shown before that 
fluorine is only a weak hydrogen bond acceptor. Similarly, through-bond stereoelectronic 
effects do not contribute to a large stabilisation as no clear gauche preference is observed 
in the neutral system. However, the presence of the positive charge in protonated systems 
may lower the C-N+ bond σ* energy and favour hyperconjugation, but this has not been 
investigated. It seems that the main explanation for the large F-C-C-N+ gauche preference 
in these systems is a charge-dipole interaction. This charge-dipole interaction is powerful 
enough to accommodate the axial orientation of fluorine and the subsequent steric 
congestion with the two methyl groups in structure (26a). 
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A large number of molecules with the F-C-C-N+ motif have been synthesised in the 
St Andrews laboratories and elsewhere. Gauche conformations are always observed, 
indicating that this effect is intrinsic to this motif. Most recently, 2-fluoroethylpyridinium 
salts have been synthesised and the putative role of hydrogen bonding is suppressed in 
these systems (27)-(29) (Figure 1.21).58 The charge-dipole interaction in the F-C-C-N+ 
gauche preference is a reasonable working hypothesis, especially as the C-F bond has a 
strong dipole. However, further studies are required to fully understand the origin of the 
gauche preference in such charged β-fluoroamines. 
 
 
 
 
Figure 1.21: Examples of molecules bearing the F-C-C-N+ motif that are enable to form an 
intramolecular N-H····F bond. 
 
 
 
1.3.2 Uses and applications of the C-F····N+-C interaction 
 
The persistence of the axial orientation for fluorine in 3-fluoropiperidinium systems 
(24)-(26) suggests that the incorporation of a C-F bond β to a protonated nitrogen can 
influence the conformation of rings in the solid state and in solution. With this idea in 
mind, 3-fluoro-1,5-diazacyclooctane HBr salt (30) has been prepared.59 The fluorine atom 
should engage in two C-F····N+ interactions and therefore influence the conformation of 
this large flexible ring system. DFT calculations have predicted the conformation with 
fluorine in the axial position (30a) to be 9.2 kcal.mol-1 lower in energy than the 
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conformation with fluorine in the equatorial position (30b). The X-ray structure of (30) has 
confirmed that fluorine occupies the axial position with no evidence of molecules bearing 
fluorine in an equatorial position.59 
 
 
 
 
 
Figure 1.22: The conformation with fluorine axial (30a) is greatly favoured over equatorial (30b). 
 
 
It follows that the C-F bond could be used as a tool to influence the solution 
conformation of biologically active amines, exactly as it does in the ring system shown 
above. There are several reasons for exploring this: Firstly, the substitution of hydrogen by 
fluorine does not induce a significant steric change in the molecule which will maintain its 
steric profile for binding to the target protein. Also, biologically active amines are usually 
protonated at physiological pH, so the large conformational preference (4-5 kcal.mol-1) for 
the gauche orientation of the F-C-C-N+ motif should influence, if not limit the solution 
conformation of the molecule. This means that a β-fluorinated amine is not able to access 
all conformations available to the non-fluorinated analogue, allowing the significant 
biologically active conformations of the given amine to be explored. Finally, the 
introduction of fluorine alters the pKa of the bio-active amines. This can have positive or 
negative consequences for their activity but it is anticipated that the fluorinated amines will 
remain sufficiently basic to be protonated at physiological pH. 
Testing the validity of this concept was exciting and the synthesis of 3-fluoro-γ-
aminobutyric acid was undertaken in this perceptive. The main focus of this research is to 
explore the conformational consequences of C-F bond on a bio-active β-fluoroamine.
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It has been argued that the C-F bond has the potential to be a powerful tool in 
influencing the conformation of organic molecules, and particularly β-fluoroamines. The 
ability could also be used advantageously in asymmetric synthesis to stabilise or destabilise 
charged reaction intermediates or transition states. However, after browsing the literature, 
it appears that very few articles report on the role of fluorine in influencing the 
stereochemical outcome of an organic reaction. One example comes from the St Andrews 
laboratories. Scheme 1.4 describes the zwitterionic aza-Claisen rearrangement of (S)-N-
allyl-2(methoxymethyl)-pyrrolidine (31) with propionyl chloride (32) and a Lewis acid. 
The reaction proceeded with a 75% de. 
 
 
 
 
Scheme 1.4: Aza-Claisen rearrangement with propionyl chloride. 
 
 
 
 
 
 
 
 
 
Scheme 1.5: The orientation of the C-F bond in the transition state can affect the stereochemical 
outcome of the zwitterionic aza-Claisen rearrangement. 
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When 2-fluoropropionyl chloride (34) was used instead, the reaction proceeded 
with a 99% de. It is thought that the C-F bond influences the diastereoselectivity of the 
reaction by stabilising the transition state where the C-F bond aligns gauche to the C-N+ 
bond and conversely destabilises the alternative diastereoisomeric transition state, where 
the C-F bond is anti to the C-N+ bond (Scheme 1.5).60 
 
Another example where the orientation of a C-F bond vicinal to a C-N+ bond is 
likely to control the stereoselectivity of a reaction has been reported for the synthesis of 
erythro-3-fluorophenylalanine (37). Reductive amination of 3-fluorophenylpyruvate (38) 
with NaBH4 proved to be stereoselective, affording the erythro isomer in >90% de 
(Scheme 1.6).  
 
 
 
 
 
 
 
 
Scheme 1.6: Transition state models for reduction of α-iminium-3-benzene-3-fluoropropanoic 
acid (39).61 
 
  
According to the Felkin model, the reduction occurs through either transition state 
(39a) or (39b). The former leads to the formation of the erythro compound (37) and the 
latter to the threo compound (40). The transition state (39a) is probably stabilised by the 
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gauche relationship between the C-F and the C-N+ bonds. This accounts for the >95% 
stereoselectivity of the reduction.61 
Although applications of such interactions with fluorine in asymmetric organic 
synthesis are rare, they do exist and raise the significance of the C-F···C-N+ interactions in 
influencing the relative stability of transition states and therefore in inducing 
stereoselectivity in asymmetric reactions.  
 
It has already been noted that (4R)-fluoroproline in the Yaa position of collagen 
peptides increases thermal stability. This example demonstrates that fluorine 
stereoelectronic effects can be advantageously applied to peptide chemistry. (4R)-
Fluoroproline adopts the Cγ-exo ring conformation to allow the C-F bond to align gauche 
to the C-N bond in a typical gauche effect (see also Figure 1.10). Similarly, (4S)-
fluoroproline adopts the Cγ-endo ring conformation, which provides some stability in the 
Xaa position. The Cγ-endo conformer requires the pyrrolidine ring to pucker towards the 
proline carbonyl (Figure 1.23).   
 
 
 
 
 
 
 
 
Figure 1.23: Preferred conformations of (4R)- and (4S)-fluoroproline derivatives (41) and (42) and 
the relative populations of the endo and exo conformations in dioxane at 25 °C.62  
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All peptide bonds in the collagen triple helix are in the trans conformation,63 
therefore the predisposition of proline derivatives to adopt a trans conformation should 
decrease the entropic penalty for triple helix formation. (4R)-Fluoroproline has the highest 
Ktrans/cis (Table 1.4) and accordingly stabilises the triple helix formation when located at the 
Yaa position, more than (4S)-fluoroproline in the Xaa position (Table 1.5). 
 
 
 
 
Xaa X Y Ktrans/cis 
proline H H 4.6 
(4R)-hydroxy-proline H OH 6.1 
(4S)-hydroxy-proline OH H 2.4 
(4R)-fluoro-proline H F 6.7 
(4S)-fluoro-proline F H 2.5 
 
Table 1.4: Values of Ktrans/cis for 4-substituted proline residues measured in D2O at 25 °C.64 
 
 Tm (°C) 
(Pro-Pro-Gly)7 -6 
(Pro-(4R)Flpro-Gly)7 45 
((4S)Flpro-Pro-Gly)7 33 
((4S)Flpro-(4R)Flpro-Gly)7 8 
 
Table 1.5: Effect of 4-fluoroproline on the conformational stability of a collagen triple helix with 
(XaaYaaGly)7 strands.40 
N
O
OMe
O
X Y
N
O
X Y
OMe
O
trans cis
Ktrans/cis
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There is a correlation between high Ktrans/cis and the stability of the collagen helix, 
but other factors, such as steric considerations are also important.39, 40 By constructing 
constrained proline analogues, Raines et al. showed that changes in trans/cis ratio arise 
from changes in ring pucker.64 However, the correlation between Ktrans/cis and exo/endo 
conformations is not well established. As described, (4R)-fluoroproline adopts the Cγ-exo 
conformation and has a high Ktrans/cis whereas (4S)-fluoroproline adopts the Cγ-endo 
conformation but has a much lower Ktrans/cis suggesting that the trans conformation is much 
less stable in this case.  
How does this difference between the two arise? It has been advanced that in the 
case of (4R)-fluoroproline, the oxygen of the amide points towards the carbon of the 
methyl ester in a n→π* stabilising interaction (41b). In the case of (4S)-fluoroproline, this 
n→π* interaction is less stabilising because the oxygen of the amide and the carboxylic 
group are further apart due to the Cγ-endo conformation. Moreover, the fluorine interacts 
unfavourably with the oxygen of the methyl ester in the trans conformation (42b), which 
disfavors the n→π* interaction. (Figure 1.24).62, 64 
 
 
 
 
 
 
 
 
Figure 1.24: Stabilisation of the trans conformer (41b) by n→π* interaction and destabilisation of 
the trans conformer (42b) due to unfavourable steric interactions between the nonbonded electrons 
on the fluoro and ester groups, which disfavours the n→π* interaction.64 
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Although it has not been discussed in the literature, the relative destabilisation of 
the trans conformer of Ac-(4S)-fluoroproline-OMe (42b) could also be explained in terms 
of an unfavourable dipole-dipole interaction between the C-F bond and the amide bond. 
This explanation could also account for the higher trans/cis ratio of Ac-(4R)-fluoroproline-
OMe as a dipole-dipole interaction between the C-F and the amide bond would also 
destabilise the cis conformer (41a) (Figure 1.25). 
 
 
 
 
 
 
 
Figure 1.25: Destabilisation of the cis conformer (41a) and trans conformer (42b) due to dipole-
dipole interaction. 
 
 
This analysis shows that the propensity of proline residues to adopt either the trans 
or cis conformation has a decisive effect on the conformation stability of proline-rich 
peptides. It also demonstrates that the fluorine gauche effect and its potential use in 
influencing the conformation of polypeptides are fully acknowledged and have already 
been utilised. 
 
It is important to note that proline has a crucial role also in the folding of proteins 
by causing turns in β-sheets or by promoting α-helix stability. Lummis and Beene65 have 
shown that striking structural and functional consequences are observed when unnatural 
Chapter 1 
_______________________________ 
 40 
proline analogues with different Ktrans/cis values are substituted for a proline residue at a 
specific position in the sequence of the 5-hydroxytryptamine type 3 receptor (5-HT3 
receptor). 5-HT3 receptors are, like GABAA receptors, neurotransmitter-gated ion channels, 
members of the Cys-loop receptor superfamily. 
 
Their study showed that proline analogues that strongly favour the trans conformer 
produced non-functional channels, i.e. channels unable to open. Conversely, proline 
analogues with a high preference for the cis conformation produced channels which stay 
open longer, suggesting that the cis/trans isomerisation of this proline residue provides the 
switch that interconverts the open and closed state of the channel (Figure 1.26). In this case 
however, (4R)-fluoroproline and (4S)-fluoroproline showed little difference from the 
natural proline residue. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.26: A proposed gating mechanism. A single 5-HT3 receptor subunit is depicted, 
illustrating how trans/cis isomerisation could function as a switch between the open and closed 
state of the channel.65 
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This provided an important insight into understanding the gating mechanism of 
ligand-gated ion channels receptors. But it is still unclear how the binding of a small 
molecule, such as  acetylcholine, serotonine (5-hydroxytryptamine) or GABA, can operate 
the conformational changes in the receptor which open the channel pore, located about 
60 Å away from the binding site of the neurotransmitter. The biological role of GABA and 
its binding on GABAA and GABAB receptors are the subjects of Chapter 2. 
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Chapter 2: The GABA-mediated inhibition 
of neuronal signals. 
 
2.1 Introduction 
 
The brain and the central nervous system (CNS) of human beings are probably the 
most sophisticated machineries in nature and certainly the most intriguing parts of 
ourselves. For example, little is known about the mechanisms involved in memory or 
information storage in the brain. The propagation of neuronal signals from the brain to the 
muscles is also a very complex system controlled or affected by a huge number of 
parameters which are not all identified. It is however crucial for the development of 
modern science to understand how neurons communicate between each other. 
Synapses are regions between neurons where the electric neuronal signal is 
converted into a chemical signal and transmitted to another neuron. When the electric 
signal depolarises the pre-synaptic nerve terminal, a neurotransmitter released from storage 
vesicles diffuses the short distance to the post-synaptic membrane where it binds to its 
receptors and opens a channel through which ions can flow into the post-synaptic neuron. 
The main neurotransmitters in the CNS are glutamate (43), γ-aminobutyric acid (GABA) 
(44), acetylcholine (45) and glycine (46).  
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GABA is the main inhibitory neurotransmitter with, depending on the brain region, 
20-50% of neuronal synapses estimated to be GABAergic (i.e. to synthesise and to utilise 
GABA as their primary neurotransmitter).1, 2 Its binding on the post-synaptic membrane 
causes the cell to hyperpolarise and thus to be less likely to fire, by allowing either a flow 
of chloride anions into the cell or a flow of cations out of the cell. GABA is involved in a 
wide range of physiological functions such as respiration,3, 4 locomotion,5 pain,6 memory7, 8 
and sleep9 and its receptors are the target of many important drugs. 
 
Chapter 2 outlines the central role of GABA in the CNS and the pharmaceutical 
importance of its receptors. The structures of GABAA and GABAB receptors are then 
discussed, as well as the models of GABA binding sites which have been proposed. The 
aim of the second part of this chapter is to discern the active conformations of GABA on 
its different binding sites. For that purpose, GABA analogues and their biological activities 
are reviewed and compared. The last part of this chapter presents the synthesis of 
neurosteroids which interact with GABA. Their synthesis was motivated to explore the 
mode of action of neurosteroids on the GABA receptors, a relationship that is not well 
understood. 
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2.2 GABA and GABA
 
receptors as key elements of the CNS. 
 
2.2.1 The importance of GABA in the CNS 
 
 
 
 
GABA (γ-aminobutyric acid) (44) is the most prevalent inhibitory neurotransmitter 
in the CNS. It is synthesised from L-glutamate (43) by the action of L-glutamic acid 
decarboxylase (GAD) which is a PLP-dependent enzyme. The mechanism of this 
transformation is outlined in Scheme 1.2. The action of this enzyme is of huge importance 
as it converts the main excitatory neurotransmitter (glutamate) into the main inhibitory 
neurotransmitter (GABA). 
GABA is then metabolised to succinic semialdehyde (47) by the enzyme GABA 
aminotransferase (GABA-AT) which is also a PLP-dependent enzyme. It converts PLP to 
PMP, then PMP is restored to PLP by transamination with α-ketoglutarate (48), 
regenerating L-glutamate. Succinic semialdehyde is converted by succinic semialdehyde 
dehydrogenase (SSADH) to succinate (49), which has a negative-feedback inhibition on 
the enzyme GAD. This auto-regulated system keeps the concentration of GABA in the 
CNS constant as the production of GABA is inhibited by an increased concentration of the 
end-product succinic acid (Scheme 2.1).  
O
-O
NH3+
44
γ
-aminobutyr ic acid GABA
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Scheme 2.1: Biosynthetic pathway and metabolism of GABA. 
 
 
Dysfunctions in the regulation of GABA lead to abnormal concentrations of the 
neurotransmitter and have serious effects on the propagation of neuronal signals. 
Particularly critical are depleted concentrations of GABA which are related to major 
neurological disorders such as Parkinson’s disease,10 Alzheimer’s disease,11 epilepsy,12 
anxiety or depression.13 These syndromes affect a large proportion of the population 
especially in industrialised countries and over the years, the pharmaceutical industry has 
introduced a number of drugs to the market to treat these disorders.  
There are different ways of enhancing the action of GABA. The first method is to 
inhibit GABA metabolism, that is, to block the action of GABA aminotransferase. This is 
the mode of action of Vigabatrin (50), sold in the United Kingdom under the trade name 
Sabril® and used successfully to treat epilepsy.14, 15 Vigabatrin is a mechanism-based 
irreversible inhibitor of GABA-AT (Scheme 2.2), with only the (S)-enantiomer displaying 
pharmaceutical activity.16, 17 Sabril® however is sold as a racemate. 
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Scheme 2.2: Mechanisms of inactivation of GABA-AT by vigabatrin.18 
 
 
 
 
 
 
 
 
 
Figure 2.1: Active site of GABA-AT after modification with vigabatrin. The ternary adduct 
has been modelled according to structure (51).19 
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The crystal structure of GABA-AT was reported in 1999.20 More recently, GABA-
AT and vigabatrin have been co-crystallised and the ternary adduct (51) of Lys329, PLP-
co-factor and vigabatrin was found in the active site (Figure 2.1). This finding supports the 
Michael addition mechanism (pathway a) however the enamine mechanism (pathway b) 
can not be ruled out.19 
A second method to enhance the action of GABA is to reduce its reuptake by 
neuronal GABA transporters. Reuptake into presynaptic terminals or surrounding glial 
cells constitutes the primary mechanism for terminating inhibitory GABAergic 
neurotransmission. Therefore, selective GABA uptake inhibitors, like Tiagabine21, 22 (53) 
exhibit interesting anticonvulsant activities. Tiagabine is used clinically for the treatment 
of epileptic disorders.23 By binding GABA transporters, this drug permits more GABA to 
be available for receptor binding on the surface of the postsynaptic membrane. GABA 
transporters have been cloned and shown to be members of the large family of Na+-
dependent neurotransmitter transporters24 but no crystal structure nor homology model is 
available yet.  
 
 
 
A third way of enhancing GABA availability is to stimulate its biosynthesis but no 
drug using this strategy has been clinically approved so far. Instead, most of the drugs 
potentiating the effects of GABA act by binding to GABA receptors, but on a different 
binding site to GABA itself. Such compounds have little or no intrinsic activity in the 
absence of GABA. They are called positive allosteric modulators of GABA and represent a 
large family of compounds which includes the clinically important barbiturates, 
benzodiazepines and neurosteroids as well as ethanol, halothane (1) and etomidate (54).
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 Barbiturates have been used since the early 1900s as sedative-hypnotics, 
anticonvulsants and anaesthetics. The most representative compound of this class is 
pentobarbitone (55) which is the oldest anticonvulsant still in use, although barbiturates as 
a class have been largely supplanted by benzodiazepines which have fewer undesired side 
effects.25  
Diazepam (56), marketed under the name Valium® is certainly the best known 
benzodiazepine. It was the top selling drug in the 1970s and is still in use today. More 
recently, neurosteroids have also been found to modulate the activity of GABA. The term 
“neurosteroid” refers to steroids which, independent of their origin, are capable of 
modifying neural activities.26 One of the most potent endogenous neurosteroids is 
allopregnanolone (57) which has been recognised to have potential therapeutic applications 
as an anaesthetic.27 
 
 
 
 
Figure 2.2: Representative compounds known to act as positive allosteric modulators of the 
GABA-mediated inhibition of neuronal signals. 
 
The five compounds shown above are clinically used or have potential use as 
anaesthetics. They are believed to act at GABA receptors, although their modes of action 
remain elusive. Their structural variety is remarkable and suggests that GABA receptors 
possess numerous binding sites for allosteric modulation. It could also be that multiple 
types of GABA receptors with diverse pharmacological profiles are expressed 
heterogeneously in the CNS. Disclosing the structural and pharmaceutical specificities of 
GABA receptors is a current challenge for both academic research and the pharmaceutical 
industry.
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2.2.2 GABAA and GABAB receptors 
 
The action of GABA is mediated mostly by two structurally and pharmacologically 
distinct receptors, termed GABAA and GABAB receptors. The GABAA receptors are 
ligand-gated chloride ion channels conveying the fast synaptic transmission. They are 
antagonised by bicuculline (58) and are insensitive to baclofen (59). GABAB receptors 
operate via second messenger systems and are coupled to Ca2+ and K+ ions channels 
through G-proteins. They produce slow, longer-lasting inhibition,28 are activated by 
baclofen and are insensitive to bicuculline. Both receptors have been cloned, GABAA first 
in 198729 and GABAB in 199730 but progress to establish their precise structure, as well as 
ligand binding and gating mechanisms have been hindered due to their membrane-bound 
protein nature, which is not conducive to structural determination by usual methods such as 
X-ray crystallography. 
 
 
 
 
 
Figure 2.3: Bicuculline (58) is a selective GABAA antagonist and (R)-baclofen (59) is a selective 
GABAB agonist.  
 
 
Bicuculline and (R)-baclofen constitute molecular tools for biologists to selectively 
“close” or “open” GABA receptors in order to understand their specific pharmacology. 
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GABAA receptors have generated a lot of interest due to their physiological 
significance and their complexity. They have been described as “the most complicated of 
the superfamily of ligand-gated ion channels in term of the large number of receptor 
subtypes and also the variety of ligands that interact with specific sites on the receptors”.25 
Indeed, GABAA receptors are composed of five subunits drawn from a library of 
sixteen subunits (α1-α6, β1-β3, γ1-γ3, δ, ε, π and θ). This structural diversity allows the 
expression of approximately thirty different functional isoforms of GABAA receptors 
which are heterogeneously expressed in the CNS and exhibit distinct physiological and 
pharmacological properties.31 Individual neurons can also produce different receptor 
subtypes. In most cases, functional receptors require the presence of α and β subunits and 
the most quantitatively prevalent receptor isoform is believed to have the structure 2α2β1γ. 
This composition is used as a model for GABAA receptors. 
 The GABA binding sites are located at the interfaces of the α and the β subunits.32 
There are therefore two GABA binding sites on the GABAA receptor and two molecules of 
the neurotransmitter are required to initiate the sequence of conformational changes which 
ultimately results in the opening of the chloride ion channel.  
 
 
 
 
 
 
 
Figure 2.4: Schematic representations of the GABAA receptor. 
GABA
GA
BA
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No crystal structure of the GABAA receptor has been published to date and this 
seriously impedes efforts to characterise precisely the structure of the GABA binding site. 
To circumvent this problem, three-dimensional models have been constructed by 
comparison with crystal structures of related proteins. The first protein which served as a 
template for the development of homology models of the GABAA receptor was the 
acetylcholine binding protein, a soluble analogue of the nicotinic acetylcholine receptor 
amino-terminal domain. Its crystal structure was reported in 2001.33 More recently in 2005, 
a crystallographic model based on cryo-electron microscopic analyses of the acetylcholine 
(ACh) receptor in Torpedo electric ray post-synaptic membranes revealed with more 
accuracy the structure of Cys-loop receptor-coupled ion channels.34 ACh and GABAA 
receptors have similar structure as they belong to the same family of transmembrane 
pentameric Cys-loop receptor ion channels. 
 
Comparative modelling, also called homology modelling is based on the 
observation that in protein families, structure is more conserved than sequence.35 
Therefore, knowing the sequence and the structure of an ACh receptor, and the sequence of 
the GABAA receptor, it is possible to align by comparison the target sequence with the 
template structure. By this method, one obtains a model whose validity depends on the 
sequence analogy between the template and the target. 
GABAA receptors have been modelled using this concept and the results depend on 
the alignment technique and on the template(s) used.36-42 
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Figure 2.5: Model structure of the extracellular domain of  
GABAA receptors published in 2003.41 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Model structure of the GABAA receptor showing the extracellular domain (β-strand 
rich) and the transmembrane domain (α-helix) published in 2007.42 
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Together with photolabelling techniques and substituted cysteine accessibility 
method (SCAM), homology modelling provides a better picture of the GABAA receptor 
and the GABA binding site structures. To date, multiple residues have been shown to 
contribute to the formation of the GABA binding site. These are Phe64, Arg66, Arg119, 
Ile120, Arg176, Val178, Val180 and Asp183 of the α1 subunit, and Tyr97, Leu99, Tyr157, 
Thr160, Thr202, Ser204, Tyr205, Arg207, and Ser209 of the β2 subunit.43-45 
From these elements, a model of the GABA binding site on the GABAA receptor 
has been constructed (Figure 2.7).38 Note that GABA is drawn in a fully extended 
conformation. It is however very difficult to assess the validity and the accuracy of this 
model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Model binding of GABA to the GABAA binding site published in 2006.38 
ARG120 
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Another GABAA binding site model has been proposed recently after the 
observation that the amino group of GABA is in close contact with the aromatic ring of 
Tyr97 in a cation-pi interaction. The GABA binding pocket is described as an aromatic 
pocket (Figure 2.8).46 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: GABA molecule docked into the proposed aromatic pocket published in 2007.46 
 
 
The last two years have witnessed great progress in the modelling and the 
understanding of the GABAA structure in order to disclose the structures of ligand 
recognition sites and gating mechanisms. This is currently a very active area of research 
and the convergence of different techniques will undoubtedly lead to the discovery of the 
full GABAA receptor structure at an atomic level in the next few years.  
It should also be mentioned that interesting studies have been published on the 
structure of GABAC receptors which are a subtype of lower complexity of GABAA 
receptors.47, 48 
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GABAB receptors were pharmacologically characterised in 198049 but their 
structure was fully elucidated only in 1998 with the discovery that they are heterodimeric 
G-protein coupled receptors, formed from the GABAB1 and GABAB2 subunits, both of 
which are required to generate functional receptors.50 The GABA binding site is located on 
GABAB1 whereas GABAB2 is responsible for G-protein coupling (Figure 2.9). No isoform 
of the GABAB2 subunit has been reported yet but the GABAB1 subunit exists mainly in two 
isoforms, GABAB(1a) and GABAB(1b). The former is predominant in the developing brain 
whereas the later is the main isoform in the adult brain.51 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Proposed structural organisation of the heteromeric GABAB receptor. Classical GABAB 
ligands bind in the cleft of the GABAB1 VFT shown on the left.52 
 
 
Mutational studies of the GABAB binding site, guided by homology models have 
shown that the Ser246, Ser269, Glu465 residues in lobe I in addition to Tyr366 and Tyr385 
in lobe II are important for agonist and antagonist binding.53 These homology models of 
the GABAB binding site have been built using the structure of leucine/isoleucine/valine-
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binding proteins (Figures 2.10 and 2.11).54, 55 It is worth noting that the phenyl ring of 
baclofen (59) can fit well between Tyr366 and Tyr395 and form a possible π-π stacking 
interaction with those groups. 
 
 
 
 
 
 
 
 
 
Figure 2.10: Model of GABA and Ca2+ docked into the ligand-binding site of GABAB1  
published in 2001.54 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Model of GABA docked into the ligand-binding site of GABAB1  
published in 2002.55 
Chapter 2 
_______________________________ 
 
 61 
 
Unlike GABAA receptors, the pharmacological diversity of GABAB receptors 
seems limited. In fact, the agonist baclofen (59) introduced to the market in 1972 to treat 
neuronal seizures is still the prototype of selective GABAB receptor agonists. The similar 
structures of selective agonists (60)56 and (61)57 and the antagonist (R)-phaclofen (62)58 
suggests that they all bind to the same recognition site. 
 
 
 
However, intensive high-throughput screening in the last few years has revealed 
some structurally different allosteric compounds, such as GS39783 (63) or 3-chloro-4-
methoxyfendiline (64) which have potential clinical applications.59 They are thought to 
bind to the GABAB2 subunit. The discovery of this allosteric modulation has suddenly 
turned GABAB receptors into more attractive targets for anaesthetic drugs. 
 
 
 
 
 
A combination of mutational and computational studies has allowed convincing 
GABA binding site models for GABAA and GABAB receptors to be constructed. This will 
help to reveal how the GABA molecule is orientated in its binding sites in order for 
example, to design more potent analogues. It should also give a better understanding of the 
conformational changes induced by GABA binding in order to disclose at the atomic level 
the gating mechanism of GABA receptors.  
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Homology modelling is certainly a useful tool to approach the three dimensional 
structure of proteins for which no crystal structure is available. However, the dynamics and 
the complex structural changes which occur during receptor activation render the current 
models inadequate for designing new potent modulators of the GABAA or GABAB 
receptors. In fact, QSAR analyses have proven so far to be the method of choice over the 
last 40 years and an impressive number of GABA analogues have been designed and found 
to selectively bind only one receptor of the GABA system. 
Selective GABA agonists or antagonists are valuable pharmaceutical tools that can 
be used as molecular keys to selectively open or close GABA receptor subtypes in order to 
elucidate their specific functions. In addition, selective GABA agonists can also have 
therapeutic applications. 
 
 
Chapter 2 
_______________________________ 
 
 63 
 
2.3 Binding studies of GABA analogues 
 
GABA is a conformationally flexible molecule. It is achiral but it binds to chiral 
proteins, namely GABAA and GABAB receptors, GABA transporters and GABA 
aminotransferase. The fact that some GABA analogues of restricted conformation exhibit 
selectivity to the above proteins indicates that GABA binds in diverse conformations to its 
binding sites. 
Despite the intensive efforts made to define the “active conformations” of GABA 
and despite the relatively large number of analogues which exhibit selectivity to one 
protein, little is known of the preferred binding conformations of GABA. The difficulty in 
solving this question lies in the fact that the potency of GABA analogues depends not only 
on their conformation in the binding site, but also in their ability to approach this site and 
to initiate the conformational changes which result in the activation of GABA receptors. 
The conformations of GABA can be characterised by the distance between the nitrogen 
and the carbon of the carboxylate, δ(N-C) and by two torsion angles τN and τC as shown in 
Figure 2.12. 
 
 
 
 
Figure 2.12: Characteristic parameters of GABA conformations. 
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Some interesting reviews have been published in the last twenty years, in order to 
draw a general picture of the preferred binding conformations of GABA and eventually to 
construct 3-D pharmacophore models for GABA binding.60-63 Tables 2.1 and 2.2 present 
the structures of some conformationally restricted GABA analogues as well as their 
biological activities on GABAA, GABAB binding and GABA uptake. The values are given 
relative to the activity of GABA which has been assigned the value 100. Also given in 
Table 2.1 and 2.2 are δ(N-C), τN and τC values. 
Curiously, the δ(N-C) distance is not a determining factor in GABAA binding ability, 
as potent GABAA agonists have δ(N-C) values ranging from 4.29 to 4.97 Å. This still 
indicates that GABA binds to GABAA receptors in a partially extended conformation. It is 
assumed that the carboxylate binds first to an arginine residue (either α1Arg66, α1Arg119 
or β2Arg207) 46, 63, 64 and that the side chain of this arginine possesses some flexibility 
within the binding pocket. The ligand then accommodates itself in the binding site to 
present the ammonium group to either some counter ion or a pi-system.46  
 
It appears after examination of Table 2.1 that negative values for both τN and τC are 
associated with high activity towards GABAA receptors. This is particularly clear by 
comparing the activities of the enantiomers (70)-(71), (72)-(73) and (74)-(75). 
However, defining further the preferred torsion angles τN and τC for GABAA 
binding is very speculative. It seems that compounds with τC between -140° and -180° 
have good GABAA activities. Similarly, τN between -130° and -170° give good GABAA 
activity as indicated by (73), (75) and (77). This however doesn’t account for the high 
efficies of isoguvacine (66) and THIP (67) which have τN values between -11° and +50°, 
depending on which GABA backbone, as well as which six-membered ring conformation 
is considered. 
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compound Structure GABAA GABAB GABA uptake δ(N-C) τN τC 
GABA 
44
H3N+
O
O-
 
100 100 100 2.72-4.96 free free 
Trans-
aminocrotonic 
acid 65
H3N+
O
O-
 
41 1.3 31.5 4.29-4.94 free 180° 
±11° ±178° 
Isoguvacine 
66 O
O-
+H2N
 
~100 <1 <1 4.29 
±50° ±160° 
±10° ±179° 
THIP 
67
O N
OH
+H2N
 
33 <1 <1 4.22 
±49° ±158° 
Muscimol 
68
H3N+
O N
OH
 
550 1.3 1.3 4.29-4.68 free 180° 
(S)-(+)-dihydro-
muscimol 
69
H3N+
O N
OH
 
825 0.2 <1 3.77-4.73 free -144° 
(1S,3S)-trans-
ACP 
70
+H3N
O
O-
 
~500 Not tested <1 4.97 -132° -140° 
(1R,3R)-trans-
ACP 
71
+H3N
O
O-
 
2.5 Not tested ~200 4.97 +132° +140° 
(4S)-ACP-1-ene 
72
+H3N
O
O-
 
~160 Not tested <1 4.96 -139° -168° 
(4R)-ACP-1-ene  
73
+H3N
O -
O
 
<1 Not tested 50 4.96 +139° +168° 
(R)-homo-β-
proline 
74
+H2N
O
-O
 
47 <1 188 4.24-4.88 -167° free 
(S)-homo-β-
proline 
75
+H2N
O
-O
 
3.7 0.4 111 4.24-4.88 +167° free 
 
 
Table 2.1: Biological activities of GABA analogues.60, 62, 65  (cont. overleaf) 
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compound Structure GABAA GABAB GABA uptake δ(N-C) τN τC 
(S)-(+)-3-OH-
GABA 
76
H3N+
O-
OOH
 
8.3 1.3 10.3 2.72-4.96 free free 
(R)-(-)-3-OH-
GABA 
77
O-
OOH
+H3N
 
3.3 8.6 4.5 2.72-4.96 free free 
(RS)-3-OMe-
GABA 
78
O-
OOMe
+H3N
 
<1 <1 <1 2.72-4.96 free free 
(R)-(-)-baclofen 
59
O-
O
+H3N
Cl
 
<1 38.5 1 3.12-4.89 free free 
 
Table 2.2: Biological activities of GABA analogues.60, 62  
 
 
A comparison of the activities of enantiomers (72) and (73), (4S)-and (4R)-(+)-4-
aminocyclopent-1-ene carboxylic acid, reveals stereochemical details on the active 
conformations of GABA in the GABAA receptor and the GABA uptake sites. Indeed, (72) 
and (73) differ only by the orientation of the amino group, but (4S)-(72) is GABAA 
selective whereas (4R)-(73) is GABA uptake selective. The other set of enantiomers (70)-
(71) also indicates that the conformation (S) is required for GABAA binding activity. The 
preferred τN, shown below for (72), is around -115°.61 It was assigned -139° in Table 2.1.62 
 
 
 
 
              72       73 
 
Figure 2.13: Best fit structures of (72) and (73) for the GABAA receptor and the uptake site 
respectively.61 
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Less information is available for selective GABAB ligands. To date, only two 
GABA analogues are reported to possess relatively good selectivity towards GABAB 
receptors: these are (R)-baclofen (59) and (R)-3-hydroxy-GABA (77). Interestingly, (77) 
shows a small preference for the GABAB receptor whereas its enantiomer (76) 
demonstrates the opposite selectivity and is more active as a GABAA agonist. It is however 
difficult to draw any conclusion for GABAB ligands because no conformationally 
restricted compound with potent GABAB activity has yet been found. 
It should be noted that the polar hydroxyl group of (R)-3-hydroxy-GABA (77) has 
the opposite stereochemical orientation to the lipophilic aromatic group of (R)-baclofen. 
Substitution of the hydroxyl by a methoxyl group suppresses the activity in (78), strongly 
suggesting that the hydroxyl interacts with polar residues on one side of the GABAB 
binding site. Conversely, the aromatic group of baclofen is directed into a lipophilic cavity 
on the other side. Since both ionised groups NH3+ and CO2- tend to orient away from the 
lipophilic cavity, it was suggested that the GABAB binding site prefers to bind GABA 
conformations having opposite signs for τN and τC (butterfly conformations).62 
 
 
 
 
 
 
 
 
Figure 2.14: Model of the GABAB binding site showing the lipophilic cavity on the right hand side 
of the GABA molecule and the polar cavity on the left hand side (adapted from J. Kniazeff et al., J. 
Neurosci., 2002).55 
Cl
Chapter 2 
_______________________________ 
 
 68 
 
Other GABA analogues have been tested on the GABA system. 2-Fluoro-GABA 
(79) for example was found to have good GABA uptake binding potency, being 2.3 times 
less potent than GABA (43% of the GABA activity).66, 67 
Interestingly, (R)-3-methyl-GABA (80) was found to be an activator of L-glutamic 
acid decarboxylase (GAD). Activation of GAD results in an increase in the GABA 
concentration in the CNS, which confers (R)-3-methyl-GABA (80) with anticonvulsant 
properties. Compound (80) was found to have the best in vitro activity on purified pig 
brain GAD of all GABA analogues tested in Silverman’s studies. However, its in vivo 
anticonvulsant activity was found to be modest. Compound (80) appears to allosterically 
activate GAD, increasing Vmax without affecting the Km of L-glutamate. Its enantiomer, (S)-
3-methyl-GABA, has very little potency.68, 69 
 
 
 
Binding studies with GABA analogues have furnished valuable information for the 
design of new ligands. For example, specific GABAB antagonists e.g. compound (81) with 
a hydroxyl group at the 3-position and with the (R) stereochemistry, have been designed 
from the observation that (77) is GABAB selective.70, 71  
 
3D-pharmacophore models based on the analyses of known ligands have been 
constructed, but often in the context of identifying low-potency GABA agonists or 
antagonists. Indeed, neither full GABA agonists nor antagonists may be useful therapeutic 
agents; therefore efforts have not focused on discovering highly potent GABA analogues, 
which are of academic interest only. This is one of the numerous reasons why the active 
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conformations of GABA on GABAA and GABAB receptors are still elusive. However, the 
data in Tables 2.1 and 2.2 will surely prove to be useful once precise models of the GABA 
binding sites can be constructed or once the crystal structures of GABA receptors can be 
solved. 
 
 
2.4 Steroid modulation of the GABA response  
 
2.4.1 The nature of steroid modulation 
 
The anaesthetic action of endogenous steroids was first observed in 194172 but it 
was only in 1984 that their ability to enhance neuronal inhibition via the GABAA receptor 
was demonstrated.73 The synthetic steroid alphaxalone, 5α-pregnan-11,20-dione (82) as 
well as endogenous steroids allopregnanolone, 5α-pregnan-3α-ol-20-one (83) and 
tetrahydrodeoxycorticosterone (THDOC), 5α-pregnan-3α,21-diol-20-one (84) are all 
active at low nanomolar concentrations and are believed to enhance the interactions of 
GABA with the GABAA receptor, thereby stabilising the open state of the receptor channel 
complex.74 However, at higher concentrations, steroids directly activate the GABAA 
receptor in the absence of GABA. This dual effect indicates that the steroid-mediated 
potentiation of GABA occurs in two distinct ways which has long complicated the 
elucidation of their mode of action. 
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Strong indications such as the selective and enantioselective nature of the steroid 
potentiation suggest the existence of a specific steroid recognition site on the GABAA 
receptor. It is selective because steroids have no effect on the GABAB receptor and 
enantioselective because ent-allopregnanolone, the non-natural enantiomer of 
allopregnanolone (83) is much less active than its natural counterpart.75 
Over the past ten years, numerous studies have been carried out on neurosteroids 
acting at GABAA receptors. Interest has been stimulated by the therapeutic potential of 
such neurosteroids as anticonvulsants, sedatives and hypnotics76 and also by the lack of 
knowledge concerning their mode of action.  
Analogues of the most potent neurosteroids have been synthesised and their 
biological activity on GABAA receptors was tested. This has allowed different classes of 
steroids to be determined.  
Thus, 3β-steroids were found to be non-competitive antagonists: they inhibit the 
potentiation induced by 3α-steroids through activation-dependent blocking of GABAA 
receptors but they also reduce barbiturate and GABA potentiation.77 3β-Sulfate steroids 
such as pregnenolone sulphate (85) have similar effects. 
 
 
 
 
The 5β-steroids were found to have similar activity to 5α-steroids on GABA 
potentiation.78 This was a rather surprising result as 5α- and 5β-steroids belong to two 
distinct structural classes with a different backbone and might be expected to bind quite 
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differently to the recognition site. Allopregnanolone (83) and pregnanolone (5β-pregnan-
3α-ol-20-one) (86) are typical representatives of both classes. 
 
 
 
 
 
 
 
 
Significant progress in understanding the neurosteroid-mediated action on GABAA 
receptors was made in 2006 in a landmark article published in Nature by A. M. Hosie and 
T. G. Smart.79 They discovered that neurosteroids regulate GABAA receptors through two 
discrete transmembrane sites: one site mediates the potentiating effect and the other the 
direct activation effect. They succeeded in localising the potentiation site by constructing 
chimera GABAA receptors having low potentiation sensitivity and lacking direct activation 
by neurosteroids. After identification of the subunit domain critical for potentiation, they 
mutated several polar residues and determined that Thr236 on the α1 subunit was critical 
for steroid activation and Gln241 also on the α1 subunit essential for steroid potentiation. 
By constructing homology models, they could then locate Thr236 and Gln241 and identify 
the other amino acid residues involved in the binding sites. Figures 2.15 and 2.16 show the 
neurosteroid activation site and potentiation site respectively. 
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Figure 2.15: Neurosteroid activation binding site spanning the β/α-subunit interface. View through 
the lipid bilayer of model GABAA receptor transmembrane region with a bound THDOC molecule. 
αThr236 and βTyr284 are predicted to face the surrounding lipid.79 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16: Neurosteroid potentiation binding site. Ribbon structure of α-subunit M1–M4, 
showing αGln241, αAsn407 and αTyr410 docking with a THDOC molecule, viewed from the 
lipid bilayer. The channel lining the M2 domain is shown in purple, and a section of M3 is omitted 
for clarity.79 
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Both binding sites are located in the transmembrane domain and are only accessible 
to hydrophobic molecules, although the potentiation site seems to lie at the base of a water-
filled cavity between the α subunit’s M1-M4 domains. It was found that the potentiation 
site cannot distinguish between 5α- and 5β-reduced steroids whereas the activation site 
may differentiate the two classes and have a different pharmacophore. As outlined in 
Figure 2.17, significant receptor activation by neurosteroids relies on occupancy of both 
the activation and potentiation sites, which is in accordance with the fact that direct 
activation is appreciable only at high concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17: Diagram of the GABAA receptor indicating how the occupation of the neurosteroid 
binding sites affects receptor activation and the potentiation of GABA responses.  
Neurosteroid activation of GABAA receptors is proposed to be a two-step process. Binding to the 
activation site is followed by occupation of the potentiation site.79  
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The identification of the steroid binding sites allows a better understanding of their 
mode of action and now allows the building of more precise 3-D binding site models and 
the design of new neurosteroids displaying improved potentiation or activation responses. 
The design of selective antagonists is pharmacologically pertinent as such 
compounds could be used in anaesthesia to selectively reverse the anaesthetic effects of 
sedative steroids, to help patients recover after surgery for example. Selective antagonists 
may also help shed light on the physiological function of GABA-potentiating neurosteroids 
in health and disease. 
However, only one compound has been reported to date to act as a selective steroid 
antagonist. Its structure was published in 200480 and immediately raised the interest of 
neurobiologists. (3α,5α)-17-Phenylandrost-16-en-3-ol, (17-PA) (87) was found to 
selectively antagonise 5α-reduced neurosteroid effects at GABAA receptors whereas 5β-
reduced steroids were only weakly affected. 17-PA (87) was also reported to have little or 
no effect on baseline GABA responses and barbiturate potentiation.80 Thus 17-PA 
represented in 2004 an attractive pharmaceutical tool of a new class to explore 
neurosteroids effects. 
 
 
 
 
Our collaborators from the School of Neurobiology in Dundee had developed an 
interest in this compound. It was decided to undertake the synthesis of 17-PA and to 
develop a series of analogues bearing different substituents on the aromatic ring in order to 
explore structure-activity relationships. 
H
HH
HO 87 17-PAH
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2.4.2 Synthesis of steroid selective inhibitors 
 
The synthesis of 17-PA (87) which was reported by Covey et al.,80 starts from 
commercially available androsterone (88). Addition of phenyllithium generated diol 
(3α,5α,17β)-17-phenylandrostane,3,17-diol (89) which was then acetylated at the 3-
position. Dehydration of tertiary alcohol (90) was achieved by adding methanesulfonyl 
chloride and triethylamine in DCM. Subsequent hydrolysis of the acetate furnished 17-PA 
as a white solid in 4 steps and 39% overall yield (Scheme 2.3).  
 
 
 
 
 
 
 
 
Scheme 2.3: Synthesis of 17-PA (87) from androsterone (88) as reported by Covey et al.80 
Reagents and conditions: a) PhLi, THF, 0°C to 25 °C, 5 h, 44%; b) Ac2O, pyridine, DMAP, 25 °C, 
5 min, 95%; c) MsCl, Et3N, DCM, 0 °C, 40 min, 99%; d) NaOH, H2O, MeOH, 65 °C, 1 h, 95%. 
 
 
Different approaches can be considered for the synthesis of 17-PA, but although 
steroid chemistry is well documented, only a few examples of C17-phenyl-substituted 
steroids have been reported.  
The use of palladium chemistry represents a possible alternative to the above 
synthesis of 17-PA. It was reported for example that the palladium-catalyzed cross-
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coupling of sodium tetraphenylborate (NaBPh4) with vinyl triflates81 proceeds smoothly 
and in good yields (Scheme 2.4 A). However, very few derivatives of tetraphenylborates 
are commercially available which renders this method unattractive to the generating of a 
series of 17-PA analogues with different substituents on the aromatic ring. Likewise, 
Negishi coupling of arylzinc chlorides with vinyl iodides82 can be envisaged as an 
alternative strategy to 17-PA (87) (Scheme 2.4 B). This method is appealing as it directly 
furnishes the unsaturated steroid and avoids the tedious protection-deprotection sequence 
shown in Scheme 2.3. Although these alternative methods were potential candidates, it was 
decided to follow the published synthesis in the first instance.80 
 
 
 
 
 
 
 
 
Scheme 2.4: Syntheses of 17-PA analogues (93) and (95) illustrating possible  
alternative syntheses to 17-PA.81, 82 
 
 
Phenyllithium was generated in situ by lithium-bromine exchange using n-BuLi 
and bromobenzene in dry Et2O at 0 °C. This mixture was added to a solution of 
androsterone (88) in THF and after work-up and purification, diol (89) was obtained. The 
procedures followed that described in the original report80 and gave (89) as a colorurless 
solid in a modest 43% yield. The low conversion is mainly due to the propensity of ketone 
(88) to enolise in the presence of aryllithium. Also, 20% of unreacted starting material was 
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recovered from this reaction. For the rest of the synthesis, the published reaction conditions 
were strictly followed and compounds (89), (90), (91) and 17-PA (87) were obtained in 
yields similar to those reported. All characterisation data were in accordance with the 
published data. 
 
With this reference compound in hand and a working knowledge of the route, we 
then addressed the synthesis of fluorinated analogues of 17-PA. As described in chapter 1, 
it was anticipated that the introduction of fluorine should induce only minor steric changes 
without altering the pharmacological profile of 17-PA. 
 
The synthesis of the meta-fluorinated 17-PA analogue was first investigated. 
Presumably, a fluorine atom in the meta-position on the aromatic ring induces some steric 
and electronic dissymmetry that can be accommodated in the recognition site by the free 
rotation of the ring. This might be beneficial for the biological activity of the compound. 
3-Fluorophenyllithium was prepared by reacting n-BuLi with 3-fluorobromo-
benzene in dry Et2O at -78 °C. Low temperature was required to prevent decomposition of 
the fluorinated aryllithium. The mixture was then added at -78 °C to a solution of 
androsterone in THF.  It should be noted that androsterone was not soluble in Et2O which 
might be preferable for this kind of reaction. After work-up and purification, the product 
(3α,5α,17β)-17-(m-fluorophenyl)androstane-3,17-diol (96) was obtained as a colourless 
solid in a low 31% yield. Acetylation of (96) under the reaction conditions used for the 
synthesis of 17-PA gave (97) in 80% yield. Subsequent dehydration of the tertiary alcohol 
and hydrolysis of the acetate as described previously, furnished the target compound 
(3α,5α)-17-(m-fluorophenyl)androst-16-en-3-ol (99) as a colourless solid in 15% overall 
yield from androsterone (Scheme 2.5).  
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Scheme 2.5: Synthesis of the m-fluorophenyl analogue of 17-PA (99) using published reaction 
conditions.80 Reagents and conditions: a) 3-Fluorobromobenzene, n-BuLi, Et2O, -78 °C to 25 °C, 
15 h, 31%; b) Ac2O, pyridine, DMAP, 25 °C, 15 min, 80%; c) MsCl, Et3N, CH2Cl2, 0 °C, 45 min, 
67%; d) NaOH, H2O, MeOH, 65 °C, 1 h, 90%. 
 
 
The synthesis of the meta-difluorophenyl analogue was then addressed. n-BuLi was 
added at -78 °C to a solution of 3,5-difluorobromobenzene (100) in Et2O. The mixture was 
stirred for 3 h and added at -78 °C to a solution of androsterone in THF. TLC analysis 
showed a complex mixture of products and purification of the crude material by column 
chromatography proved to be difficult. However, NMR and mass spectroscopy analyses of 
selected fractions were found to be consistent with the formation of two main products, 
(101) and (102) although these compounds could not be fully purified.  
 
 
 
 
 
 
 
 
Scheme 2.6: Attempted synthesis of (101). The combined electron withdrawing effect of the two 
fluorine atoms render the ortho hydrogen susceptible to exchange, leading to a mixture of (103) 
and (104). 
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As shown on Scheme 2.6, the increased acidity of the hydrogen atom ortho to the 
fluorine atoms promotes lithium-hydrogen exchange to the detriment of lithium-bromine 
exchange, leading to a mixture of 1,3-difluorophenyl-5-lithium (103) and 1,3-
difluorophenyl-2-lithium (104). This generates the product mixture of (101) and (102) after 
reaction with androsterone. 
This example shows the importance of controlling and understanding the formation 
of the phenyllithium derivative for the synthesis of 17-PA analogues. The lithium-bromine 
exchange reaction using n-BuLi and an aryl bromide was first described in 1938 by Wittig 
and co-workers83 and has been widely used since then. Yet, its mechanism remains unclear 
because competing reactions such as β-eliminations and Wurtz-type couplings as well as 
the fact that organolithium compounds do not exist as monomers in solution, complicate its 
examination. Halophilic attack of n-BuLi to the halogen or a radical-mediated process are 
the two main explanations for this mechanism.84  
The particular reactivity of fluorinated bromobenzenes with n-BuLi has also been 
studied. Generally, fluorinated phenyllithiums are stable only at very low temperature. In 
the case of ortho-fluorophenyllithiums, elimination of LiF occurs above -50 °C and 
generates benzynes.84-87  
 
Preparation of the fluorinated analogues of 17-PA, (105), (106) and (107) were also 
attempted but were unsuccessful, either because the lithium-bromine or lithium-hydrogen 
exchange reaction failed or because the fluorinated steroid could not be obtained in a 
satisfactory yield after purification. 
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The synthesis of the para-fluorinated analogue (109) of 17-PA was however 
successful. Preparation of 4-fluorophenyllithium was achieved by reacting n-BuLi with 4-
fluorobromobenzene in Et2O. The mixture was then added at -78 °C to a solution of 
androsterone in THF. After work-up and purification, (3α,5α,17β)-17-(p-
fluorophenyl)androstane-3,17-diol (108) was obtained in 40% yield. The development of a 
strongly UV-active compound after leaving (108) in CHCl3 for a few days was an 
indication that the tertiary alcohol was not stable under acidic conditions. It is known that 
tertiary alcohols are prone to dehydrate by an E1 mechanism. Therefore, the acid-catalysed 
dehydration of (108) was attempted in order to shorten the synthesis of these 17-PA 
analogues to two steps. A catalytic amount of p-toluenesulfonic acid monohydrate (pTSA) 
was added to a solution of (108) in DCM and the mixture was heated under reflux for 4 h.  
NMR analysis of the crude material revealed the formation of the desired product 
(3α,5α)-17-(p-fluorophenyl)androst-16-en-3-ol (109) along with a slightly less polar 
compound (~15% according to crude NMR analysis). The separation by column 
chromatography of these two products was achievable but difficult. Nevertheless, (109) 
was obtained as a colourless solid in 60% yield from (108) and was fully characterised 
(Scheme 2.7). 
 
 
 
 
 
Scheme 2.7: Synthesis of the p-fluorophenyl analogue of 17-PA (109).  
Reagents and conditions: a) 4-Fluorobromobenzene, n-BuLi, Et2O, -78 °C to 25 °C, 12 h, 40%; 
b) pTSA, DCM, reflux, 4 h, 60%. 
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As shown in Scheme 2.7, the para-fluorophenyl analogue (109) of 17-PA could be 
prepared in two steps from androsterone by direct dehydration of the tertiary alcohol under 
acidic conditions. It was interesting to examine whether the meta-fluorophenyl analogue 
(99) could also be prepared by this shorter route.  
Accordingly, a solution of (96) in DCM was treated with pTSA and heated under 
reflux. Forcing conditions (i.e. two equivalents of pTSA and heating under reflux for 5 h) 
had to be applied to achieve complete dehydration of (96). A mixture of two products was 
obtained but this time, the major one was not the expected strongly UV-active compound 
(99). Despite the difficulty of separating the two products by column chromatography, it 
was possible to isolate the unknown compound in 52% yield. NMR analysis revealed the 
absence of the ethylenic proton on C16 and a different pattern in 1H NMR and 13C NMR on 
the D ring of the steroid. The structure of compound (110) was elucidated by NMR 
analyses, in collaboration with Dr Tomáš Lébl at the University of St Andrews. The 13C 
NMR spectrum of (110) was also fully assigned (Scheme 2.8). 
 
 
 
 
 
Scheme 2.8: Formation of 17α-(m-fluorophenyl)-17β-methyl-5α-androsten-13-3α-ol (110)  
by Wagner-Meerwein rearrangement under acidic conditions. 
 
 
The structure of (110) shows that the methyl group C18H3 has migrated from C13 
to C17. This type of rearrangement on similar substrates has been observed on many 
occasions.88-93 After elimination of H2O and the development of a carbocation on C17, the 
adjacent methyl group, which stands almost perpendicular to the skeleton of the steroid, 
Chapter 2 
_______________________________ 
 
 82 
migrates to C17, generating a carbocation on C13. Subsequent elimination of H14 gives the 
product (110). Full assignment of the structure was necessary because the 13C NMR 
spectrum presented only twenty-four distinct peaks for twenty-five expected carbons. It 
was found that C2 and C6 have exactly the same chemical shift. High resolution mass 
spectroscopy confirmed the chemical composition of (110) to be C25H33OF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18: 1H NMR spectra of (99) (above) showing the presence of the ethylenic proton H16 at 
5.93 ppm. This signal has disappeared on the 1H NMR spectrum of (110). 
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The reactivity of the meta-fluorophenyl steroid (96) is noticeably different from 
that of the para-fluorophenyl steroid (108) and illustrates the significance of the fluorine 
position on reactivity. It seems according to these two examples that fluorine in the meta-
position destabilises the carbocation on C17 due to the inductive effect and promotes the 
rearrangement whereas in the para-position, fluorine stabilises the positive charge by the 
mesomeric effect and promotes the formation of the desired product. 
 
This early indication that electron-donating groups on the aromatic ring may favour 
the dehydration of the tertiary alcohol under acidic conditions prompted us to synthesise 
the para-methyl (112) and the para-methoxyl (114) derivatives. The para-methyl 
derivative of 17-PA  was synthesised in a two-step sequence by addition at RT of a 
solution of p-toluenelithium in Et2O to a solution of androsterone in THF followed by 
dehydration of the tertiary alcohol (111) with pTSA in DCM (Scheme 2.10).  
 
 
 
 
 
Scheme 2.10: Synthesis of the p-toluene analogue of 17-PA (112).  
Reagents and conditions: a) 4-bromotoluene, n-BuLi, Et2O, RT, 12 h, 43%; 
b) pTSA, DCM, RT, 2 days, 71%. 
 
 
The rearranged product was formed in less than 5 % conversion in this case and 
(3α,5α)-(17-p-toluene)androst-16-en-3-ol (112) was obtained as a colourless solid in a 71% 
yield. 
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The para-methoxyl analogue was prepared using the same sequence. It is 
interesting to note that the tertiary alcohol (113) could not be kept in solution and 
dehydrated rapidly. This is consistent with the donor ability of the methoxyl group. The 
dehydration step was therefore straightforward as a catalytic amount of pTSA with stirring 
at RT for 8 h was sufficient to isolate, after purification, the desired product (3α,5α)-17-(p-
methoxyphenyl)androst-16-en-3-ol (114) as a colourless solid in 90% yield. No side 
product was detected in this reaction (Scheme 2.11). 
 
 
 
 
 
Scheme 2.11: Synthesis of the p-methoxyl analogue of 17-PA (114).  
Reagents and conditions: a) 4-bromoanisole, n-BuLi, Et2O, RT, 12 h, 30%;  
b) pTSA, DCM, RT, 8 h, 90%. 
 
 
This two-step procedure is very convenient for the preparation of the p-methyl- and 
the p-methoxyl analogues of 17-PA (112) and (114) and is appreciably shorter than the 
published four-step route to 17-PA.  
However, in the situations where a significant amount of undesired product is 
formed during the acid-mediated dehydration step, the four-step procedure is 
recommended. This is because the desired product and the rearranged compound are not 
easily separable. Moreover, the desired product is generally isolated in low yields when the 
aromatic ring does not bear electron-donating substituents. 
The outcome of the dehydration of the tertiary alcohol under acidic conditions 
strongly depends on the nature and the position of the substituent on the aromatic ring. It is 
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tempting to correlate the amount of rearranged product to the Hammett parameter of the 
substituent (Table 2.3). 
 
Structure 
F
96
HO
 
89
HO
 
108
HO
F
 
111
HO
 
113
HO
OMe
 
% of 
rearranged 
product 
~75 30 15 ~5 0 
σ +0.34 0 +0.06 (or +0.15)94 -0.17 -0.29 
 
Table 2.3: Influence of the aromatic substituent on dehydration under acidic conditions. 
 
 
It seems clear from Table 2.3 that the more electron-donating the substituent, the 
less favoured is the rearranged product. It is also clear that such substituents promote 
elimination of H2O by stabilising the subsequent carbocation on C17. Elimination of H16 
results then in the formation of the conjugated olefin product (102). If the carbocation at 
C17 is destabilised by an electron-withdrawing substituent, it quickly rearranges by 
migration of the methyl group to a more stable carbocation on C13. This is then followed 
by elimination of H14 to form the rearranged product. 
Although the Hammett parameter of fluorine in the para-position is positive, it 
appears from Table 2.3 that it can stabilise the carbocation at C17 better than hydrogen. It is 
recognised by both theoretical and experimental observations that fluorine, despite being 
considered as an electron-withdrawing substituent has an ability to stabilise a positive 
charge at the para-position, because its pi-donor ability overcomes its σ-electron-
withdrawing effect.95-97 Conversely at the meta-position, only the σ-electron-withdrawing 
effect is observed. 
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At the end of this aspect of the study, a set of five compounds, bearing different 
substituents on the aromatic ring, was prepared. 
 
 
 
 
 
 
 
In order to add some structural diversity in this series of 17-PA analogues, it was 
decided to hydrogenate the C16-C17 double bond. The hydrogenation is face selective and 
the resulting saturated compound has the lipophilic aromatic group above the D ring of the 
steroid in a similar orientation to the acetate moiety in allopregnanolone (83). 
In this event, the para-methyl (112) and para-methoxyl (114) analogues of 17-PA 
were hydrogenated with palladium on carbon as a catalyst. This furnished the saturated 
compounds (115) and (116) in good yields and as single stereoisomers (Scheme 2.12). 
 
 
 
 
 
Scheme 2.12: Preparation of saturated 17-PA analogues. 
Reagents and conditions: a) Pd/C, H2 (1 atm), EtOAc, 91-93%. 
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The hydrogenation of each double bond is diastereoselective and the stereo-
chemistry at C17 was confirmed by NOESY experiments on (115), showing that the 
protons of the C18 methyl group are close to the aromatic protons and not on the same side 
as H17. 
 
The observation by Prof. Lambert that the steroid analogues of 17-PA were very 
poorly water-soluble, even at the µM concentrations required for biological assays spurred 
us on to synthesise more polar analogues. Organon Ltd is a company which has a lot of 
experience in the synthesis of steroids. They have developed water-soluble analogues of 
androsterone and allopregnanolone98, 99 and generously supplied us with 2β-(4-
morpholinyl)-3α-hydroxy-5α-androstan-17-one (117) as a starting material. The adjunction 
of a morphilino group at the 2-position generally improves the water solubility without 
altering the pharmacological profile of steroids, certainly in most cases. 
A solution of (117) in THF was treated at RT with a solution of p-toluenelithium in 
Et2O prepared by addition of p-bromotoluene and n-BuLi at RT. After work-up and 
purification, (118) was obtained as a white solid in 50% yield (Scheme 2.13).  
 
 
 
 
Scheme 2.13: Preparation of (118).  
Reagents and conditions: a) 4-Bromotoluene, n-BuLi, Et2O, RT, 12 h, 50%. 
 
 
The dehydration of diol (118) to generate the target unsaturated compound (119) 
was expected to proceed similarly to the non-morphilino series. It proved however to be 
much more difficult. Addition of pTSA to (118) did not produce any elimination even after 
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adding more than one equivalent and heating under reflux in DCM for 24 h. After 
screening various dehydration conditions, including the use of HCl in ether, trifluoroacetic 
acid, and bases such as DBU, it was found that the addition of trimethylsilyl chloride gave 
the best results. Thus, treating (118) in MeCN with five equivalents of TMSCl for an 
extended period gave 2β-(4-morpholinyl)-(3α,5α)-(17-p-toluene)androst-16-en-3-ol (119) 
as a white solid in 45% yield. The TMS-protected alcohol which probably forms at C3 is 
hydrolysed in situ by quenching the reaction with potassium carbonate allowing the free 
alcohol at C3 to be recovered. It is not clear why TMSCl is the best reagent in this case 
(Scheme 2.14). The modest yield of the reaction is due to the difficulty in purifying the 
desired product and to the probable formation of the rearranged compound (120) in ~30% 
conversion, according to NMR analysis of the crude reaction mixture. (120) was not 
isolated. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.14: Synthesis of (119). Reagents and conditions: a) 4-Bromotoluene, n-BuLi, Et2O, RT, 
12 h, 50%; b) TMSCl, MeCN, 50 °C, 3 days, K2CO3, 45%. 
 
 
The para-methoxyl analogue (122) was prepared in a similar manner 
(Scheme 2.15). The dehydration of tertiary alcohol (121) was more straightforward here 
than in the previous case although (121) was markedly more stable under acidic conditions 
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than the non-morphilino compound (113). It is probably the nitrogen of the morphilino 
group that protonates first, but this does not fully explain why the tertiary alcohol on the 
right-hand side of the molecule does not dehydrate so readily under acidic conditions. It 
was found that addition of pTSA failed to form (122) and forcing conditions resulted only 
in decomposition of the starting material. 
 
 
 
 
 
Scheme 2.15: Synthesis of (122). Reagents and conditions: a) 4-Bromoanisole, 
n-BuLi, Et2O, RT, 18 h, 37%; b) TMSCl, DCM, RT, 24 h, K2CO3, 62%. 
 
 
The target product 2β-(4-morpholinyl)-(3α,5α)-17-(p-methoxyphenyl)androst-16-
en-3-ol (122) was finally obtained in 62% yield by addition of TMSCl and stirring at RT 
for 24 h. The compound resulting from the Wagner-Meerwein rearrangement, as well as 
other by-products were detected in the crude mixture but not purified.  
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2.4.3 Biological results 
 
A total of nine steroids were prepared in this project. They were all given to our 
collaborators at the School of Neurobiology at Ninewells Hospital in Dundee to be tested 
on recombinant GABAA receptors expressed in Xenopus laevis oocytes. 
 
 
 
 
 
 
 
The inhibitory action of 17-PA (87) against 5α- and 5β-steroids was assessed and 
found to be in accordance with the results published by Mennerick et al.80  Preliminary 
results suggested that para substitution (F, CH3 and OMe) had a significant impact on the 
biological activity, but a definitive assessment was not forthcoming due mainly to poor 
solubility.  
The discovery of 17-PA was considered at the time of its publication as an 
important development in the understanding of the steroid modulation of the GABA-
response. 17-PA remains today a unique pharmaceutical tool to block the action of 
anaesthetic neurosteroids on GABAA receptors but the more recent publication by M. 
Hosie and T. G. Smart79 has somewhat reduced the interest for 17-PA since the existence 
and the localisation of two discrete binding sites have now been established.  
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The future of 17-PA and 17-PA analogues lies in the fact that they remain the only 
selective steroid antagonists identified. However, 17-PA is not an ideal compound to work 
with: high concentration (10 µM) is required to obtain a maximum of around 40% 
inhibition of the potentiating effect induced by allopregnanolone at 300 nM. This shows 
that 17-PA is not a potent antagonist and its structure should be taken only as a lead for the 
development of more efficient antagonists.  Improving the water-solubility of 17-PA may 
reduce the concentration needed and modifying its structure at C17 may result in better 
inhibition. 
The low water-solubility of 17-PA undeniably constitutes its major drawback. It is 
hoped that the morphilino-analogues (119) and (122) will exhibit better activities. Despite 
the morphilino group, we found that (122) was insoluble at 10 µM in ethanol and addition 
of DMSO was necessary to solubilise the steroid. Neurobiologists also observed that 17-
PA in DMSO partially precipitates during the biological assays once added into water. 
Increasing the ionic strength of the solution with a suitable buffer or using surfactants or 
complexing agents such as cyclodextrins100, 101 may hold the compound in solution. 
However optimisation of the solubility to improve the assay by such methods was not 
explored. 
 
More studies are required to define the role of 17-PA in blocking respectively the 
activation (i.e. direct gating) and the potentiation effects of neurosteroids. The localisation 
of the two steroid binding sites should inspire neurobiologists to design new experiments 
with 17-PA analogues. It was found in 2004 that 17-PA was more effective at blocking the 
activation effects of allopregnanolone than the potentiation effects, but this led to the 
wrong suggestion that allopregnanolone may act at a single binding site.80  
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2.4.4 Conclusions  
 
The preparation of nine 17-PA analogues bearing different substituents on the 
aromatic ring was achieved in this project. Some compounds were prepared following the 
four-step synthesis published by Covey et al.80 Some others were prepared using a two-
step sequence which proved convenient with electron donating substituents on the aromatic 
ring. However, the formation of a rearranged product was also observed. This work is a 
first step towards the design of more potent neurosteroid antagonists. Evaluating their 
biological activities and possibly docking them into the modelled steroid binding sites 
developed by M. Hosie and T. G. Smart79 should give useful information for the design of 
a second generation of 17-PA analogues. 
17-PA (87) and 2β-(4-morpholinyl)-(3α,5α)-17-(p-methoxyphenyl)androst-16-en-
3-ol (122) were re-crystallised from DCM and n-hexane and the colourless needles 
obtained were suitable for X-ray crystallography. Their crystal structures, which were 
solved by Prof. Alexandra Slawin (St Andrews), could be used later for the design of other 
17-PA analogues (Figure 2.19). 
 
  87 
 
 
 
 
  122 
Figure 2.19: X-ray structures of 17-PA (87) and the more water-soluble 17-PA analogue (122) 
bearing a morphilino group at the 2-position and a methoxy group at the para-position on the 
aromatic ring.  
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Chapter 3: Synthesis and evaluation of 3-
fluoro-GABA enantiomers. 
 
3.1 Introduction 
 
 
This chapter describes the enantioselective synthesis and analysis of the 
enantiomers of 3-fluoro-γ-aminobutyric acid (123) and (124). 
 
 
 
 
The presence of fluorine at the 3-position in (123) and (124) is expected to 
influence the conformational populations of the molecules, particularly with respect to C-F 
and C-N+ bonds orientations. A strong gauche effect is observed in protonated β-
fluoroamines, where the ammonium group prefers to align gauche to the C-F bond. This 
situation exists in 3-F-GABA and gauche conformations are estimated to be 4-5 kcal.mol-1 
lower in energy than the conformations where the C-N+ bond is anti to the C-F bond. With 
such an energy difference, the anti conformations will hardly be populated in solution and 
we can assume that either (123) or (124) will be a poor mimic of GABA if the binding 
conformations to a GABA receptor or enzyme required the C-F and C-N+ bonds to adopt 
an anti relationship. Thus, the introduction of the C-F bond can be viewed as a tool to 
influence the conformation of GABA and explore the conformational requirements for 
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GABA binding to a target protein. The torsion angle τN of 3-F-GABA is limited in this 
case to only two values for each enantiomer, corresponding to the two most stable 
conformations: -60° and +180° for (3R)-F-GABA and +60° and +180° for (3S)-F-GABA. 
It follows that the two enantiomers (123) and (124) are likely to display different biological 
activities on GABA receptors as they can adopt distinctive conformations (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Newman projections along the F-C-C-N+ bond showing the three staggered 
conformations for both enantiomers (3R)-F-GABA and (3S)-F-GABA. The conformations 
highlighted in boxes are predicted to be the most populated in solution as they have C-F/C-N+ 
gauche relationships. 
 
 
Figure 3.1 shows the different staggered conformations A/A’, B/B’ and C/C’ with 
rotation around the C-C-C-N+ bond and for which τN has the values -60°, +180° and +60° 
respectively. Both enantiomers (3R)- and (3S)-F-GABA can access the B/B’ conformation 
in which the fluorine atom and the ammonium group are gauche. As the conformations 
with the fluorine anti to the amino group are expected not to be significantly populated in 
solution, conformation C is not accessible to (3R)-F-GABA and conformation A’ is not 
accessible to (3S)-F-GABA. 
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It follows that a comparison of the relative biological activities of (3R)- and (3S)-F-
GABA on GABA binding sites should reveal the active conformations of GABA. For 
example, if the biological activity of (3R)- and (3S)-F-GABA on a GABA receptor were 
found to be similar, this would suggest that the active conformations have τN values close 
to +180° (conformer B/B’). Conversely, if (3R)-F-GABA was significantly more active 
than its enantiomer, we could conclude that the most active conformation at this GABA 
receptor is close to τN = -60° (conformer A/A’). If (3S)-F-GABA was more active than its 
enantiomer, then conformer C/C’ would be more relevant. Experiments can be conducted 
on GABAA or GABAB receptors, GABA transporters and the metabolising enzyme GABA 
aminotransferase. The working hypothesis implies that GABA recognition sites do not 
distinguish between conformations B and B’ which differ only by the orientation of the 
fluorine atom. This appears a reasonable assumption at the outset as fluorine is a good 
hydrogen mimic introducing only a minor steric perturbation. 
 
The 3-F-GABA enantiomers have never previously been synthesised or evaluated 
in any biological system. It was considered that such an evaluation should furnish useful 
additional information on active GABA conformations. Such information can be compared 
with the accumulated data from previous experiments using constrained GABA analogues 
(see Tables 2.1 and 2.2). 
Additionally, the synthesis of 3-F-GABA enantiomers was motivated to validate 
the concept of using the C-F bond as a new tool to influence the conformational mobility 
of biologically active amines.   
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3.2 Previous syntheses of 3-Fluoro-GABA 
 
3.2.1 The dehydrofluorination approach 
 
Prior to this study, only racemic 3-fluoro-γ-aminobutyric acid (125) has been 
reported. The synthesis, published in 1979 by J. Kollonitsch et al.1 involved fluorination of 
DL-3-hydroxy-γ-aminobutyric acid (126) in anhydrous liquid HF with SF4 at -78 °C. After 
ion-exchange purification and re-crystallisation from EtOH, racemic 3-F-GABA (125) was 
obtained in 50% yield (Scheme 3.1). The method is rather expeditious as the target 
molecule is prepared in a single step and interestingly, no protection of the amine or the 
carboxylic acid is required. Unfortunately, it makes use of quite hazardous chemicals 
which cannot be readily manipulated in a standard research laboratory. Moreover, this 
method is not applicable to the preparation of enantiopure 3-F-GABA from the enantiopure 
precursor alcohol, as such fluorodehydroxylation reactions using SF4 are known to proceed 
via both SN1 and SN2 mechanisms. Therefore, the reaction of enantiopure 3-hydroxy-
GABA with SF4 would probably not result in a complete inversion of stereochemistry.  
 
 
 
 
Scheme 3.1: Preparation of 3-F-GABA using the SF4 methodology.1  
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In order to overcome the limitations of the SF4 methodology, milder fluorinating 
agents such as diethylaminesulfur trifluoride (DAST) (127) and the thermally more stable 
bis(2-methoxyethyl)aminosulfur trifluoride (DeoxofluorTM) (128) have been developed. 
The mechanism for the fluorination of alcohols using such fluorinating agents proceeds via 
the formation of an alkoxydialkylaminosulfur difluoride intermediate (129), followed by 
the nucleophilic attack of the fluoride ion in a predominant SN2 mechanism (Scheme 3.2). 
 
 
 
 
 
Scheme 3.2: Schematic mechanism of the deoxofluorination of an alcohol with a 
dialkylaminesulfur trifluoride fluorinating agent. 
 
 
 
Deoxofluorination is a practical and widely used method for the introduction of a 
fluorine atom into an organic molecule. In retrosynthetic analyses, the nucleophilic 
replacement of oxygen with fluorine is an obvious option, but it is not always the most 
successful as illustrated in the following pages. Indeed, due to the very poor 
nucleophilicity and the high basicity of fluoride ion, deoxofluorination is often 
accompanied by loss of stereochemistry, elimination or rearrangements resulting from 
neighbouring group participation.  
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Previously in the St Andrews labs (R. Gilmour, 2002),2 a first retrosynthetic 
approach towards the synthesis of enantiopure 3-F-GABA was explored. The 
retrosynthetic analysis in Scheme 3.3 shows that 3-F-GABA is accessible by hydrolysis of 
4-fluoropyrrolidin-2-one (130) which can itself be obtained from commercially available 
4-hydroxypyrrolidin-2-one (131) by deoxofluorination. This constituted a very direct 
strategy for the preparation of 3-F-GABA. Unfortunately, fluorination of (131) with DAST 
under a variety of conditions failed to produce (130).2 Mesylation of (131) followed by 
treatment with tetrabutylammonium fluoride (TBAF) was also unsuccessful. 
 
 
 
 
Scheme 3.3: First retrosynthetic analysis to 3-F-GABA.2 
 
 
An alternative retrosynthesis was developed, starting from (3S)-hydroxy-γ-
aminobutyric acid (76) and using a classical protection-deprotection sequence as shown in 
Scheme 3.4. The most problematic step in this synthesis was the fluorination of (132) 
which afforded an inseparable 1:1 mixture of (133) and of an elimination product. 
 
 
  
Scheme 3.4: Alternative retrosynthesis starting from 3-hydroxy-GABA.2 
 
 
Attempts to transform the elimination product into a more polar constituent by 
Sharpless dihydroxylation met with some success but demonstrated the impracticality of 
this synthesis as a reasonable preparative method.2 Other protecting groups were also 
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explored but without significant success. Again, mesylation of (132) followed by reaction 
with TBAF failed to produce the desired product. In retrospect, conversion of the amine 
into a dimethoxycarbamate or use of Deoxofluor may have reduced the production of the 
elimination product but this was not explored.  
 
3.2.2 The Gabriel synthesis approach 
 
Due to the lack of success of the direct deoxofluorination methods described above, 
an approach was taken to introduce the fluorine atom at an early stage of the synthesis and 
to construct 3-F-GABA from a simple building block. Scheme 3.5 shows the eight-step 
route of racemic 3-F-GABA developed by Dr. F. Chorki in St Andrews.3 This route was 
successful but was inefficient and gave only 37 mgs of racemic 3-F-GABA (126) in 3% 
overall yield starting from 3-buten-1-ol (134).  
 
 
 
 
 
 
 
 
 
 
Scheme 3.5: Synthesis of racemic 3-F-GABA using the Gabriel synthesis approach.3 Reagents and 
conditions: a) NaH, BnBr, THF, 96%; b) mCPBA, DCM, 95%; c) HF-Pyridine, DCM, 59%; 
d) MsCl, Et3N, DMAP, THF, 64%; e) Potassium phthalimide, DMF, reflux, 75%; f) H2, P=40 bars, 
Pd(OH)2/C, 40%; g) NaIO4, RuCl3.xH2O, CCl4/MeCN/H2O, 65%; h) H2NNH2.H2O, EtOH, 44%. 
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The key step in the above synthesis is the hydrogen fluoride mediated ring opening 
of epoxide (136) which gave a 3:1 mixture of regioisomers (137) and (138). Fortunately, 
they could be separated by column chromatography.  
 
With some of the elements of this route in place, a strategy evolved to address an 
enantioselective synthesis of (3R)-F-GABA (Scheme 3.6). Starting from commercially 
available (S)-1,2,4-butanetriol, the chiral epoxide (145) was obtained in five steps and in 
50% overall yield. The subsequent steps were similar to those already developed for the 
racemic synthesis. A small amount of (123) was prepared but it was not pure and its 
enantiopurity was not evaluated. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.6: Enantioselective preparation of (3R)-F-GABA using the Gabriel synthesis approach. 
Reagents and conditions: a) Acetone, pTsOH (cat), RT, 24 h, 95%; b) NaH, BnBr, THF, RT, 24 h, 
92%; c) AcOH/H2O, 50° C, 1 h, 88%; d) TsCl, Pyridine, RT, 7 h, 76%; e) Triton B, Et2O, RT, 
85%; f) HF-Pyridine, DCM, 47%; g) MsCl, Pyridine, DMAP, THF, 70%; h) Potassium 
phthalimide, DMF, reflux, 65%; i) H2, P=40 bars, Pd(OH)2/C, 50%; j) NaIO4, RuCl3.xH2O, 
CCl4/MeCN/H2O, 60%; k) H2NNH2.H2O, EtOH. 
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In addition to the large number of steps and the poor overall yield, this synthesis 
presented two additional problems. The first one is the opening of the enantiomerically 
pure epoxide (145) with HF which can result in some cases in a significant loss of 
stereochemistry.4 The second problem is the cleavage of the phthalimide group with 
hydrazine in the final step. A long reaction time was required to achieve an acceptable 
conversion but this also promoted the formation of a by-product by β-elimination. More 
problematic was the presence of another zwitterionic amino acid by-product which could 
not be separated from 3-F-GABA. This by-product was identical spectroscopically to 
GABA and could have formed by reduction of the β-elimination product with hydrazine. 
Reduction of unsaturated compounds with hydrazine in the presence of oxygen has been 
reported.5 The nucleophilic substitution of fluorine by hydrazine has also been 
demonstrated in 1997 by M. Bols.6  
Therefore, it appears from this work that, due to the complications occurring during 
its hydrolysis with hydrazine, phthalimide is not a suitable protecting group for the 
synthesis of such β-fluoroamines. 
 
The apparent simplicity of 3-F-GABA as a target molecule and the unsuccessful 
efforts experienced in its synthesis, emphasize the difficulties and the frustrations which 
often come with the synthesis of fluorinated organic molecules.  The recognition that a 
reaction first published in 1982 could be used for the synthesis of 3-F-GABA in an 
enantioselective manner gave a new impulse to this project.  
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3.3 Amino acids as precursors of 3-Fluoro-GABA 
3.3.1 The serine approach 
 
A. Shanzer and L. Somekh observed in 1982 that treatment of N,N-dibenzyl-L-
serine benzyl ester (152) with DAST provided N,N-dibenzyl-α-fluoro-β-alanine benzyl 
ester (153) in 90% yield and in an enantiomerically pure form.7 The proposed mechanism 
for this transformation via an aziridinium intermediate (154) is presented in Scheme 3.7. 
 
 
 
 
 
 
 
Scheme 3.7: Synthesis of (2R)-3-(dibenzylamino)-2-fluoropropanoic benzyl ester (153) from (2S)-
dibenzylamino-3-hydroxypropanoic acid benzyl ester (152) via formation of the aziridinium (154).7 
 
 
This reaction has been reproduced several times8-11 in the last twenty years and the 
product has been used for the building of chemical probes10, 11 or for studies of β-peptide 
conformations.8, 9 The formation of aziridinium (154) as an intermediate in the above 
reaction has been confirmed and can be explained by the fact that intramolecular reactions 
are faster than intermolecular reactions. It also shows that the dibenzyl-protected amine is 
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more nucleophilic than fluoride anion. The opening of aziridinium (154) by fluoride is both 
regio- and enantio-selective. The stereointegrity of this reaction7, 11 makes the DAST-
mediated rearrangement of β-hydroxylamines a useful method for the synthesis of 
enantiopure β-fluoroamines.  
 
The applicability of this reaction for the enantioselective synthesis of 3-F-GABA is 
evident. N,N-Dibenzyl-α-fluoro-β-alanine benzyl ester (153) emerges as a precursor to 
(3S)-F-GABA as indicated in the retrosynthetic analysis shown below (Scheme 3.8). 
 
 
 
 
 
 
 
Scheme 3.8: Retrosynthetic analysis starting from L-serine. 
 
 
(3S)- And (3R)-F-GABA are according to the proposed retrosynthesis, accessible 
from L- and D-serine respectively. The key step for this approach is the homologation of 
the α-fluoro-ester (153). Typically, carboxylic acids can be homologated smoothly using 
the Arndt-Eistert procedure, a convenient and widely used method which converts simple 
α-amino acids into β-amino acids in only two steps.12, 13 
 
Accordingly, L-serine (155) was tribenzylated using standard procedures8, 14 to give 
(2S)-(dibenzylamino)-3-hydroxypropionic acid benzyl ester (152) in 51% yield. This 
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compound was then dissolved in THF and reacted with DAST, affording (153) in 85% 
yield. The reaction proceeded very cleanly and the product had spectroscopic data identical 
to those reported in the literature.14 Mild alkaline hydrolysis of the benzyl ester with LiOH 
gave the carboxylic acid (156) in 74% yield. It is noteworthy that mild alkaline hydrolyses 
of α-fluoro-esters have been reported to proceed without loss of enantiopurity at the 
stereogenic centre.10, 15 The free acid was then converted to the acyl chloride with SOCl2 
and was directly added into an ethereal solution of diazomethane to generate diazoketone 
(157) (Scheme 3.9). 
 
 
 
 
 
  
Scheme 3.9: Attempted synthesis of 4-dibenzylamino-(3S)-fluorobutyric acid methyl ester (158) 
via Arndt-Eistert homologation of acid (156). Reagents and conditions: a) BnBr, K2CO3, NaOH, 
H2O, 100 °C, 1 h, 51%; b) DAST, THF, 0 °C, 85%; c) LiOH 0.5 N, THF, RT, 18 h, 74%; d) SOCl2, 
DCM, reflux, 2 h; e) CH2N2, THF, RT, 14 h. 
 
 
 
Diazomethane was prepared from Diazald® (Scheme 3.10) using published 
procedures.16, 17 
 
 
 
 
Scheme 3.10: Schematic mechanism of the preparation of diazomethane (159) from 
Diazald® (160). 
Chapter 3 
_______________________________ 
 
 110 
 
Only a few α-fluorodiazoketones have been reported in the literature18-20 and most 
of these have been described as reasonably stable. In our case, (3R)-1-diazo-4-
(dibenzylamino)-3-fluorobutan-2-one (157) was not purified but was characterised by full 
NMR analysis and by IR analysis which showed the typical absorption of the N=N bond at 
2112 cm-1. However, diazoketone (157) was contaminated with a significant amount of 
methyl ester (161), arising from direct esterification of the carboxylic acid (156) with 
diazomethane. This is probably due to incomplete conversion to the acyl chloride or 
competing hydrolysis. The ratio of the mixture (157)/(161) was determined by NMR to be 
around 65/35. 
 
 
 
 
Scheme 3.11: Preparation of diazoketone (157) and methyl ester (161) from carboxylic  
acid (156). Reagents and conditions: a) SOCl2, DCM, reflux, 2 h; b) CH2N2, THF, RT, 14 h. 
 
 
 
 
 
 
  
 
 
 
 
Figure 3.2: DEPT NMR spectrum (CDCl3, 75 MHz) of fluorinated diazoketone (157) contaminated 
with methyl ester (161). 
Chapter 3 
_______________________________ 
 
 111 
 
 
 
 
 
 
 
 
 
Figure 3.3: 19F NMR spectrum of the diazoketone (above) and its simulated spectrum (below) from 
which JH-F couplings are extracted. 
 
 
The key step for the Arndt-Eistert homologation procedure is the Wolff 
rearrangement21 from the diazoketone which forms a ketene intermediate, which is 
subsequently hydrolysed to the homologated ester. More than one hundred years after its 
discovery, questions remain about the mechanism of this rearrangement, for example 
whether the loss of N2 is concerted or not, with the migration of the alkyl group. It seems 
than both pathways co-exist although it has been suggested that diazoketones adopt the Z 
conformation in the Wolff rearrangement. In this conformation, the migrating and leaving 
groups are antiperiplanar, which indicates -at least- a partially concerted mechanism 
(Scheme 3.12). The migratory aptitude of the R group has also been studied and it appears 
that phenyl groups migrate faster than methyl groups.  
 
 
 
 
Scheme 3.12: Schematic mechanism of the Wolff rearrangement. 
JH-F Hz 
2JH-F 50.3 
3JH-F 30.5 
3JH-F 23.0 
4JH-F 4.0 
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Perfluorinated alkyl groups display a poor ability to migrate in the Wolff 
rearrangement22, 23 and E. R. Larsen et al. have shown that perfluorinated acids failed to 
undergo the Arndt-Eistert reaction in a normal manner. They concluded after a series of 
experiments that at least two methylene groups are required between the carbonyl and the 
perfluorinated chain for the Wolff rearrangement to proceed conveniently.24 Interestingly, 
trifluoroacetic acid is conveniently homologated using standard conditions,24-26 and it is not 
clear why this should be so. 
 
It was exciting to test the feasibility of the Wolff rearrangement on α-
fluorodiazoketone (157). Successful homologation of (156) to β-fluoroacid (158) using the 
Arndt-Eistert procedure, would open up a new route to this class of compounds for which 
very few methods have been developed. In the event, (157) failed to undergo the Wolff 
rearrangement in our hands. Crude diazoketone (157) was dissolved in various solvents 
(BnOH, THF/water, DCM/MeOH), the solution was protected from the light and the 
catalyst silver benzoate C7H5O2Ag was added to the mixture at 10-20 mole %. Sonication, 
heating or addition of Lewis acids also failed to induce the desired rearrangement. It is not 
clear why the homologation of this α-fluorodiazoketone did not proceed in the expected 
way but two explanations can be advanced: firstly, the presence of fluorine could reduce 
the migrating ability of the alkyl group. Secondly, if ketene (162) does form, its hydrolysis 
could result in loss of fluoride (Scheme 3.13). The later explanation appears more probable 
as unsaturated compounds were detected in the crude mixture after the Wolff 
rearrangement but it was not possible to isolate any homologated product from the 
reactions. 
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Scheme 3.13: Putative mechanism of the Wolff rearrangement on α-fluorodiazoketone (157). 
 
 
At this stage, it is not possible to give a definitive answer about the aptitude of α-
fluorodiazoketones to undergo the Wolff rearrangement and further experiments perhaps 
merit investigations. However, the lack of success during this work and the lack of 
precedent in the literature suggest that α-fluorodiazoketones are unsuitable substrates for 
the Arndt-Eistert reaction. This led us to reconsider our approach to the synthesis of 3-F-
GABA.  
As homologation appeared not to be compatible with an α-fluorinated substrate, the 
order of the fluorination and homologation steps presented in Scheme 3.9 was inverted. 
Accordingly, the β-homoserine derivative (164) now emerges as the key compound in the 
new retroanalysis (Scheme 3.14). 
 
 
 
 
 
 
 
 
Scheme 3.14: Revised retrosynthetic analysis.  
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3.3.2 The aspartic acid approach 
 
Fluorination via the aziridinium intermediate (154) as shown in scheme 3.7 is 
obviously not limited to serine derivatives and can be applied to any N,N-dibenzyl-
protected β-amino-alcohol. In fact, similar rearrangements have been observed with 
various N,N-dimethyl-β-amino-alcohols27 and N-piperidine-β-alcohols,28 which extends the 
scope of this reaction. Thus, fluorination of β-homoserine derivative (164) with DAST or 
Deoxofluor is expected to behave similarly to that experienced previously with benzylated 
serine (152), although the regioselectivity of the opening of the aziridinium might be less 
specific in this case. 
 
 
 
β-Homoserine (165) is a well known compound for which different syntheses have 
been reported. However, homologation procedures such as Arndt-Eistert or Kowalski29 
procedures are not attractive in this case because scale up of these procedures is 
impractical and expensive. An efficient method giving access to (164) or its enantiomer 
(166), avoiding tedious protection-deprotection manipulations was needed. It rapidly 
emerged that aspartic acid, which contains four carbons like GABA, was an ideal starting 
material for the synthesis of 3-F-GABA. Scheme 3.15 shows the key intermediates of the 
retrosynthetic analysis starting from aspartic acid (167). 
165
O
OH
HO
NH2
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Scheme 3.15: Retrosynthetic analysis starting from L-aspartic acid. 
 
 
The synthesis of β-aminoalcohol (166) from L-aspartic acid (167) requires selective 
reduction of the α-carbonyl in the presence of the β-carbonyl group of the side chain. This 
has already been reported many times.30-32 Typically, aspartic acid is selectively esterified, 
Boc-protected and then reduced with sodium borohydride NaBH4 or borane BH3 
(Scheme 3.16). 
 
 
 
Scheme 3.16: Example of a preparation of (169).30, 33, 34  
 
The fluorination step with DAST requires a N,N-dibenzyl-protected nitrogen and 
can not be performed on a Boc-protected amino acid such as (169). It was therefore 
decided, in order to reduce the number of synthetic steps and protecting group 
manipulations to attempt the reduction reaction on a dibenzyl-protected amino acid. 
Accordingly, a new route was designed and it started with the esterification of aspartic 
acid. 
The selective β-esterification of aspartic acid was straightforward, using the 
procedure published in the 1950s by D. Coleman.33 Addition of thionyl chloride to a 
methanolic solution of aspartic acid furnished, after re-crystallisation from EtOH/Et2O,    
β-methyl aspartate hydrochloride (170) in 70% yield. The selectivity of the reaction 
originates from the formation of the anhydride (171) which is opened by methanol in a β/α 
ratio higher than eight (Scheme 3.17).35 
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Scheme 3.17: Preparation of β-methyl aspartate hydrochloride (170). 
 
 
The dibenzyl protection of the amino group was achieved by reductive amination, a 
method which does not affect the free α-carbonyl. The reaction proceeded smoothly, by 
addition of benzaldehyde and sodium cyanoborohydride to a solution of amino acid (170) 
in methanol. NaCNBH3 reduces imines but is not reactive enough to reduce esters or 
carboxylic acids. In the event, (S)-N,N-dibenzylaspartic acid β-methyl ester (172) was 
isolated in 64% yield (Scheme 3.18). 
 
 
 
 
Scheme 3.18: Synthesis of (172) from L-aspartic acid via reductive amination. Reagents and 
conditions: a) SOCl2, MeOH, RT, 62%; b) benzaldehyde, NaCNBH3, MeOH, 64%. 
 
 
Compound (172) now bears differentiated carboxylate groups which were 
anticipated to react differently in the presence of a reducing agent such as borane BH3 
which is known to efficiently reduce carboxylic acids but not esters.36  
However, such experiments with BH3 failed. No reaction was observed after 
addition of one or two equivalents of BH3, at room temperature or even after reflux in 
THF. The addition of three or more equivalents of BH3, and heating under reflux, resulted 
in a complex mixture of non-reacted, partially reduced and doubly-reduced products, 
showing that the reduction of (172) with borane is not selective. More forcing conditions 
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produced the doubly-reduced chiral diol (173) which was isolated in 75% yield (Scheme 
3.19). 
 
 
Scheme 3.19: Reduction of (172) with borane is not selective. 
 
 
This unsuccessful result illustrated that dibenzyl-protection of the amine renders the 
reduction of the α-carboxylic acid more difficult. The conclusion is that β-homoserine is 
more conveniently synthesised by the method showed on Scheme 3.16 which involves 
protection of the nitrogen as a carbamate and then reduction with NaBH4. 
 
Examination of the literature revealed that compound (166) is unstable in solution 
and prone to lactonisation37, 38 (Scheme 3.20). In fact, it has been reported to lactonise 
quantitatively after a few days in the refrigerator.37 Although the ring open form can be 
recovered by acidic treatment, this behaviour mitigates against (166) as a good substrate 
for the fluorination reaction. 
 
 
 
Scheme 3.20: Lactonisation of (166). 
 
 
Therefore, investigations of the route using aspartic acid as a starting material were 
discontinued at this point. Once again, a new approach was required and again, it was 
decided to begin the synthesis of 3-F-GABA from another natural amino acid. This time, 
phenylalanine (175) was chosen. 
 
O
OH
NH2
175
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3.4 The phenylalanine route 
 
Amino acids are potentially practical starting materials for the synthesis of 
enantiopure β-fluoroamines as illustrated by the sequence in Scheme 3.21. They are 
conveniently reduced to β-hydroxylamines and have the potential to be transformed into β-
fluoroamines by fluorination with DAST or Deoxofluor.  
 
 
 
Scheme 3.21: Schematic synthesis of enantiopure β-fluoroamines from α-amino acids. 
 
 
In the context of 3-F-GABA synthesis, substituent R could clearly be a carboxylic 
acid but competing lactonisation occurs in this case as discussed above. Interestingly, 
aromatic rings can be used as masked carboxylic acid functionalities where the carboxylic 
acid is released by ozonolysis, potassium permanganate39 or ruthenium-catalysed 
oxidations. M. Schüler in the St Andrews lab, recently demonstrated the applicability of 
this approach on fluorinated substrates by converting 1,2-difluoro-diphenylethane (176) 
into 2,3-difluorosuccinic acid (177) by ozonolysis.40, 41 Ruthenium-catalysed oxidations of 
aromatic rings can also by conducted with fluorinated substrates (Scheme 3.22).42-46 
 
 
 
 
 
Scheme 3.22: Examples of ozonolysis (above) and ruthenium-catalysed oxidations (below) on 
fluorinated substrates.41, 44 
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The envisaged retrosynthetic analysis starting from L-phenylalanine (175) is 
outlined in Scheme 3.23. This synthesis contains two important steps which involve 
fluorination of (178) and then oxidation of the phenyl ring. Prior to the oxidation step, it is 
required to convert the dibenzyl protecting group of (179) into a group compatible with 
oxidation conditions. 
 
 
 
 
 
 
 
Scheme 3.23: Retrosynthetic analysis starting from L-phenylalanine. 
 
 
Preparation of amino alcohol (178) was straightforward and was achieved using 
published procedures.47-49 Accordingly, L-phenylalanine was perbenzylated using benzyl 
bromide and K2CO3 in EtOH. This reaction was performed on a large scale and the crude 
product obtained after work-up appeared clean enough to be taken through directly for the 
further step. However, an analytical sample of (2S)-(dibenzylamino)-3-phenylpropanoic 
acid benzyl ester (180) was obtained after purification. Reduction of (180) was achieved 
with LiAlH4 in THF at 0 °C. The excess of LiAlH4 was quenched by the careful addition of 
water. After work-up and purification, (2S)-(dibenzylamino)-3-phenylpropan-1-ol (178) 
was obtained in 85% yield over two steps as a colourless solid (Scheme 3.24).  
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Scheme 3.24: Preparation of (2S)-(dibenzylamino)-3-phenylpropan-1-ol (178) from L-
phenylalanine.47-49 Reagents and conditions: a) BnBr, K2CO3, EtOH, 70 °C, 3 days; b) LiAlH4, 
THF, 0 °C, 2 h, 85%. 
 
 
The (R)-enantiomer (183) was prepared in a similar manner to the (S)-enantiomer 
from D-phenylalanine methyl ester hydrochloride (181) (Scheme 3.25).  
 
 
 
 
Scheme 3.25: Preparation of (2R)-(dibenzylamino)-3-phenylpropan-1-ol (183) from D-
phenylalanine methyl ester hydrochloride. Reagents and conditions: a) BnBr, K2CO3, MeCN, 
80 °C, 16 h, 79%; b) LiAlH4, THF, 0 °C, 2 h, 93%. 
 
 
Fluorination of (178) with Deoxofluor was reported in 2002 to give the non-
rearranged product (2S)-N,N-dibenzyl-1-fluoro-3-phenylpropan-2-amine (184) in 78% 
isolated yield.50 However, in 2004, the reaction was reported to give a mixture of (179) and 
(184) in a 4:1 ratio (Scheme 3.26) favouring the rearranged product.51 The later publication 
was an encouraging observation for our synthesis of 3-F-GABA. 
 
 
 
 
78% yield50 
          71% yield51           /      15% yield51 
 
Scheme 3.26: Fluorination of (178) as reported by J. M. Shreeve et al.50, 51 
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The fluorination of N,N-dibenzyl-β-amino alcohols is reported to be concentration-
dependent, with a higher concentration of Deoxofluor benefiting the formation of the non-
rearranged product, possibly by direct substitution.51 It was therefore decided to perform 
the fluorination of (178) under more dilute conditions. 
Accordingly, 0.6 mM solution of Deoxofluor in DCM was added dropwise at          
-10 °C to a 0.1 mM solution of (178) in DCM. The reaction mixture was allowed to warm 
slowly to room temperature and was stirred for 15 h. After work-up and purification by 
flash chromatography, the desired product (179) was obtained as a colourless oil in 75% 
yield and the isomer (184) isolated in ~12% yield. The dilute reaction conditions appear to 
favour the intramolecular reaction and the formation of the aziridinium ring (185). 
Consequently, the formation of (184) results most probably from non-regioselective 
opening of aziridinium (185) by fluoride (Scheme 3.27). 
 
 
 
 
Scheme 3.27: Proposed mechanism for the formation of (179) and (184).  
Reagents and conditions: Deoxofluor, DCM, -10 °C, 75% (179). 
 
 
The influence of solvent and temperature on the regioselectivity of aziridinium 
ring-opening was found to be very limited. DCM was the most convenient solvent for this 
reaction, providing a high ratio (179)/(184) (Table 3.3). Carrying out the reaction at room 
temperature, -10 °C or -78 °C had no significant impact on the ratio (179)/(184). Also, 
DAST and Deoxofluor gave very similar results. This series of experiments indicated that 
the regioselectivity of the reaction could not be easily improved but this was not essential 
as (2R)-N,N-dibenzyl-2-fluoro-3-phenylpropan-1-amine (179) could be isolated readily and 
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in good isolated yield (75% yield). The enantiomer (2S)-N,N-dibenzyl-2-fluoro-3-
phenylpropan-1-amine (186) was obtained similarly in 76% yield from (183). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1: Ratio 179/184 of the fluorination reaction in various solvents.  
Ratio was measured directly by 19F NMR analysis. 
 
 
The enantioselectivity of the fluorination reaction with substrate (178) was not 
previously reported in the literature and although this type of rearrangement was found to 
be enantioselective on the serine derivative (152), possible involvement of a phenonium 
anion41 or a SN1 pathway had the potential to reduce the enantiopurity. Also, the αD values 
of enantiomers (179) and (186) were found to be very low ([α]20D +1.1 and -1.0 
respectively) so that enantiopurity could not be determined by measurement of the optical 
activity. It was therefore essential to verify the enantioselectivity of the reaction and this 
was accomplished with Mosher’s amides, which are the most widely used chiral 
derivatising agents for assessing enantiopurity of chiral amines.52  
Using parallel procedures, both the (R)- and (S)- enantiomers (179) and (186) were 
debenzylated by hydrogenolysis in MeOH using Pd(OH)2/C as a catalyst. After filtration of 
the solids and evaporation of the solvent, the crude amines were directly coupled to (R)-(-)-
MTPA-Cl (187) with DMAP and Et3N in DCM. The reactions were quenched by the 
addition of water and the solvents were removed. The residues were finally taken up in 
CDCl3 and analysed by 19F NMR (Scheme 3.28). 
Solvent Ratio 179/184  
(at 0 °C) 
THF 73/27 
MeCN 74/26 
DCM 80/20 
CCl4/DCM (3/1) 82/18 
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Scheme 3.28: Preparation of the Mosher’s amides (188) and (189). 
 
 
The 19F NMR signal for the fluorine at the stereogenic centre for compounds (188), 
(189) and the mixture of the two diastereoisomers is shown in Figure 3.4. Single peaks are 
observed for pure Mosher’s amides derived from enantiomers (179) and (186) suggesting 
that the two enantiomers are enantiopure. To confirm that peaks at -184.87 ppm for (R, S) 
(188) and -184.73 ppm for (S, S) (189) are not artefacts, the two Mosher’s amides were 
then mixed in one tube and the NMR spectrum of the mix showed unambiguously two 
distinct peaks, proving the very high enantioselectivity of the fluorination reaction.  
Chapter 3 
_______________________________ 
 
 124 
 
 
 (a) 
 
 
 
 (b) 
 
 
 
 (c) 
 
 
Figure 3.4: 19F NMR analysis of Mosher’s amides (188) (spectrum a) and (189) (spectrum b) and 
mix of (188) and (189) (spectrum c) showing the high enantiopurity of amines (179) and (186). 
 
 
In appropriate cases, absolute configuration can be determined by X-ray crystal 
structure analysis. For that reason, the hydrochloric salt of the dibenzyl-protected amine 
(179) was prepared. Thus, (179) was first subjected to hydrogenolysis, and after filtration 
of the palladium catalyst, 1 M HCl in diethyl ether was added to the methanolic solution of 
the amine to generate the hydrochloride (Scheme 3.29).  
 
 
 
 
Scheme 3.29: Preparation of (2R)-fluoro-3-phenylpropan-1-amine hydrochloride (190) 
Reagents and conditions: a) Pd(OH)2/C, H2, MeOH; b) HCl, EtOH/Et2O, 76%. 
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Crystals of the hydrochloric salt (190) were obtained by re-crystallisation from 
EtOH/Et2O and one of these was amenable to crystal structure analysis. X-ray analysis 
confirmed the absolute configuration of the amine to be (R). The C-F bond lies gauche to 
the C-N+ bond, with a torsion angle F-C-C-N+ of 62.9° (Figure 3.5). This is consistent with 
recent observations indicating this as a preferred conformation in β-fluoroamines.  
 
 
 
 
Figure 3.5: The absolute configuration of (190) was determined  
by X-ray structure analysis to be (R).  
 
 
 
 
 
 
 
 
 
Scheme 3.30: Enantioselective syntheses of chiral β-fluoroamines (179) and (186) from L- and D-
phenylalanine derivatives (180) and (182) respectively. Reagents and conditions: LiAlH4, THF, 
0 °C, 2 h, 85-93%; b) Deoxofluor, DCM, -10 °C, 15 h, 75-76%. 
 
 
As the enantiopurity and the absolute configuration of β-fluoroamines (179) and 
(186) was unambiguously established, the synthesis could be progressed toward the 
oxidation of the phenyl ring.  
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A suitable protecting group, stable under strongly oxidative conditions and 
preferably easily introduced and removed was required to replace the dibenzyl protecting 
group. Examination of the literature revealed many examples of Sharpless oxidations 
carried out with a Boc-protected amine.53-55 Therefore, (179) and (186) were converted 
using standard procedures into (R)- and (S)-tert-butyl-2-fluoro-3-phenylpropylcarbamate 
(191) and (192) respectively as indicated in Scheme 3.31. The two enantiomers were 
obtained as colourless crystals amenable to X-ray structure analyses (Figure 3.6). 
 
 
 
 
 
 
 
Scheme 3.31: Preparation of N-Boc-protected amines (191) and (192). 
Reagents and conditions: a) Pd(OH)2/C, H2, MeOH, 3 h; b)  Boc2O, 14 h, RT, 90%. 
 
 
 
 
          191 
 
 
          192 
 
Figure 3.6: X-ray crystal structures of enantiomers (R)-(191) and (S)-(192). 
Torsion angles F-C-C-N are -66.8° in (191) and 66.4° in (192). 
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Aromatic compounds (191) and (192) were then subjected to ruthenium-catalysed 
oxidation following Sharpless conditions:56 Enantiomer (191) was mixed in a biphasic 
solution (CCl4/MeCN/H2O; 1/1/1.5) with sodium periodate NaIO4 (20 equivalents). 
Ruthenium trichloride hydrate RuCl3.xH2O was then added (6-10% mol eq.) and the 
mixture was vigorously stirred at room temperature for two to four days. Filtration over 
Celite followed by evaporation of CCl4 and then extraction of the aqueous phase into 
EtOAc emerged as the most practical work-up. Disappointingly, 19F NMR analysis of the 
crude material showed the formation of several fluorinated products which could not be 
easily isolated by flash column chromatography (Figure 3.7). The oxidised product may 
have been formed in a low yield but the purification proved too problematical.  
Encouragingly, no aromatic products were detected in the reaction.  
  
 
 
 
 
 
 
 
 
Figure 3.7: 19F NMR spectrum (CDCl3 at 280 MHz) of the crude material from  
the ruthenium-catalysed oxidation of (191). 
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The oxidative cleavage of aromatic rings by ruthenium is believed to proceed 
according to the simplified mechanism showed in Scheme 3.32. RuCl3 is first oxidised by 
water to give RuO2 which is further oxidised to the active ruthenium tetroxide species by 
concomitant reduction of IO4- to IO3-. RuO4 adds at the IPSO carbon of the aromatic ring 
to form intermediate (193). Note that addition at another position on the ring leads to the 
formation of the same intermediate (194).57 The C-C bond cleavage of (193) results in the 
formation of aldehyde (195) which is further oxidised in a similar manner to compound 
(194).  Under Sharpless conditions, (194) becomes hydrated and then oxidised by periodate 
or ruthenium oxide to generate carboxylic acid (196).  
 
 
 
 
 
 
 
 
Scheme 3.32: Schematic mechanism of the ruthenium-catalysed  
oxidative cleavage of aromatic ring. 
 
 
Although the oxidation of N-Boc-2-fluoro-3-phenylpropylamine (191) turned out to 
be disappointing, the fact that the aromatic oxidation had occurred was encouraging and 
prompted further investigation to optimise the reaction. As stated in the literature,58 the 
reaction time of the oxidation was found to be significantly shortened by the addition of 
HIO4 instead of NaIO4 as co-oxidant, but this again, gave rise to a complex mixture of 
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compounds. Conversely, addition of NaHCO3 was prejudicial to the reaction and a 
substantial amount of starting material was recovered, even after longer reaction times. It is 
also clear from the literature that the oxidation is very temperature-sensitive and must be 
carried out between 25 °C and 40 °C.58 It can stop if the temperature falls below 20°C or if 
stirring is insufficient. Hence, the reaction mixture was immersed in a temperature-
controlled water bath at 25 °C and the development of a black-coloured spot, which 
indicates the presence of oxidised ruthenium, was also carefully examined. After 
modifications to the reaction conditions failed to produce any improved results, it was 
decided to undertake the oxidation step with a different substrate and to prepare the di-
Boc-protected amines (197) and (198). 
 
The second tert-butylcarbonyl group was introduced onto (179) and (186) using 
standard methodology, in aprotic solvent with a catalytic amount of DMAP. The removal 
of the dibenzyl group, and its replacement with a diBoc group was performed in one step, 
by evaporating MeOH after installation of the first Boc group, dissolving the residue in 
MeCN and heating the mixture under reflux after addition of Boc2O and DMAP. 
Accordingly, the di-Boc-protected amine was obtained as a colourless oil in 80% yield 
from the dibenzyl protected amine (Scheme 3.33). 
 
 
 
 
 
 
Scheme 3.33: Preparation of N,N-diBoc-protected amines (197) and (198). 
Reagents and conditions: a) Pd(OH)2/C, H2, MeOH, 3 h; b)  Boc2O, RT, 14 h;  
c) Boc2O, DMAP, MeCN, 80 °C, 14 h, 78-80%. 
 
Chapter 3 
_______________________________ 
 
 130 
 
Subjecting compounds (197) and (198) to the standard Sharpless conditions 
furnished the targeted products (R)- and (S)- N,N-diBoc-3-fluoro-GABA (199) and (200). 
The reaction was surprisingly clean as shown by the 19F and 1H NMR spectra of the crude 
product mixture. The only problem encountered in this reaction was the cleavage of one 
Boc group which presumably occurred during the acidic extraction of the aqueous phase. 
This could be avoided by extracting the water phase without acid but with a large volume 
of EtOAc. Purification by flash column chromatography afforded (199) and (200) in 75% 
and 76% yield respectively, showing the reliability and efficiency of this transformation. 
 
 
 
 
 
 
 
 
           * 
 
          * 
 
 
 
                 * 
 
 
 
 
 
 
 
 
Figure 3.8: 19F (in CDCl3 at 280 MHz) and 1H NMR spectra (in CDCl3 at 300 MHz) of crude (199) 
product showing a clean conversion. The 1H NMR spectrum is contaminated only by residual 
EtOAc.  
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Scheme 3.34: Syntheses of (199) and (200) by ruthenium-catalysed oxidative cleavage of aromatic 
ring. Reagents and conditions: NaIO4 (18 eq), RuCl3.xH2O (6% mol), CCl4/MeCN/H2O, 25 °C, 
3 days, 75-76%. 
 
 
The final step of the synthesis required acidic cleavage of the tert-butylcarbonyl 
groups, for which trifluoroacetic acid (TFA) is a common reagent. However, TFA can be 
difficult to separate from amines and we have found during our synthesis of racemic 3-
fluoro-GABA that purification on ion-exchange column can also be problematic. 
Consequently, it was judged that removal of the diBoc group would be more conveniently 
achieved with HCl gas. Re-crystallisation would then yield 3-fluoro-GABA as its 
hydrochloride salt. 
 
Deprotection of the Boc protecting groups, followed by purification were indeed 
straightforward: HCl gas, generated by addition of concentrated sulfuric acid on sodium 
chloride was bubbled through a solution of (199) or (200) in dry DCM at 0 °C. 
Precipitation of the 3-fluoro-GABA hydrochloric salt occurred within 10 minutes, and 
single re-crystallisation from EtOH and Et2O afforded (3R)- and (3S)-fluoro-4-
aminobutyric acid hydrochloride (123) and (124) as colourless crystalline solids, in around 
80% yield (Scheme 3.35). 
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Scheme 3.35: Synthesis of (3R)- and (3S)-fluoro-GABA hydrochloride by HCl gas treatment of 
diBoc-protected amines (199) and (200).  
Reagents and conditions: a) HCl gas, DCM, 0 °C, 10 min, 80% 
 
 
In order to confirm the integrity and absolute stereochemistry of the products, X-
ray crystallography was explored. Obtaining crystals suitable for X-ray structure analysis 
was however more challenging than expected as the compounds re-crystallised as light 
flakes. Finally and despite the small size of the crystals, sufficient diffraction enabled 
structure elucidation of (3R)- and (3S)-fluoro-GABA hydrochloride, (123) and (124) 
(Figure 3.9). 
 
 
 
 
 
 
 
 
 
 
     123              124 
 
 
Figure 3.9: X-ray crystal structures of (3R)-fluoro-GABA. HCl (123)  
and (3S)-fluoro-GABA.HCl (124). 
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3.5 Conformation and evaluation of 3-Fluoro-GABA 
enantiomers 
 
3.5.1 Conformational and NMR analyses 
 
As expected, the ammonium aligns gauche to the fluorine in both enantiomers 
(3R)- and (3S)-fluoro-GABA hydrochloride (Figure 3.9). The F-C-C-N+ torsion angle is      
-56.0° for the (R)-enantiomer and 64.8° for the (S)-enantiomer and although these two 
values are different, they remain close to the perfect gauche angle (±60°). It is perhaps not 
surprising that both enantiomers re-crystallised in different conformations as 3-F-GABA, 
like GABA, is a flexible molecule. The (S)-enantiomer crystallised in a fully extended 
conformation, having the ammonium group and the four carbons in a same plane. The (R)-
enantiomer adopted a slightly twisted conformation, with the carbon of the carbonyl 
pointing out of the plane formed by the ammonium and the three other carbons. The 
different conformations observed between the two enantiomers probably result from 
slightly different crystallisation conditions.  
Crystal structures of GABA hydrochloride are available from the Cambridge 
Structural Database, under the codes GAMBAC01 and GAMBAC10. Both structures show 
GABA.HCl in an extended conformation (Figure 3.10 A). Also, at least three different 
conformations were found for GABA re-crystallised as a zwitterion (GAMBUT01, 
GAMBUT04 and GAMBUT10), indicating the flexibility of the molecule (Figure 3.10 B, 
C and D).  
X-ray structure analysis confirms that 3-F-GABA and GABA can access various 
conformations in the solid state, but it gives only limited information on the most stable 
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conformation in solution. The conformational behaviour of 3-F-GABA in aqueous solution 
is important in understanding its binding properties on GABA recognition sites. 
 
 
 
            B            C 
        A 
 
            D 
 
Figure 3.10: Crystal structures and conformations of GABA.HCl (A) and GABA (B, C and D) 
obtained from the CSD. 
 
 
Similarly, the identification of low energy rotamer structures of GABA in the 
aqueous phase can furnish useful information on possible relevant biologically active 
conformations. 1H NMR analysis is not useful for a conformational analysis of GABA due 
to the achirality and rotational mobility of the molecule (Figure 3.11). Ab initio 
calculations however have proven to be more informative in the case of small molecules 
such as glycine,59 adrenaline60 or glutamic acid.61 The neurotransmitter GABA has also 
been studied in this way,61-63 and recently, M. J. Jordan et al. have investigated GABA and 
GABA analogues structures in aqueous solution using computational methods.64, 65   
 
 
 
 
 
 
Figure 3.11: 1H NMR spectrum of GABA in MeOD (300 MHz). 
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The major problem facing computational chemists is to adequately model the 
hydration of GABA in order to obtain geometries related to experimental results. It is 
known that GABA exists in solution as a zwitterion and binds GABAA receptors in 
extended conformations. Failure to account for GABA’s hydration gives misleading 
conclusions that neutral or folded structures are the most stable in solution. Hydration of 
GABA can be modelled by the explicit inclusion of water molecules or by estimating long-
range water interactions with GABA using a polarised continuum model with the dielectric 
constant associated with water. In this model, GABA is enclosed into a water cavity with a  
surface built according to GABA’s van der Waals surface.66 To date, computation is still 
limited in such predictions and it was stated in 2004 that by using an ab initio approach, “it 
remains unclear … which conformation, or conformations of GABA are biologically 
active.”65 
Thanks to the presence of fluorine, the solution conformations of 3-fluoro-GABA 
can be disclosed more readily by the careful interpretation of the 19F and 1H NMR spectra 
which contain much more information than the 1H NMR spectrum of GABA. The 
stereogenic centre present in 3-F-GABA renders the protons of both methylene groups 
diastereotopic, with different coupling constants with the fluorine atom. This can be 
observed in the 19F NMR spectrum which is a multiplicity of 25 signals (Figure 3.12). A 
total of 32 lines is expected in theory from the coupling of five protons but some peaks 
clearly overlap. Because of the high resolution of the 19F NMR multiplicity, an attempt was 
made to extract the coupling constants from the spectrum. With the coupling constants in 
hand, it is then possible to reconstruct the geometry of the molecule and suggest the stable 
conformation(s) of 3-F-GABA in solution. 
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 (a) 
 
 
 
 
 
 (b) 
 
 
 
 
 
Figure 3.12: 19F NMR (a) and 1H NMR (b) spectra of 3-F-GABA in D2O at 500 MHz. 
 
 
The similar chemical shifts of the diasterotopic protons and their large JHF coupling 
constants generate a second-order spectrum where coupling constants cannot be read 
directly. To access these values, it proved necessary to simulate the spectrum and retrieve 
the coupling constants in that way. The NMR simulation software DAISY which is part of 
the NMR processing package TOPSPIN was used for this study. 
In a separate evaluation, theoretical values for all coupling constants of the 3-F-
GABA six-spin system were calculated ab initio (Dr Tanja van Mourik, St Andrews 
University). Firstly, the ten most stable conformers were identified and optimised using 
Density Functional Theory (DFT) with the B3LYP 67 functional and the 6-31+G* basis set 
(Figure 3.13). The coupling constants of ten conformers were then calculated and are 
presented in Table 3.2. 
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Figure 3.13: Ten most stable conformers of 3-F-GABA calculated using DFT. 
 
 
 
 
N° ∆E0 (kJ/mol) 
 
3JH5-F 3JH4-F  3JH3-H4 3JH3-H5  3JH2-F 3JH1-F 
 
3JH1-H3 3JH2-H3  2JH4-H5 2JH1-H2  2JH3-F 
1 0.00 
  
2.59 28.80  0.47 6.20  4.60 49.22  1.73 6.61  -14.18 -17.70 
  
47.95 
2 3.95 
  
-1.40 13.97  2.04 10.46  4.43 15.53  2.73 11.22  -12.46 -16.43 
  
47.64 
3 4.09 
  
17.27 33.99  1.02 4.45  1.23 22.58  7.91 10.48  -15.04 -11.88 
  
51.54 
4 14.53 
  
-1.40 17.76  8.05 8.84  17.75 49.93  3.00 4.78  -12.44 -15.75 
  
52.74 
5 22.50 
  
7.09 30.59  0.99 4.65  4.35 11.13  4.69 12.34  -14.20 -17.27 
  
48.65 
6 24.10 
  
8.75 27.52  1.97 11.06  14.37 51.73  1.37 10.78  -13.94 -16.10 
  
55.54 
7 24.69 
  
9.80 30.51  1.75 10.12  3.49 14.19  4.21 11.29  -13.75 -16.52 
  
56.42 
8 29.90 
  
10.70 29.62  1.65 10.50  5.53 52.26  1.57 6.37  -14.58 -16.18 
  
56.84 
9 30.67 
  
6.75 29.05  1.20 4.18  15.03 49.78  1.25 11.82  -14.32 -15.69 
  
47.85 
10 38.07 
  
0.20 8.36  3.31 11.04  14.37 51.73  1.37 10.78  -13.94 -16.10 
  
55.54 
 
Table 3.2: Relative energy and coupling constants of the ten most stable conformers calculated 
with DFT-B3LYP for 3-F-GABA. 
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The four lowest energy structures in Figure 3.13 have intramolecular hydrogen 
bonding between the ammonium and the carboxylate groups, and although they emerged 
as the lowest energy conformers, they are not expected to be relevant in an aqueous 
medium. The next six structures are more interesting, especially structures 6 and 7 which 
closely mimic the conformations found in the solid state structures of (3S)-F-GABA.HCl 
and (3R)-F-GABA.HCl (Figure 3.9). The coupling constants associated with conformation 
6 were then entered into the NMR simulation software DAISY and used as approximate 
values which were then refined by the software several times by iteration to match the 
simulated spectrum with the experimental one. It was finally possible a find a good match 
between the experimental spectrum and the simulated one (Figure 3.14 and 3.15). The 
coupling constants determined by the software were found to match equally well for the 1H 
NMR and 19F NMR recorded at 400 MHz and 500 MHz (Table 3.3). 
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Figure 3.14: Experimental (above) and simulated (below) 1H NMR spectra of 3-F-GABA at 
500 MHz in D2O at 25 °C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Experimental (above) and simulated (below) 19F NMR spectra of 3-F-GABA at 
500 MHz in D2O at 25 °C. 
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 H1 H2 H3 H4 H5 
F 31.33 17.02 49.43 34.04 14.55 
H1  -15.03 3.97 0 0 
H2   8.05 0 0 
H3    2.34 9.47 
H4     -13.11 
 
Table 3.3: Experimental coupling constants extracted from simulated NMR spectra. 
 
 
The experimental coupling constants in Table 3.3 can then used to reconstruct the 
most appropriate geometries of 3-F-GABA conformers. As 3-F-GABA has a degree of 
conformational flexibility, it is expected that it can adopt several low-energy 
conformations in solution, particularly with rotation around the C2-C3 bond. The coupling 
constants in Table 3.3 are consistent with an extended structure of 3-F-GABA in solution 
(such as structure 6) computational studies are expected to confirm this. 
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3.5.2 pKa studies 
 
The introduction of a fluorine atom does not induce a significant steric perturbation 
but it can of course change the electronic distribution in the molecule. This aspect of 
fluorine substitution has to be taken into account during the design of fluorinated medicinal 
chemistry compounds and in particular, in the case of β-fluorinated amines, as it is known 
that the fluorine causes adjacent functional groups to become more acidic. The effect of 
fluorine substitution on the pKa of primary amines is not well documented but a few 
reports indicate that it lowers the pKa by one to two pKa units (Figure 3.16). 
In the case of 3-fluoro-GABA, fluorine can potentially influence the zwitterionic 
nature of the molecule by lowering the pKa of the amine and this could affect its 
protonation in vivo. It was therefore of interest to measure the pKa of 3-fluoro-GABA.  
 
 
 
 
 
 
 
 
Figure 3.16: Examples of the fluorine substitution on the pKa of some primary amines.68, 69 
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It is noteworthy that the pKa of cyclopropylamine (201) which has a fluorine atom 
and an ammonium group locked in a cis relationship, is almost 0.4 of a pKa unit higher 
than isomer (202) in which the fluorine and ammonium substituents are anti.69 
Cyclopropylamine (201) is therefore less acidic than (202) and less prone to deprotonate. 
The lower acidity of (201) can be accounted for by an optimal charge···dipole interaction 
which stabilises the molecule and makes it more difficult to abstract a proton from the 
ammonium group (Figure 3.17). It follows that conformations which have the C-F and the 
C-N+ bonds gauche are more difficult to deprotonate than those in which the C-F and C-N+ 
bonds are anti.  
 
 
 
Figure 3.17: Stabilising charge···dipole interaction in (a). 
 
 
The pKa values of GABA measured in water at 25 °C are 4.03 and 10.55.70, 71 
Before measuring 3-F-GABA hydrochloride, the potentiometric titration of GABA 
hydrochloride was carried out in order to validate the titration method.  
Accordingly, GABA HCl (6 mg) was diluted in pure deionised water (2 mL) and 
the solution was immersed in a temperature-controlled water bath at 25 °C and 
magnetically stirred. A pH electrode designed for the titration of small volumes was 
soaked into the GABA solution and the pH values were read on a pH meter which had 
previously been calibrated with standard solutions at pH 4 and pH 7. The NaOH titration 
solution (2.073×10-2 mol.L-1) was calibrated with a known tartaric acid solution by acid-
base titration using phenolphthalein as an indicator. Under these conditions, the added 
volume of NaOH solution at the equivalent point was around 2 mL, which induced a 
significant dilution factor. However, after minor correction, the experimental pKa values 
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for GABA. HCl turned out to be very close to the theoretical ones, confirming that this 
titration method was reliable (Graph 3.1). The pKa values can be read graphically on the 
curve in Graph 3.1 or more accurately from the volume of NaOH (2.073×10-2 mol.L-1) 
added.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 3.1: Potentiometric titration of GABA HCl. 
 
 
Similarly, 3-fluoro-GABA HCl (7.1 mg) was titrated against NaOH solution and 
the titration curve is presented in Graph 3.2. The experimental pKa values can be read 
graphically on the curve and according to the volume of NaOH (2.073×10-2 mol.L-1) 
added. 
 
 
 
 
 
 
 
 
Graph 3.2: Potentiometric titration of 3-F-GABA HCl. 
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As illustrated on the titration curve in Graph 3.2, the fluorine substituent in 3-F-
GABA lowers the pKa of the carboxylic acid by 0.75 pKa unit and the amine by 1.6 pKa 
unit (Table 3.4). The pKa value of 3-F-GABA (pKa=8.95) is in the same range as other 
fluorinated primary amines, such as fluoroethylamine (pKa=8.97) and fluorinated GABA 
analogue (2R)-(3-amino-2-fluoropropyl)sulfinic acid (203) (pKa= 8.5), a structure that was 
recently published in 2007.72  
 
 
 
Table 3.4: pKa of GABA.HCl and 3-F-GABA.HCl 
 
Interestingly, (203) was prepared from tert-(2R)-fluoro-3-hydroxypropylcarbamate 
(204) by mesylation and reaction with tert-butyl thiol. Sulfide (205) was then oxidised with 
mCPBA and reacted with trifluoromethanesulfonic acid to give (203). Compound (204) 
was presumably prepared from L-serine (155) as described previously but details of the 
synthesis were not given as a patent was deposited by AstraZeneca for this class of 
compounds.73, 74  
 
 
 
Scheme 3.36: Schematic synthesis of novel fluorinated GABA analogue (203).72-74 
 
A pKa of 8.95 signifies that 3-F-GABA will exist as a zwitterion in vivo and 
therefore will likely behave as a GABA analogue in that respect. pKa values are most 
probably not determining factors for the binding affinity of GABA analogues. As an 
example, muscimol (68) also shown in Table 2.1 is one of the most potent GABA analogue 
 pKa1 pKa2 
GABA.HCl 4.03 10.55 
3-F-GABA.HCl 3.30 8.95 
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at GABAA receptors but has pKa values of 4.8 and 8.4. Muscimol is isolated from the 
white-spotted red mushroom Amanita Muscaria.  
 
 
3.5.3 Conclusions 
 
The first successful enantioselective synthesis of both (3R)- and (3S)-fluoro-GABA 
hydrochloride was executed as summarised in Scheme 3.37. Over 100 mgs of both 
enantiomers were obtained in six steps and in an overall yield of 31% from L-
phenylalanine and D-phenylalanine methyl ester hydrochloride respectively. In this 
synthesis, it was shown that the fluorination of the dibenzylamino alcohol (178) is 
enantioselective and that the oxidation of the aromatic ring proceeds cleanly to furnish the 
carboxylic acid (199). More generally, this synthesis shows that enantiopure β-
fluoroamines are accessible from α-amino acids. 
 
 
 
 
 
 
 
 
 
Scheme 3.37: Enantioselective synthesis of (3R)-fluoro-GABA hydrochloride (123) from L-
phenylalanine (175). Reagents and conditions: a) BnBr, K2CO3, EtOH, 90%; b) LiAlH4, THF, 
95%; c) Deoxo-FluorTM, DCM, 75%; d) 1.Pd(OH)2/C, H2, Boc2O, MeOH, 2.Boc2O, DMAP, 
MeCN, 80%; e) NaIO4, RuCl3, CCl4/MeCN/H2O, 76%; f) HCl gas, DCM, 80%. 
68
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3.6 Biological studies 
3.6.1 Studies on GABA receptors 
 
The activities of 3-F-GABA enantiomers were evaluated at the School of 
Neurobiology at Ninewells Hospital in Dundee on recombinant GABAA receptors 
expressed in Xenopus laevis oocytes. To generate cloned GABAA receptors, DNAs 
encoding the human GABAA α1β2γ2 subunits were used to produce cRNA transcripts, 
which were injected intranuclearly into Xenopus laevis oocytes. Recordings were then 
made from oocytes two to twelve days after cRNA injection. Such a procedure allows the 
expression of human GABAA receptors at the surface of oocyte membranes and this has 
proven to be an effective experimental model for exploring GABA induced chloride flux 
across membranes. The activities of GABA agonists were measured by recording induced 
currents at a holding potential of –60mV. In the data presented below, Emax refers to the 
maximal current produced by a saturating concentration of the agonist and EC50 refers to 
the concentration of agonist that produces a response 50% of the maximum Emax.  
Unfortunately, a comprehensive study on the effects of 3-F-GABA enantiomers at 
GABAA receptors can not be presented here as, to date, only preliminary results were 
obtained from biological testing. Nevertheless, a general picture of the action of 3-F-
GABA enantiomers on human GABAA receptors can be drawn and it appears that (3R)- 
and (3S)-fluoro-GABA have similar activity on GABAA receptors (Table 3.5 and 
Graph 3.3). 
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Table 3.5: Activities of GABA and 3-F-GABA enantiomers on GABAA receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 3.3: Activities of GABA (■), (3R)-F-GABA (▲) and (3S)-F-GABA (●) on GABAA 
receptors.  
 
 
The curves in Graph 3.3 indicate that (3R)-fluoro-GABA (123) requires to be seven 
times more concentrated than GABA to reach the EC50 response of GABA, and in that 
respect, the (R)-enantiomer is 14% as active as GABA on GABAA receptors. The (S)-
enantiomer is only 10% as active. By comparison, (3R)-hydroxy-GABA is 3.3% as active 
as GABA and (3S)-hydroxy-GABA is 8.3% as active (see Table 2.2 p 66).  Drawing any 
 Emax EC50 
GABA 100% 4.9 10-5 M 
(3R)-F-GABA 77% 2.4 10-4 M 
(3S)-F-GABA 82% 3.8 10-4 M 
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conclusion at this point would be too speculative, but it appears from these data that; 
firstly, GABAA receptors do not distinguish significantly between (R)- and (S)-
enantiomers, suggesting that τN in GABA binding conformations is close to 180° and that, 
3-F-GABA, despite its close steric resemblance with GABA, exhibits poor binding 
activity. It is hoped that further experiments will allow the respective biological effects of 
both enantiomers to be refined. 
 
 
3-F-GABA enantiomers were also tested on a whole tadpole system where the 
effects of GABA and 3-F-GABA were observed for motorneuronal activity associated with 
the fictive swimming response of the tadpole (Figure 3.18). The experiments were 
conducted at the School of Biology in St Andrews in Prof. K. Silar’s research labs. 
 
 
 
 
 
 
Figure 3.18: Schematic representation of the biological tests conducted on tadpoles. 
 
 
Experiments performed on racemic 3-F-GABA (prepared by F. Chorki) showed 
that the compound largely retained the properties of GABA and bind to both GABAA and 
GABAB receptors. The GABAB response was indicated by the reversal of its effects by 
selective GABAA and GABAB antagonists.75 It was also noticed that 3-F-GABA, when 
compared to GABA, reduced significantly the swim episode duration of the tadpole (Graph 
3.4). The swim episode duration is the time between the first and the last burst in the 
swimming episode provoked by the stimulation of the nervous system. The fact that the 
Caudal 
ventral 
root 
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tadpole stopped swimming quicker with 3-F-GABA suggested that it remained available 
longer than GABA, which could be the result of a lower affinity of 3-F-GABA for GABA 
transporters or that it is metabolised more slowly by GABA aminotransferase. 
 
 
 
 
 
Graph 3.4: Analysis of the effect of GABA and racemic 3-F-GABA on swim episode duration.75 
 
 
Experiments performed on enantiopure 3-F-GABA showed a clear difference in the 
swimming response between the (R)- and (S)-enantiomers, with (S) being more potent than 
(R). When GABAA receptors were blocked with bicuculline (58), a marked difference was 
still observed between the two enantiomers. It was advanced that 3-F-GABA and 
particularly the (S)-enantiomer was GABAB selective. Interestingly, very few compounds 
are known to exhibit selective GABAB activity, baclofen (59) being the only GABAB 
agonist approved for clinical use. But recently, (2R)-(3-amino-2-fluoropropyl)sulfinic acid 
(203) was reported to have a high GABAB/GABAA selectivity.72, 73  
 
 
 
The close structural and stereochemical analogy between (203) and (3S)-F-GABA 
(124) clearly support the idea that the latter is GABAB selective, but in vivo experiments on 
tadpoles are unsuitable to validate this hypothesis. However, it could be confirmed by 
experiments on cloned GABAB receptors. Obviously, such experiments merit 
investigation.
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3.6.2 Studies on GABA aminotransferase 
 
Early observations that racemic 3-F-GABA might remain metabolically available for 
longer than GABA prompted us to test 3-F-GABA enantiomers as substrates or inhibitors 
of GABA aminotransferase (GABA AT). As stated in chapter 2, GABA AT is a PLP-
dependent enzyme which metabolises GABA to succinic semialdehyde (47) (Scheme 1.3 
and 2.1). In 1981, R. Silverman et al.76 investigated the activity of racemic 3-F-GABA and 
found that it was a substrate for GABA AT but without conversion of PLP to PMP. 3-F-
GABA was able to bind to the enzyme but was not oxidised to succinic semialdehyde in 
the normal manner with concomitant PLP reduction to PMP (see scheme 1.3). Instead, it 
emerged that the enzyme catalysed the elimination of HF from the substrate, converting it 
ultimately to succinic semialdehyde by a process summarised in Scheme 3.38. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.38: Elimination of HF from 3-F-GABA catalysed by GABA AT. 
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Samples of the 3-F-GABA enantiomers were sent to Prof. R. Silverman at the 
Northwestern University of Evanston (Illinois, USA) to be evaluated with GABA AT. 
Consistent with the previous results with racemic 3-F-GABA, neither enantiomer was 
found to be a substrate for transamination but both underwent HF elimination. 
Interestingly, elimination of HF from the (R)-enantiomer proceeded at a rate of 6.63×10-2 
µmoles.min-1.mg-1 whereas HF elimination from (S)-enantiomer was ten times slower at 
6.26×10-3 µmoles.min-1.mg-1.  These values were obtained using a fluoride ion selective 
electrode, but HF elimination was also measured by the evaluation of succinic 
semialdehyde production.77 However, the rate of succinic semialdehyde production from 
(S)-enantiomer was too slow to calculate kinetic constants using this method.  
 
The ability of both enantiomers of 3-F-GABA to bind to the active site of GABA 
AT was then examined. In order to achieve this, (3R)- and (3S)-F-GABA were assayed as 
competitive inhibitors of GABA transamination according to the following principle: the 
oxidation of one molecule of GABA to succinic semialdehyde generates one molecule of 
PMP, which in the presence of radiolabeled [14C] α-ketoglutarate (48) produces one 
molecule of radiolabeled [14C] L-glutamate (43) (see Scheme 2.1). 3-F-GABA does not 
generate PMP, therefore the amount of α-ketoglutarate converted to (43) is representative 
of GABA transamination. The conversion of (48) to (43) was then measured with different 
concentrations of (3R)- and (3S)-F-GABA (Table 3.6). In the event, it was found that the 
(R)-enantiomer (123) showed substantial competitive inhibition of GABA transamination 
whereas the (S)-enantiomer (124) showed no significant inhibition.  
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Table 3.6: Inhibition of GABA transamination as measured by a reduction in the rate of conversion 
of [14C] α-ketoglutarate to [14C] L-glutamate over 15 min.77 
 
 
The data in Table 3.6 clearly indicate that the (S)-enantiomer does not bind well to 
the active site of GABA AT, as such binding would inhibit the transamination of GABA, 
resulting in a reduction in the rate of glutamate production. Conversely, the (R)-enantiomer 
causes inhibition of transamination, suggesting that this enantiomer binds much more 
efficiently to the enzyme. In another experiment, it was shown that the (R)-enantiomer 
inhibited GABA AT at least ten times better than the (S)-enantiomer, indicating an 
improved binding affinity of (R) over (S). 
These findings suggests that the preferred conformation in solution of (3R)-F-
GABA (123) is more optimal for binding to the enzyme than the preferred conformation in 
solution of (3S)-F-GABA (124). A possible interpretation of these results, based on the 
conformational analysis shown in Figure 3.1 (p 99) is that the preferred torsion angle τN for 
binding to the GABA AT is close to -60°. Only the (R)-enantiomer can access this binding 
conformation whereas in the case of the (S)-enantiomer, such a conformation is much 
higher in energy. The preferred binding modes of GABA, (3R)- and (3S)-F-GABA are 
described in Scheme 3.39. 
% α-KG (48) converted to Glu 
(43)/unit time 
 
Concentration of 
3-F-GABA 
enantiomer (nM) 
(3R)-F-GABA 
(123) 
(3S)-F-GABA 
(124) 
0.000 6.79 6.79 
0.050 6.97 7.28 
0.250 3.89 7.00 
0.500 1.87 7.23 
1.000 0.97 6.74 
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Scheme 3.39: Topological description of the preferred binding conformations of GABA and 3-F-
GABA enantiomers for GABA AT. In (3S)-F-GABA (124), the conformation with τN=-60° is high 
in energy due to the anti relationship of the C-F and C-N+ bonds. 
 
 
The difference in binding affinity of both enantiomers (3R)- and (3S)-F-GABA is 
interpreted as an indication that GABA binds to GABA AT with a torsion angle τN close to 
-60°. This statement is supported by mechanistic considerations of 3-F-GABA binding to 
the active site of GABA AT. After entering the substrate binding site of GABA AT, the 
substrate follows a cascade reaction involving, first the deprotonation of one ammonium 
proton, then the attack to the imine carbon of the Lys329-PLP adduct and then the 
formation of the 3-F-GABA-PLP adduct. The approach of the nucleophilic amino group of 
3-F-GABA to the electrophilic imine carbon occurs with a Bürgi-Dunitz trajectory.78 
Deprotonation of the ammonium is assisted by the side chain hydroxyl group of residue 
Thr353, located 3.6 Å away, top and back side of the imine carbon atom (Thr353 can be 
seen in the background of the active site of GABA AT in Figure 2.1). The threonine-
assisted deprotonation and the nucleophilic attack imply that the ligand adopts the 
conformation shown in Scheme 3.40 with the torsion angle τN=-60°. 
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Scheme 3.40: Illustration of the dynamic binding process of (123) and (124). The conversion of 
(124) to the active conformation needs energy penalty as the C-F bond becomes anti to the C-N+ 
bond. In (123), the C-F and the C-N+ bonds remain gauche.77 
 
 
This study suggests that GABA has a preferred binding conformation on GABA 
AT and that only the (3R)-F-GABA enantiomer can easily access this binding mode in 
solution.  
The difference in activities observed between 3-F-GABA enantiomers on GABA 
AT validates for the first time the concept of using the C-F bond as a tool to influence the 
conformational mobility of biologically active amines. It also demonstrates that the C-F 
bond can be used as a conformational probe to reveal the binding conformation(s) of 
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GABA. Further conformational studies will now be conducted on other GABA recognition 
sites, such as GABAB receptors and GABA transporters. 
 
3.6.3 Conclusions 
 
(R)- and (S)- 3-Fluoro-GABA enantiomers have been found to possess similar 
activities on cloned GABAA receptors expressed in Xenopus laevis oocytes. They are 
respectively 14% and 10% as active as GABA. A clear difference in activity was observed 
in vivo on tadpoles. Interestingly, the (S)-enantiomer was found to be much more potent 
than the (R)-enantiomer. This difference could arise from GABAB selectivity but further 
experiments on cloned GABAB receptors are required. A marked difference was also 
noticed on GABA-AT, with the (R)-enantiomer being metabolised ten times quicker than 
the (S)-enantiomer. This study has shown that the stereoselective introduction of the C-F 
bond at the 3-position in 3-F-GABA influences the conformational mobility and the 
biological activity of the molecule.  
Importantly, the concept of using the stereoelectronic influence of fluorine to limit 
the conformational mobility of bioactive molecules can potentially be applied to many 
other biological targets including amines and amides, in which the fluorine atom is known 
to exercise a strong conformational influence. This offers exciting prospects for future 
research. 
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3.7 Toward the synthesis of 3-fluoro-GABA analogues. 
 
3.7.1 Synthesis of conformationally constrained GABA analogues 
 
3-F-GABA, despite the conformational constraints introduced by the presence of 
the C-F bond, remains a flexible molecule. Its most stable conformations in solution do not 
inform for instance on the preferred orientation of the carbonyl group of GABA on GABA 
binding sites. An interesting example of a conformationally constrainted GABA analogue 
is (1S,3S)-trans-3-aminocyclopentane carboxylic acid (70) (see Table 2.1) which exhibits 
high activity on GABAA receptors whereas its enantiomer is much less active.79 The 
cyclopentane ring obviously induces conformational constraints but is still quite flexible. 
Thus, compound (70) can access different conformations such as (70a) and (70b) 
as illustrated in Figure 3.19. In the scope of this work, it was thought that the introduction 
of a fluorine atom β to the amino group, at the 2-position (206) or at the 4-position (207) of 
the cyclopentane ring, could further constrain the conformational mobility of the 
cyclopentane ring. Indeed, conformations (206b) and (207b) are not expected to be 
significantly populated in solution due to the anti relationship between the C-F and the C-
N+ bonds. 
Amino acids (1R,2S,3S)-3-amino-2-fluorocyclopentane carboxylic acid (206) and 
(1R,3R,4R)-3-amino-4-fluorocyclopentane carboxylic acid (207) are unknown and present 
challenging target molecules for synthesis. In particular, compound (206) and its (2R)-
isomer can be regarded as conformationally restricted analogues of 3-F-GABA. For that 
reason, it was judged interesting to assess these analogues for testing on GABAA and 
GABAB receptors. 
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     70a     70b 
 
 
 
 
     206a     206b 
 
 
 
 
     207a     207b 
 
Figure 3.19: Illustration of the cyclopentane ring flexibility in (70) and the effect of the C-F bond 
on the conformational mobility of (206) and (207). Conformations (206b) and (207b) have the C-F 
and C-N+ bonds in an anti relationship. 
 
 
It should be noted that close analogues of (206) and (207) have already been 
prepared and tested as inhibitors of GABA-AT, but all of them (208), (209), (210) have the 
amino and the carboxylic acid groups in a cis relationship, which appears to be optimal for 
GABA AT inhibition. They were all synthesised from commercially available (-)-2-
azabicyclo[2.2.1]hept-5-en-3-one (211) (Scheme 3.41).80, 81 
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Scheme 3.41: Preparation of halogenated 3-amino-cyclopentane carboxylic acid derivatives  
from (211).80, 81 
 
 
It is known that a trans relationship between the amino and carboxylic groups is 
preferable for GABAA binding activity.79 Trans compounds such as (70) have been 
prepared by thermal isomerisation of cis compounds82 or by re-crystallisations83 of 
cis/trans mixtures, but no straightforward and appealing stereoselective synthesis of (70) 
has emerged. The synthesis of cis-3-aminocyclopentane carboxylic acids is however 
straightforward from (211). It was decided to prepare such compounds and then, to 
investigate the enantioselective synthesis of fluorinated and non-fluorinated analogues of 
(70) for biological evaluations. 
 
Non-fluorinated cis-3-aminocyclopentane carboxylic acids were readily prepared 
following published procedures,84, 85 starting from 2-azabicyclo[2.2.1]hept-5-en-3-one 
(211) which is commercially available in enantiomeric pure form and as a racemate. 
Accordingly, enantiopure amino acids (213) and (214) were synthesised from (-)(211) by 
hydrogenation over Pd/C and/or acidic hydrolysis of the amine bond (Scheme 3.42).  
  
 
 
Scheme 3.42: Synthesis of enantiopure cyclopentane amino acids (213) and (214).84, 85. Reagents 
and conditions: a) Pd/C, H2, EtOAc, 18 h, RT, 95%; b) HCl 4 N, AcOH, 5 h, 70 °C, 60-72%. 
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Similarly, racemic amino acids (215) and (216) were obtained from racemic 
(±)(211) (Scheme 3.43).  
 
 
 
Scheme 3.43: Synthesis of racemic cyclopentane amino acids (215) and (216).84, 85 
Reagents and conditions: a) Pd/C, H2, EtOAc, 18 h, RT; b) HCl 4 N, AcOH, 5 h, 70 °C. 
 
 
The synthesis of trans-3-aminocyclopentane carboxylic acid derivatives was then 
investigated. The proposed retrosynthetic analysis presented in Scheme 3.44 was motivated 
by the observation that oxazabicyclo[2.2.1]-hept-5-ene (217) reacts under specific 
conditions with alcohols or Grignard reagents to give trans-1,4-substituted cyclopentane 
derivatives as shown in Scheme 3.45.86-88  
 
 
 
Scheme 3.44: Proposed retrosynthetic analysis of (70). 
 
 
 
 
 
Scheme 3.45: Opening of (217) by methanol.87, 88 
 
 
Accordingly, (±)-N-(carbo-tert-butoxy)-2,3-oxazabicyclo[2.2.1]hept-5-ene (219) 
was prepared using published procedures,89 from cyclopentadiene and t-butyl-N-
hydroxycarbamate (220). This compound was then oxidised with NaIO4 to form the 
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dienophile nitroso species (221) which reacted in situ with cyclopentadiene in a hetero 
Diels-Alder reaction. The reaction proceeded cleanly and the product (219) was obtained 
as a brown solid in 72% yield (Scheme 3.46). 
 
 
 
 
Scheme 3.46: Preparation of (219) by hetero Diels-Alder reaction.89 
Reagents and conditions: a) Boc2O, K2CO3, Et2O, 0 °C, 15 h, 89%;  
b) Cyclopentadiene, NaIO4, MeOH, 0 °C, 30 min, 72%. 
 
 
The nucleophilic ring opening of (219) with cyanide was then attempted. Different 
sources of cyanide, such as potassium copper cyanide K2Cu(CN)3, trimethylsilyl cyanide 
Me3SiCN or potassium cyanide KCN were examined with different Lewis acids such as 
CuSO4 or FeCl3 under various conditions, but the target compound was never detected. 
Instead, when Me3SiCN and CuSO4 were added to a solution of (219) in DMF and stirred 
at 60 °C for 20 h, an unexpected compound was obtained as a white solid in 57% yield.  
NMR and high resolution mass spectroscopy analyses allowed its structure to be solved.  
X-ray crystallography confirmed the structure to be oxazol-2-one (222) (Figure 3.20). A 
mechanism to account for its formation is suggested in Scheme 3.47.  
 
 
 
 
 
Figure 3.20: X-ray crystal structure of (222) 
 
N
O
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Scheme 3.47: Proposed mechanism for the formation of (222). 
 
 
The Lewis acid CuSO4 promotes the opening of (219). The carbonyl of the 
carbamate then attacks the allyl cation to generate intermediate (223), which upon 
elimination of isobutene, generates the product (222). This mechanism is based on a 
reaction mechanism published by G. Procter for the formation of oxazolidinone (224) 
(Scheme 3.48).90, 91 
 
 
 
 
Scheme 3.48: Formation of oxazolidinone (224).90, 91 
 
 
Presumably, the formation of compound (222) could be avoided by replacing the 
Boc protecting group by a benzyl group. However, this route was abandoned, mainly 
because the priorities of the project changed at this point, to address a synthesis of the 
enantiomers of 3-F-GABA. It may be worth in the future to re-investigate the synthesis of 
3-F-GABA analogues (206) and (207). 
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3.7.2 Towards the synthesis of a fluorinated analogue of carnitine 
 
(R)-Carnitine (225) is a close structural analogue of 3-hydroxy-GABA (77). It is 
ubiquitous in mammalian tissues and is essential for energy metabolism, transporting 
activated fatty acids to the mitochondria, where they are broken down via β-oxidation. 
Chemically, carnitine can be prepared from 3-hydroxy-GABA, and of relevance to this 
study, the 3-fluoro analogue of carnitine (226) is potentially accessible from 3-F-GABA. 
 
 
 
(R)-Carnitine biosynthesis (Scheme 3.49) starts from N6-trimethyl lysine (227) 
which is hydroxylated at the 3-position to give (228). Aldol cleavage of (228) then yields 
glycine (46) and 4-N-trimethylaminobutyraldehyde (229), the latter of which is oxidised to 
γ-butyrobetaine (230). In the last step, γ-butyrobetaine is hydroxylated at the 3-position by 
γ-butyrobetaine hydroxylase to yield (R)-carnitine (225).92, 93 In Escherichia coli, carnitine 
is then metabolised by dehydration to γ-butyrobetaine via the formation of crotonobetaine 
(231).94 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.49: Biosynthetic pathway and metabolism of (R)-carnitine.92, 93  
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Fluorine, in addition to being a good hydrogen mimic can also mimic the hydroxyl 
group. Moreover, as for 3-F-GABA, the C-F and C-N+ bonds are expected to orientate 
gauche to each other in (226), introducing conformational constraints in the molecule. 3-
Fluoro-N-trimethylaminobutyric (226) could potentially be utilised for conformational 
binding studies or as a carnitine inhibitor of enzymes involved in carnitine biosynthesis or 
metabolism. As such, 3-fluoro-N-trimethylaminobutyric (226) emerged as an interesting 
carnitine analogue which could presumably be prepared by direct methylation of 3-F-
GABA enantiomers. However, an alternative and perhaps more straightforward synthesis 
of (226) was sought.  
 
Thus, carnitine isobutyl ester (232) was first prepared using a published procedure95 
and was then treated with Deoxofluor under various conditions. The best results were 
obtained when Deoxofluor (2 eq) was added at room temperature to a solution of (232) in 
DCM. Unfortunately, the desired product (233) was detected only by NMR analysis of the 
crude reaction mixture and in only 5-10% conversion and it could not be isolated. Addition 
of a larger excess of Deoxofluor may have resulted in a better yield but this was not 
attempted. Other deoxofluorination methods, such as the conversion of the hydroxyl group 
to a mesylate and fluorination with TBAF were explored, but again, these approaches led 
to a very poor conversion and/or elimination side products (Scheme 3.50). This study 
suggested that deoxofluorination of (232) was not a practical method for the synthesis of 
(226).  
 
 
 
Scheme 3.50: Attempted synthesis of (233) by deoxofluorination from carnitine (225). Reagents 
and conditions: a) Isobutanol, HCl gas, reflux, 2 h, 92%. 
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In 2006, J. Bonjoch et al.96 demonstrated that the β-lactone (234) can be ring 
opened by chloride ion with full stereocontrol, to give the corresponding β-chloro-α-amino 
acid (235) (Scheme 3.51). Curiously, very few publications describe the ring opening of β-
lactones by halogens96-100 and there are none with fluorine. Therefore, it appeared worth 
exploring this reaction with fluoride.   
 
 
 
Scheme 3.51: Opening of β-lactone (234) by chloride ion.96 
 
 
Fluoride is a much poorer nucleophile than chloride but it was thought that 
triethylamine trihydrofluoride Et3N.3HF, which is used to open epoxides, would be a 
suitable reagent for this kind of reaction.  To test the feasibility of ring opening of β-
lactones by fluoride, commercially available and inexpensive β-butyrolactone (236) was 
selected as a substrate. Et3N.3HF (2 eq) was added to a solution of (236) in DCM and the 
mixture was heated under reflux for five days. After quenching and purification, the target 
product 3-fluorobutanoic acid (237) was isolated in 34% yield. The product of elimination, 
crotonic acid (238) was also formed and was difficult to separate from 3-fluorobutanoic 
acid. To ensure that crotonic acid was not an intermediate in the reaction and the substrate 
of an addition reaction with HF, crotonic acid was reacted with Et3N.3HF in DCM and 
heated under reflux for ten days. No fluorinated product was detected in this case, 
suggesting that β-butyrolactone (236) is opened directly by nucleophilic attack of fluoride 
(Scheme 3.52). 
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Scheme 3.52: Synthesis of 3-fluorobutanoic acid (237) by ring opening of β-butyrolactone (236). 
Reagents and conditions: a) Et3N.3HF, DCM, reflux, 5 days. 
 
 
3-Fluorobutanoic acid was fully characterised by NMR analysis and although it is 
structurally a simple molecule, NMR simulation software DAISY proved useful to extract 
the coupling constants from the 19F NMR spectrum. The fluorine signal is, as expected, a 
doublet of doublet of doublet of quadruplet (dddq). Coupling constants are 47.7 Hz (CHF), 
28.8 Hz (CH2), 14.0 Hz (CH2) and 23.8 Hz (CH3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: Experimental (above) and simulated (below) 19F NMR signal of (237). 
 
 
The synthesis of 3-fluorobutanoic acid from β-butyrolactone represents the first 
reported example of fluoride ion ring opening of a β-lactone. In order to evaluate the 
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enantioselectivity of this transformation, it was decided to test this reaction on 
enantiomerically pure (R)-4-(trichloromethyl)-2-oxetanone (239). Disappointingly, 
addition of Et3N.3HF to a solution of (239) in DCM and heating under reflux for ten days 
failed to produce any fluorinated product. This result indicated that the nucleophilic 
opening of β-lactone by fluoride is apparently deactivated by electron withdrawing 
substituents such as the trichloromethyl group (Scheme 3.53).  
 
 
 
 
Scheme 3.53: (239) is inert to ring opening with Et3N.3HF. 
 
 
In view of the inert nature of (239) to Et3N.3HF treatment, it seems unlikely that 
the opening of β-lactone by fluoride can be applied to the synthesis of 3-fluoro-N-
trimethylaminobutyric acid (226) as drawn in Scheme 3.54 because of the electron 
withdrawing nature of the N+(CH3)3 group. It has been reported however that intermediate 
(240) can be opened by sodium azide NaN3,95 so perhaps conditions could be found to 
mediate a successful fluoride ion ring opening  
 
 
 
Scheme 3.54: Improbable retrosynthesis of (226) from (R)-carnitine by fluorine  
ring opening of (240). 
 
 
Assuming that the fluoride ring opening of β-lactone is enantioselective, which 
would of course have to be established, this methodology could potentially be applied in 
the future to an enantioselective synthesis of 3-F-GABA (Scheme 3.55).  
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Scheme 3.55: Possible alternative retrosynthetic analysis for the synthesis of 3-F-GABA. 
 
 
The synthesis of 3-fluorobutanoic acid (237) from β-butyrolactone (236) has shown 
that ring opening of a β-lactone by fluoride is achievable and presents a novel approach 
towards the synthesis of β-fluorocarboxylic acids.  
 The enantioselective synthesis of 3-fluoro-GABA, which is both a β-
fluorocarboxylic acid and a β-fluoroamine was presented in this chapter. The synthesis 
developed from L- and D- phenylalanine, has demonstrated that this α-amino acid can be 
successfully converted to a β-fluoroamine in a stereoselective manner. The next chapter 
illustrates the feasibility and the practicality of this general transformation with another α-
amino acid. 
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Chapter 4: Synthesis of 2-fluorohexane-1,6-
diamine and 2-aminomethylpiperidine from 
L-lysine 
 
4.1 Introduction 
 
The synthesis of the enantiomers of 3-F-GABA has proven that L- and D- 
phenylalanine can be converted in an enantioselective manner to a β-fluoroamine in three 
steps. Serine and aspartic acid emerged also as potential precursors of β-fluoroamines. In 
fact, all α-amino acids can potentially be used as starting materials for the synthesis of β-
fluoroamines as long as their side chain functional groups are compatible with the three 
chemical steps presented in Scheme 4.1. Despite the fact that this transformation is 
straightforward and that β-fluoroamines form an interesting class of compounds, this 
methodology has not been explored in much detail (Scheme 4.1). 
 
 
 
 
Scheme 4.1: Transformation of α-amino acids into β-fluoroamines. 
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Interestingly, N-benzylprolinol (242) was reported by Shreeve et al.1 to give 3-
fluoropiperidine (243) via an aziridinium intermediate, and fluoromethylpyrrolidine (244) 
after reaction with Deoxofluor (Scheme 4.2). 3-Fluoropiperidine derivatives have 
interesting applications, not least because of the C-F···C-N+ gauche relationships observed 
in these compounds. However, this method is not an efficient way to synthesise 3-
fluoropiperidine (243) as it forms an inseparable mixture with (244).  
 
 .  
 
Scheme 4.2: Preparation of N-benzyl-3-fluoropiperidine (243) from (242).1 
 
 
From the list of the twenty proteinogenic α-amino acids, L-lysine (245) emerged as 
an attractive starting material. Indeed, its transformation into the corresponding β-
fluoroamine was anticipated to give (2R)-fluorohexane-1,6-diamine (248) (Scheme 4.3).  
 
 
 
 
 
 
Scheme 4.3: Schematic synthesis of (2R)-fluorohexane-1,6-diamine (248) from L-lysine. 
 
 
(2R)-Fluorohexane-1,6-diamine (248) is an analogue of 1,6-diaminohexane (249) 
which has found a wide range of applications, particularly in polymer chemistry, where it 
is used for example to produce nylon 6,6. In biology, 1,6-diaminohexane (249) can enter 
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the composition of polyamines which are known to bind to DNA molecules and induce 
bending of macroscopic DNA.2-4 (2R)-Fluorohexane-1,6-diamine (248) can also be 
envisaged as a precursor for the synthesis of a 2-fluorinated analogue of hexamethonium 
(250) which is an important nicotinic acetylcholine receptor antagonist.5 Although 
homology model crystal structures of nicotinic acetylcholine receptors have recently been 
published,6, 7 little is known about the binding site of (250).8  
 
 
 
Compounds (249) and (250) highlight the interest in synthesising 2-fluorohexane-
1,6-diamine (248) but obviously, the 1,6-diaminohexane moiety is part of many other 
important molecules, for which it might be interesting to explore a 2-fluoro analogue. At 
this position, the fluorine atom is likely to reduce the pKa value of the amine and the C-F 
bond is anticipated to align gauche to the C-N bond, particularly if the amine is protonated. 
The fact that 2-fluorohexane-1,6-diamine has not been reported yet, and the apparent 
simplicity of its preparation from L-lysine prompted us to investigate its synthesis. 
 
4.2 Synthesis of (2R)-fluorohexane-1,6-diamine 
4.2.1 The lysine approach 
 
The methodology applied previously to the synthesis of 3-F-GABA was used in 
this study. Accordingly, L-lysine was perbenzylated by addition of benzyl bromide and 
K2CO3 in DMF/water (10/1). The mixture was stirred at 60 °C for 3 days and the product 
was extracted into Et2O. The light yellow oil obtained was taken on directly for reduction, 
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but an analytical sample of perbenzylated lysine (251) was obtained after purification. The 
reduction was achieved with LiAlH4 and the resultant amino alcohol (246) was obtained 
after purification as a colourless oil in 62% yield over the two steps (Scheme 4.4). 
 
 
 
 
Scheme 4.4: Preparation of dibenzyl-α-amino alcohol (246) from L-lysine. Reagents and 
conditions: a) BnBr, K2CO3, DMF/H2O, 60 °C, 3 days; LiAlH4, THF, 0 °C, 2 h, 62%. 
 
 
Fluorination of amino alcohol (246) was conducted with DAST (1.15 eq) in DCM 
at room temperature. The crude product was purified by chromatography and the early 
fractions contained a small amount of the desired fluorinated compound (247) and its 
isomer (252) in a 85/15 ratio (Scheme 4.5). This ratio was similar to that observed for the 
fluorination of N,N-dibenzylphenylalaninol (178) for which the ratio of rearranged/non-
rearranged product isomers was 80/20. After two re-crystallisations from Et2O/hexane, 
(247) was isolated as a colourless crystalline solid albeit in a low 11% yield. 
 
 
 
 
 
 
 
Scheme 4.5: Preparation of (247) and (252). The conversion of (246) to fluorinated products (247) 
and (252) was low, yielding (247) in only 11% yield. Reagents and conditions: a) DAST, DCM, 
RT. 
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Tetrabenzyl-(2R)-fluorohexane-1,6-diamine (247) was fully characterised but its 
enantiopurity was not investigated. The crystals collected were amenable to X-ray structure 
analysis but were found to diffract very poorly. The structure was disordered about the 
C(3)/C(3A) bond, although a X-ray crystal structure of suitable quality for structure 
identification was obtained (Figure 4.1).  
 
 
 
 
 
 
 
Figure 4.1: X-ray crystal structure of tetrabenzyl-(2R)-fluorohexane-1,6-diamine (247). 
 
 
The very low conversion of amino alcohol (246) to β-fluoroamine (247) was 
disappointing and was most probably due to the formation of by-products occurring during 
the fluorination reaction. Although it was not possible to isolate any of these products, a 
very polar by-product was identified. High resolution mass spectroscopy analysis indicated 
that the compound had a mass of 475.3123, which matches the molecular formula 
(C34H39N2)+ (-0.1 ppm). Presumably, this could correspond to the nucleophilic attack of 
N6-nitrogen on aziridinium (253) (Scheme 4.6). 
 
 
 
Scheme 4.6: Putative formation of polar by-product (254) occurring during fluorination of amino 
alcohol (246). 
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The structure (254) drawn in Scheme 4.6 is consistent with mass spectrometric 
analysis and is based on the hypothesis that aziridinium (253) is formed, and that 
nucleophilic attack on the aziridinium occurs preferentially at the most substituted carbon 
to form a six-membered ring (favoured six-exo-tet ring closure). An attack on the other 
carbon (dashed line in Scheme 4.6) would result in the less favourable formation of a 
seven-membered ring (unfavoured seven-endo-tet ring closure). At this stage however, the 
structure (254) could not be clearly established. 
 
The formation of the putative cyclic by-product (254) is favoured over the 
formation of the fluorinated compound (247) which indicates that the dibenzyl-protected 
nitrogen is a better nucleophile than fluoride and consequently, that β-fluoroamine (247) 
will not be synthesised efficiently from 2,6-bis(dibenzylamino)hexan-1-ol (246). 
Nevertheless, the formation of (247), albeit in a low yield but in a good (247)/(252) ratio, 
suggests that if the nucleophilicity of the (ε)-nitrogen could be suppressed, the desired 
fluorinated product (247) might be formed more efficiently. 
 
 
 
 
 
 
 
 
 
Scheme 4.7: The treatment of (246) with DAST in DCM at RT gives a complex mixture of at least 
three compounds, most probably (254),  (247) and (252) in a 83/15/2 ratio of the crude reaction 
mixture.  
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4.2.2  The N(ε)-Z-L-lysine route 
 
 
 
The chemistry of L-lysine, as one of the common amino acids, is well developed. 
Many derivatives of L-lysine, orthogonally protected or not, have been prepared and are 
now commercially available. For example, N(ε)-benzyloxycarbonyl-L-lysine (255) is 
available from Aldrich at £20.50 for 5 g. The benzyloxycarbonyl protecting group appears 
ideal at first sight, as it suppresses the nucleophilicity of the N(ε) nitrogen and it can be 
cleaved by hydrogenolysis. Fortuitously, N(ε)-benzyloxycarbonyl-L-lysine methyl ester 
hydrochloride (256) was found in our laboratories and was used as starting material.  
 
 
 
 
 
 
Scheme 4.8: Synthesis of dibenzyl-α-amino alcohol (258) from (256). Reagents and conditions:  
a) BnBr, K2CO3, MeCN, 80 °C, 20 h, 97%; b) LiAlH4, THF, -10 °C, 50 min, 94%. 
 
 
Compound (256) was benzylated under standard conditions to give (257) in 
excellent yield (97%). (256) was then reduced with LiAlH4 in THF at -10 °C to furnish 
dibenzyl-α-amino alcohol (258) after work-up and purification, in a very good yield. It is 
worth noting that the benzyloxycarbonyl group was stable under these conditions.  
255
O
OH
H
N
NH2O
O
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The fluorination of dibenzyl-α-amino alcohol (258) was carried out with 
Deoxofluor (1.2 eq) in DCM at -10 ° C. The reaction mixture was allowed to warm to 
room temperature over six hours and was quenched by the addition of K2CO3. 19F NMR 
analysis of the crude reaction mixture revealed the presence of two fluorinated compounds 
in a 85/15 ratio, corresponding to the formation of (259) and (260). The ratio of rearranged 
(259) to non-rearranged (260) product was similar to that observed previously for (247) 
and (252). 1H NMR analysis of the crude product mixture was difficult to interpret but the 
existence of a non-fluorinated compound could also be detected in around 25% yield. This 
compound was less polar than the β-fluoroamines (259) and (260) and was isolated after 
purification by column chromatography, as a colourless oil and in a 20% yield. NMR and 
mass spectrometric analyses were consistent with structure (261) (Scheme 4.9). 
Compounds (259) and (260) which eluted after (261) were then collected as a 90/10 
mixture and as a colourless oil in 67% yield.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.9: Formation of fluorinated compounds (259) and (260) along with cyclic (261) by 
treatment of (258) with Deoxofluor. Reagents and conditions: a) Deoxofluor, -10 °C, 6 h. 
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The formation of the fluorinated compounds (259) and (260) was anticipated and 
can be explained by nucleophilic attack (paths a and b) of fluoride on aziridinium (262) 
(Figure 4.2). The formation of the cyclic compound (261) was however more surprising 
but can be rationalised by nucleophilic addition of the benzyloxycarbonyl-protected 
nitrogen to the aziridinium (262) (path c). Under the conditions used, the N(ε)-nitrogen is 
apparently nucleophilic enough to attack (262), but cyclisation occurred with a much lower 
conversion than found with the dibenzyl-protected N6-nitrogen in compound (246).   
 
 
 
 
Figure 4.2: Reactivity of intermediate (262). The aziridinium ring can be opened in three different 
ways, producing compounds (259), (260) and (261). Attack at the most substituted carbon is 
favoured (paths a and c). 
 
 
Compounds (259) and (260) could not be separated from each other by column 
chromatography and it was found more convenient to take the mixture directly through to 
the hydrogenolysis step. Nevertheless, an analytical sample of (259) was obtained as a 
colourless crystalline solid after re-crystallisation from Et2O/hexane. Crystals were 
amenable to X-ray structure analysis and a structure is shown in Figure 4.3. 
 
 
 
 
 
Figure 4.3: X-ray crystal structure of (259). Torsion angle N-C-C-F is 70.7 °.  
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Hydrogenolysis of (259) in MeOH was first conducted at atmospheric pressure 
with H2 and a catalytic amount of Pd(OH)2/C. However, only partial debenzylation was 
observed under these conditions. Interestingly, compound (263) was isolated in a good 
yield and was identified by NMR analysis. However, it was re-subjected to hydrogenolysis 
to generate (248) and was not fully characterised. 
 
 
 
Hydrogenolysis of (259) was then performed under a pressure of H2 (20 bars) in an 
autoclave for two days. After filtration of the solids on Celite, 1 M HCl in Et2O was added 
and the mixture was re-crystallised from MeOH/EtOH/Et2O. Three successive re-
crystallisations were required to purify dihydrochloride salt (248) from the by-product 
(264). In the end, (248) was obtained, as a colourless amorphous solid in 73% yield 
(Scheme 4.10).  
 
 
 
 
 
 
Scheme 4.10: Synthesis of (2R)-fluorohexane-1,6-diamine dihydrochloride (248) from L-lysine 
derivative (256). Reagents and conditions: a) BnBr, K2CO3, MeCN, 80 °C, 20 h, 97%; b) LiAlH4, 
THF, -10 °C, 50 min, 94%; c) Deoxofluor, DCM, -10 °C, 67%; d) Pd(OH)2/C, MeOH, H2 
(20 bars), 48 h, 73%. 
 
 
Standard re-crystallisations furnished (2R)-fluorohexane-1,6-diamine (248) as a 
white amorphous solid, presumably because of the long flexible alkane chain which is not 
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favourable for crystallisation. Nevertheless, very slow re-crystallisation by solvent 
diffusion at +4 °C yielded (428) as small white crystals which could be used for X-ray 
structure analysis (Figure 4.4). 
  
 
 
 
 
Figure 4.4: X-ray crystal structure of (2R)-fluorohexane-1,6-diamine dihydrochloride (248). 
Torsion angle F-C-C-N+ is 62.7° and the absolute configuration, determined by X-ray is (R). 
 
 
The absolute configuration of (248) was assessed by X-ray analysis to be (R), 
supporting the inversion of configuration via aziridinium intermediate (262). The 
enantiopurity of this compound was then investigated using (S)- and (R)- Mosher acids as 
derivatising reagents. In parallel procedures, (S)-(-)-Mosher acid and (R)-(+)-Mosher acid 
were added respectively to two mixtures containing 2-fluorohexane-1,6-diamine (248), 
Et3N and DMAP in DCM.  The two reactions were stirred for twelve hours and after 
evaporation of the solvent, the residues were dissolved in CDCl3 and analysed by 19F 
NMR.  
Compound (265) is the coupled product of (248) with two molecules of (S)-Mosher 
acid, and compound (266) comes from the coupling of (248) with two molecules of (R)-
Mosher acids. The 19F NMR signals for the fluorine at the stereogenic centres of 
respectively (265) and (266) are shown in Figure 4.5. Single peaks were found indicating 
that (248) was enantiopure. When compounds (265) and (266) were added in one tube, two 
distinct 19F NMR signals were observed. This clearly demonstrates the enantiopurity of 
(2R)-fluorohexane-1,6-diamine (248) from the fluorination reaction with Deoxofluor. 
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(a) 
 
 
 
(b) 
 
 
 
 (c) 
 
Figure 4.5: 19F NMR analysis (CDCl3, 375 MHz) of (S)-Mosher acid derivative (265) (a), (R)-
Mosher acid derivative (266) (b) and the mixture of both (c) showing the high enantiopurity of 
(248). 
 
The synthesis of (2R)-fluorohexane-1,6-diamine (248), developed from N(ε)-Z-L-
lysine methyl ester (256) is another example that α-amino acids can be converted to 
enantiopure β-fluoroamines. Around 500 mg of (248) was produced by this route, in a 45% 
overall yield from (256). This constitutes an efficient and robust synthesis of (248), using 
relatively cheap materials, with Deoxofluor being the most expensive. The main drawback 
of this route is probably the formation of the cyclic piperidine (261). It might be possible to 
avoid its formation with a more judicious choice of protecting group at the N6-nitrogen.    
A Boc protecting group for example, which could be installed prior to the fluorination step 
may give better results as it would reduce the nucleophilicity of the N6-nitrogen. However, 
it seems that the non-regioselective opening of the aziridinium intermediate (262) by 
fluoride, from which fluorinated compound (260) is formed as a by-product, is inherent to 
this kind of reaction and cannot be easily circumvented. 
Chapter 4 
_______________________________ 
 
 185 
 
4.3 Synthesis of (2R)-aminomethylpiperidine 
 
The formation of (2R)-((dibenzylamino)methyl)piperidine-1-benzoxycarbonate 
(261) as a minor product was judged to be worth investigation, because this compound 
could potentially be converted by hydrogenolysis to chiral diamine (2R)-aminomethyl-
piperidine (261) which has potential application in catalysis for example. 
Hydrogenolysis of (261) with Pearlman’s catalyst Pd(OH)2/C in MeOH under a 
pressure of H2 (20 bars) yielded, after addition of 1 M HCl and re-crystallisation from 
MeOH/Et2O, chiral diamine (267) as its dihydrochloride salt. The diamine (267) was 
obtained in 14% overall yield from (256) (Scheme 4.11).   
 
 
 
 
 
 
 Scheme 4.11: Synthesis of (2R)-aminomethylpiperidine dihydrochloride (267) from L-lysine 
derivative (256). Reagents and conditions: a) BnBr, K2CO3, MeCN, 80 °C, 20 h, 97%; b) LiAlH4, 
THF, -10 °C, 50 min, 94%; c) Deoxofluor, DCM, -10 °C, 20%; d) Pd(OH)2/C, MeOH, H2 
(20 bars), 48 h, 75%. 
 
Interestingly, benzylamine (268) was isolated in a good yield (79%) when 
hydrogenolysis was performed under an atmospheric pressure of H2. Benzylamine (268) 
was characterised only by NMR and was then re-subjected to hydrogenolysis. 
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Re-crystallisation of the dihydrochloride salt of (267) yielded large, colourless 
crystals which were amenable to X-ray structure analysis. The absolute configuration was 
assigned unambiguously by X-ray to be (R), as shown in Figure 4.6. 
 
 
 
 
 
 
Figure 4.6: X-ray crystal structure of (2R)-aminomethyl-piperidine dihydrochloride (261). 
 
 
Chiral diamines form an important class of compounds which have found a wide 
range of applications in chemistry, particularly as bidentate ligands for the design of 
asymmetric catalysts. 1,2-Diaminocyclohexane (269) for example is used in Trost’s 
catalyst (270) for asymmetric allylic alkylation reactions9, 10 and also in salen-type ligands 
(Jacobsen’s catalyst)11 for enantioselective epoxidation (271).  
 
 
 
 
 
 
2-Aminomethylpiperidine however has not been widely used in the design of chiral 
ligands. A possible explanation for this could be its limited availability. Indeed, 
enantiopure 2-aminomethylpiperidine is not commercially available and although 
enantiomers can be prepared by the resolution of the racemate12 or from pipecolic acid 
(272) by amidation and reduction,12-14 this does not constitute a practical route to 
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synthesise (267) in reasonable quantities. Pipecolic acid (272) is an expensive starting 
material, compared to L-lysine from which (2R)-aminomethylpiperidine (267) was 
prepared in this work. The synthesis from L-lysine constitutes a novel preparation of (267) 
and due to its high potential in asymmetric catalysis, it was decided to optimise the 
synthesis presented in Scheme 4.11.  
 
 
 
 
The most vulnerable step in the synthesis of 2-aminomethylpiperidine (267) is 
clearly the low 20% yield obtained from the fluorination reaction. To improve this yield, 
the intramolecular nucleophilic attack of N6-nitrogen needs to be favoured over the 
intermolecular reaction with fluoride.  
Taking advantage of the strength of the Si-F bond, silica (SiO2) was added to the 
reaction mixture of amino alcohol (258) in DCM. The idea was to trap fluoride anions with 
silica before they can react with the aziridinium intermediate (262). Empirically, it was 
chosen to add 200 mg of dry silica to a mixture of 200 mg of (258) in DCM at -78 °C. 
Deoxofluor (1.5 eq) was then added and the reaction was stirred at -78 °C for six hours. 
Pleasingly, only traces of fluorinated products (259) and (260) were detected by 19F and 1H 
NMR analysis of the crude reaction mixture. After purification, the piperidine (261) was 
isolated in ~50% yield, which represented a significant improvement on the 20% yield 
obtained from the reaction without silica at -10 °C.  
Interestingly, another product was isolated in 28% yield from this reaction. Mass 
spectroscopy analysis revealed that this compound had the same mass as the starting 
material (258) but its NMR spectra were clearly different and suggested structure (273) 
(Scheme 4.12). 
272
NH
O O H
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Scheme 4.12: Fluorination of (258) with addition of silica. Reagents and conditions: a) SiO2, 
Deoxofluor, DCM, -78 °C, 6 h. 
 
 
Compound (273) was not fully characterised and it is not clear how and when it is 
formed. Manifestly, it results from the opening of aziridinium (262) by a species 
containing a hydroxyl group. 
The amount of silica added to this reaction was not optimised but this experiment 
proved that addition of silica is an efficient and effective method to suppress the 
nucleophilicity of fluoride anions in the reaction mixture. 
 
At this point, it seemed that the synthesis of 2-aminomethylpiperidine could be 
simplified and that Deoxofluor activation could be replaced by some alternative method. 
Mesylate activation was considered. This would, of course, suppress the problem 
encountered with side reactions involving fluoride anions because mesylate MsO- is a 
relatively poor nucleophile which does not open the aziridinium ring. It is known that an 
aziridinium intermediate is formed by addition of Ms2O, MsCl or Tf2O to solutions of N,N-
dibenzyl-α-amino alcohols.15-19.  
Disappointingly, treatment of Ms2O and Et3N (1.5 eq) with amino alcohol (258) 
failed to produce the desired cyclic product (261). Addition of MsCl also failed and 
generated the chlorinated compound (274) instead, as evidenced by NMR and mass 
spectroscopy analyses (Scheme 4.13). This type of reaction has already been reported and 
is not surprising given the higher nucleophilicity of chloride over the benzyloxycarbonyl-
protected amine.19 
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Scheme 4.13: Treatment of (258) with MsCl generates (274). 
 
 
Similarly, treatment of (246) with MsCl also failed to form cyclic salt (254), which 
was formed initially in ~83% upon treatment with DAST. This time however, chlorinated 
compound (272) was detected by NMR and mass spectroscopy analyses (Scheme 4.14).  
 
 
 
 
Scheme 4.14: Treatment of (246) with MsCl generates (275). 
 
 
The intramolecular ring opening of in situ-generated aziridinium ring systems has 
been reported many times, but it is not clear why in our case it worked only with 
Deoxofluor. In a related reaction published by Gmeiner et al., glutamine (276) was used to 
prepare dibenzyl-α-amino alcohol (277), which upon treatment with Tf2O, underwent 
cyclisation via an aziridinium intermediate to give (278). After elimination and 
hydrogenolysis, the product (279) was obtained and was found to be enantiopure 
(Scheme 4.15).20 
 
 
 
 
Scheme 4.15: Example of cyclisation from dibenzyl-α-amino alcohol (277) via an aziridinium 
intermediate.20 
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It is not clear why methanesulfonic anhydride did not promote the intramolecular 
reaction but the synthesis of (261) was not optimised any further. Nevertheless, (2R)-
aminomethylpiperidine hydrochloride (267) could be prepared in 34% overall yield from 
commercially available N(ε)-Z-lysine methyl ester (256). The key step mediated by 
Deoxofluor, was significantly improved by the addition of silica gel to the reaction 
mixture. 
It was shown in this study that dibenzyl-α-amino alcohol (258) can give mainly 
either the β-fluoroamine (259) or piperidine (261), depending on the conditions used 
(Scheme 4.16). The enantiopurity of (2R)-aminomethylpiperidine (267) has not been 
assessed in a definitive manner and the optical rotation found does not match satisfactorily 
that reported in the literature. Further work is required to optimise the synthesis of (267) 
and to assess its enantiopurity by the transformation shown in Scheme 4.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.16: Amino alcohol (258) as precursor of β-fluoroamine (259) and diamine (261). 
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5 Chapter 5: Experimental 
 
5.1 General methods 
5.1.1 Reagents, solvents and reaction conditions 
All reagents were of synthetic grade and were used without further purification 
unless otherwise stated. Dry diethyl ether and dry THF were distilled from sodium wire 
and benzophenone; dry methanol and dry DCM were distilled from calcium hydride. 
All moisture sensitive reactions were carried out under a positive pressure of nitrogen in 
oven-dried glassware (140 °C). Reaction temperatures of -78 °C to -40 °C were 
obtained using solid CO2 in acetone or a bath cooling apparatus LP Technology RP-
100-CD; reaction temperature of -10 °C was obtained using an ice/acetone bath. 
Organic extracts were dried over MgSO4. 
 
5.1.2 Chromatography and mass spectrometry 
Thin layer chromatography (TLC) was performed using Macherey-Nagel 
Polygram Sil G/UV254 plastic plates; visualisation was achieved by inspection under UV 
light (255 nm) or by the use of potassium permanganate stain, molybdenum-based stain, 
ferric chloride stain, bromocresol green stain or ninhydrin spray. Column 
chromatography was performed using silica gel 60 (40-63 micron) from Apollo 
Scientific Ltd. Ion-exchange chromatography was performed using Dowex® 50 W-
X8100 resin with 50-100 mesh particules. GC-MS analyses were obtained using an 
Agilent 5890 gas chromatograph equipped with an Agilent 5973N mass-selective 
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detector. High-resolution mass spectrometry was performed by Mrs. C. Horsburgh on a 
Waters LCT or GCT time-of-flight mass spectrometer. 
 
5.1.3 Nuclear magnetic resonance spectroscopy (NMR) 
NMR spectra were recorded on either Bruker AV-300 (1H at 300.06 MHz, 13C at 
75.45 MHz, 19F at 282.34 MHz), or Bruker AV-300 (1H at 300.13 MHz, 13C at 75.48 
MHz), or Bruker AV-500 (1H at 499.90 MHz, 19F at 470.33 MHz). Chemical shifts δ 
are reported in parts per million (ppm) and quoted relative to internal standard Me4Si 
for 1H and 13C and to external standard CFCl3 for 19F. 1H, 13C and 19F spectroscopic data 
were assigned on a routine basis by a combination of one- and two- dimensional 
experiments (COSY, HSQC, HMBC, NOESY). 
 
5.1.4 Other analysis 
Melting points were measured using a GallenKamp Griffin MPA350.BM2.5 
melting point apparatus and are uncorrected. Optical rotations were determined using a 
A-1000 polarimeter (Optical Polarimeter Ltd) or a Perkin Elmer Model 341 polarimeter, 
[α]D values are measured at 589 nm and given in 10-1deg.cm2.g-1. Elemental analyses 
were carried out by Mrs. S. Williamson on a CE instrument EA 1110 CHNS analyser. 
IR spectra were recorded on a Perkin Elmer Spectrum GX FT-IR system as KBr disc or 
as thin film on NaCl plates. Single X-ray diffraction analyses were carried out by Prof. 
A.M.Z Slawin. pKa Determinations were conducted on a Fisherbrand Hydrus 300 pH 
meter equipped with a Hamilton biotrode pH electrode calibrated at pH 4 and pH 7 with 
standard buffer solutions.  
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5.2 Protocols 
5.2.1  (3α,5α,17β)-17-Phenylandrostane-3,17-diol (89)1  
 
 
 
 
n-BuLi (3.2 cm3, 2.5 M in hexane, 8.0 mmol) was added at 0 °C under N2 to a 
solution of bromobenzene (1.41 g, 9.0 mmol) in dry diethyl ether (6 cm3). The mixture 
was stirred for 30 min at 0 °C and 1 h at RT. The solution was then cooled to -10 °C and 
added dropwise via canula to a solution of androsterone (300 mg, 1.0 mmol) in dry THF 
(20 cm3). The reaction mixture was stirred 2 h at -10 °C and 16 h at RT. A saturated 
solution of NH4Cl (10 cm3) was added and the organic phase was extracted into EtOAc 
(3 × 50 cm3). The combined extracts were washed with brine and dried. After 
evaporation of the solvent under reduced pressure, the product was purified over silica 
gel (hexane/ EtOAc 6:1) to give (89) as a colourless solid (165 mg, 43%). 
 
Mp: 190-192 °C (from hexane/EtOAc), lit1 193-196 °C (from hexanes/EtOAc); 
δH (300 MHz, CDCl3) 7.19-7.27 (5 H, m, Ar-H), 3.89-3.93 (1 H, m, C3H),  2.30 (1 H, 
ddd, J=5.2 Hz, J=9.8 Hz, J=14.3 Hz, C16HA), 2.01 (1 H, ddd, J=4.6 Hz, J=12.5 Hz, 
J=14.3 Hz, C16HB), 0.73-1.78 (20 H, m), 0.97 (3 H, s, C18H3), 0.68 (3 H, s, C19H3), 0.23-
0.40 (2 H, m); δC (75 MHz, CDCl3) 146.5 (Ar), 127.7 (2 × C, Ar), 127.6 (2 × C, Ar), 
127.1 (Ar), 86.4 (C17), 66.9 (C3), 54.1 (C9), 49.5 (C14), 47.1 (C13), 39.5 (C5), 39.0 (C16), 
36.6 (C8), 36.5 (C10), 36.2 (C4), 34.0 (C12), 32.4 (C1), 32.1 (C7), 29.3 (C2), 28.8 (C6), 
24.8 (C15), 20.7 (C11), 15.3 (C18), 11.6 (C19). 
These data are in accordance with the literature.1
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5.2.2 (3α,5α,17β)-17-Phenylandrostane-3,17-diol, 3-acetate (90)1  
 
 
 
 
Ac2O (0.5 cm3) and 4-DMAP (24 mg) were added to a solution of (3α,5α,17β)-
17-phenylandrostane-3,17-diol (89) (180 mg, 0.5 mmol) in pyridine (2.5 cm3). The 
mixture was stirred at RT for 15 min and poured into 10% NaHCO3 (20 cm3). After the 
mixture was stirred for 10 min, the product was extracted into EtOAc (3 × 40 cm3). The 
combined organic extracts were dried and evaporated under reduced pressure. The 
product was purified over silica gel (hexane/EtOAc 10:1) to give (90) as a colourless 
amorphous solid (180 mg, 90%). 
 
Mp: 198-199 °C (from hexane/EtOAc), lit1 196-198 °C; δH (300 MHz, CDCl3) 
7.23-7.39 (5 H, m, Ar-H), 4.94-4.98 (1 H, m, C3H), 2.38 (1 H, ddd, J=4.8 Hz, J=9.7 Hz, 
J=14.3 Hz, C16HA), 2.04-2.15 (1 H, m, C16HB),  1.99 (3 H, s, CH3CO2), 0.79-1.88 (19 H, 
m), 1.05 (3 H, s, C18H3), 0.77 (3 H, s, C19H3), 0.32-0.49 (2 H, m); δC (75 MHz, CDCl3) 
171.1 (CO2), 146.7 (Ar), 127.8 (2 × C, Ar), 127.6 (2 × C, Ar), 127.1 (Ar), 86.3 (C17), 
70.5 (CH), 54.0 (CH), 49.9 (CH2), 47.1 (C13), 40.3 (CH), 38.9 (CH2), 36.6 (CH), 36.2 
(C10), 34.0 (CH2), 33.2 (CH2), 33.1 (CH2), 32.0 (CH2), 28.7 (CH2), 26.4 (CH2), 24.8 
(CH2), 21.9 (CH2), 20.7 (CH3CO2), 15.3 (CH3), 11.8 (CH3). 
These data are in accordance with the literature.1 
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5.2.3 (3α,5α)-17-Phenylandrost-16-en-3-ol acetate (91)1  
 
 
 
 
Et3N (0.6 cm3) and MsCl (0.18 cm3, 2.3 mmol) were added at 0 °C to a solution 
of (3α,5α,17β)-17-phenylandrostane-3,17-diol, 3-acetate (90) (170 mg, 0.4 mmol) in 
dry DCM (15 cm3). The solution was stirred for 1 h at 0 °C and DCM was removed 
under reduced pressure. The product was purified over silica gel (hexane/EtOAc 15:1) 
to give (91) as a colourless amorphous solid (140 mg, 86%). 
 
Mp: 143-145 °C (from CHCl3), lit1 152-153 °C (from hexanes); δH (300 MHz, 
CDCl3) 7.10-7.31 (5 H, m, Ar-H), 5.82 (1 H, dd, J=1.7 Hz, J=3.2 Hz, C16H), 4.92-4.96 
(1 H, m, C3H), 2.12 (1 H, ddd, J=3.3 Hz, J=6.3 Hz, J=15.5 Hz, C15HA), 1.86-2.01 (2 H, 
m), 1.97 (3 H, s, CH3CO2), 0.73-1.70 (17 H, m), 0.94 (3 H, s, C18H3), 0.77 (3 H, s, 
C19H3); δC (75 MHz, CDCl3) 171.1 (CO2), 155.3 (C17), 137.8 (Ar), 128.5 (2 × C, Ar), 
127.6 (C16), 127.1 (3 × C, Ar), 70.5 (CH), 58.1 (CH), 54.9 (CH), 47.8 (C13), 40.7 (CH), 
36.4 (C10), 35.9 (CH2), 34.4 (CH), 33.3 (CH2), 33.2 (CH2), 32.2 (CH2), 31.9 (CH2), 28.8 
(CH2), 26.5 (CH2), 22.0 (CH3CO2), 21.2 (CH2), 17.2 (CH3), 11.8 (CH3). 
These data are in accordance with the literature.1 
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5.2.4 (3α,5α)-17-Phenylandrost-16-en-3-ol (87)1  
 
 
 
 
 5 N NaOH (1 cm3) was added at RT to a solution of (3α,5α)-17-phenylandrost-
16-en-3-ol acetate (91) (130 mg, 0.33 mmol) in MeOH (15 cm3). The mixture was 
heated under reflux for 1 h and cooled to RT. Water (8 cm3) was added and the product 
was extracted into DCM (3 × 40 cm3). The combined extracts were dried and the 
solvents removed under reduced pressure. The product was purified over silica gel 
(hexane/EtOAc 9:1) to give (3α,5α)-17-phenylandrost-16-en-3-ol (87) as a colourless 
amorphous solid (104 mg, 89%). 
Mp: 169-170 °C (from CHCl3), lit1 174.5-175.5 °C (from hexanes/EtOAc); 
[α]20D +23.0 (c 1.5 CHCl3); (Found: C, 85.84; H, 10.21 %, C25H34O requires C, 85.66; 
H, 9.78 %); νmax(KBr plate)/cm-1 3361 (br), 2925, 2855, 1603, 1493, 1445, 1370, 1262, 
1033, 753, 691; δH (300 MHz, CDCl3) 7.18-7.38 (5 H, m, Ar-H), 5.88 (1 H, dd, 
J=1.7 Hz, J=3.1 Hz, C16H), 4.02-4.06 (1 H, m, C3H), 2.20 (1 H, ddd, J=3.3 Hz, 
J=6.2 Hz, J=15.4 Hz, C15HA), 1.93-2.07 (2 H, m), 0.81-1.78 (18 H, m), 1.02 (3 H, s, 
C18H3), 0.83 (3 H, s, C19H3); δC (75 MHz, CDCl3) 155.3 (C17), 137.8 (Ar), 128.5 (2 × C, 
Ar), 127.6 (C16), 127.1 (2 × C, Ar), 127.0 (Ar), 67.0 (CH), 58.1 (CH), 55.1 (CH), 47.8 
(C13), 39.8 (CH), 36.7 (C10), 36.3 (CH2), 35.9 (CH2), 34.5 (CH), 32.5 (CH2), 32.3 (CH2), 
31.9 (CH2), 29.4 (CH2), 28.9 (CH2), 21.2 (CH2), 17.2 (CH3), 11.6 (CH3); m/z (+CI), 
found MH+: 351.2683, C25H35O requires 351.2688 (-1.5 ppm). 
These data are in accordance with the literature.1
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5.2.5 (3α,5α,17β)-17-(m-Fluorophenyl)androstane-3,17-diol (96) 
 
 
 
n-BuLi (2.0 cm3, 2.5 M in hexane, 5.0 mmol) was added at -78 °C under N2 to a 
solution of 3-fluoro-bromobenzene (0.55 cm3, 5.0 mmol) in dry diethyl ether (5 cm3). 
The mixture was stirred for 30 min at -78 °C and added dropwise via canula over 
10 min to a solution of androsterone (300 mg, 1.0 mmol) in dry THF (20 cm3). The 
reaction mixture was stirred 3 h at -78 °C and the temperature was allowed to warm to 
RT over 15 h. A saturated solution of NH4Cl (10 cm3) was added and the organic phase 
was extracted into EtOAc (3 × 50 cm3). The combined organic extracts were washed 
with brine and dried. After evaporation of the solvent, the product was purified over 
silica gel (hexane/EtOAc 6:1) to give (96) as a colourless solid (125 mg, 31%). 
Mp: 182-188 °C (from hexane/EtOAc); [α]20D +25.3 (c 0.4, CHCl3); 
νmax(KBr plate)/cm-1 3422 (br), 2926, 2854, 1613, 1586, 1437, 1262, 1096, 1016, 804; 
δH (300 MHz, CDCl3) 6.92-7.45 (4 H, m, Ar-H), 3.95-4.01 (1 H, m, C3H),  2.33 (1 H, 
ddd, J=5.3 Hz, J=9.7 Hz, J=14.4 Hz, C16HA), 2.08 (1 H, ddd, J=4.4 Hz, J=12.5 Hz, 
J=14.4 Hz, C16HB), 0.53-1.87 (20 H, m), 1.03 (3 H, s, C18H3), 0.76 (3 H, s, C19H3), 0.29-
0.49 (2 H, m); δC (75 MHz, CDCl3) 162.6 (d, J=244.2 Hz, Ar-F), 149.5 (d, J=6.4 Hz, 
Ar), 128.9 (d, J=8.1 Hz, Ar), 123.4 (d, J=2.4 Hz, Ar), 115.0 (d, J=22.1 Hz, Ar), 113.9 
(d, J=21.1 Hz, Ar), 86.3 (C17), 66.8 (CH), 54.1 (CH), 49.5(CH), 47.2 (C13), 39.4 (CH), 
39.1 (CH2), 36.6 (CH), 36.4 (C10), 36.2 (CH2), 34.0 (CH2), 32.4 (CH2), 32.0 (CH2), 29.3 
(CH2), 28.8 (CH2), 24.7 (CH2), 20.7 (CH2), 15.3 (CH3), 11.6 (CH3); δF (282 MHz, 
CDCl3) -114.6 (1 F, ddd, J=6.1 Hz, J=8.4 Hz, J=11.0 Hz); m/z (+ES), found (M+Na+): 
409.2512, C25H35O2NaF requires 409.2519 (-1.8 ppm). 
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5.2.6 (3α,5α,17β)-17-(m-Fluorophenyl)androstane-3,17-diol, 3-acetate (97) 
 
 
 
 
Ac2O (0.2 cm3) and 4-DMAP (8 mg) were added to a solution of (3α,5α,17β)-
17-(m-fluorophenyl)androstane-3,17-diol (96) (62 mg, 0.16 mmol) in pyridine 
(0.5 cm3). The mixture was stirred at RT for 15 min and poured into 10% NaHCO3 
(8 cm3). After further stirring for 20 min, the product was extracted into EtOAc (3 × 
20 cm3). The combined organic extracts were dried over MgSO4 and evaporated under 
reduced pressure. The product was purified over silica gel (hexane/ EtOAc 10:1) to give 
(97) as a colourless solid (55 mg, 80%). 
 
Mp: 195-197 °C (from CHCl3); δH (300 MHz, CDCl3) 6.92-7.31 (4 H, Ar-H), 
4.93-4.98 (1 H, m, C3H), 2.34 (1 H, ddd, J=5.3 Hz, J=9.7 Hz, J=14.5 Hz, C16HA), 2.09 
(1 H, ddd, J=4.2 Hz, J=12.4 Hz, J=14.4 Hz, C16HB), 1.99 (3 H, s, CH3CO2), 0.57-1.94 
(19 H, m), 1.04 (3 H, s, C18H3), 0.77 (3 H, s, C19H3), 0.31-0.51 (2 H, m); δC (75 MHz, 
CDCl3) 171.1 (CO2), 162.6 (d, J=244.3 Hz, Ar-F), 149.5 (d, J=6.3 Hz, Ar), 128.9 (d, 
J=8.1 Hz, Ar), 123.4 (d, J=2.4 Hz, Ar), 115.0 (d, J=22.1 Hz, Ar), 113.9 (d, J=21.0 Hz, 
Ar), 86.3 (C17), 70.5 (CH), 54.0 (CH), 49.5 (CH2), 47.3 (C13), 40.3 (CH), 39.1 (CH2), 
36.6 (CH), 36.2 (C10), 34.0 (CH2), 33.2 (CH2), 33.1 (CH2), 31.9 (CH2), 28.6 (CH2), 26.4 
(CH2), 24.7 (CH2), 21.9 (CH3CO2), 20.7 (CH2), 15.3 (CH3), 11.7 (CH3); δF (282 MHz, 
CDCl3) -114.6 (1 F, ddd, J=6.1 Hz, J=8.4 Hz, J=11.1 Hz). 
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5.2.7 (3α,5α)-17-(m-Fluorophenyl)androst-16-en-3-ol acetate (98) 
 
 
 
 
Et3N (0.2 cm3) and MsCl (60 µL, 0.77 mmol) were added at 0 °C to a solution of 
(3α,5α,17β)-17-(m-fluorophenyl)androstane-3,17-diol, 3-acetate (97) (50 mg, 
0.12 mmol) in dry DCM (5 cm3). The solution was stirred for 45 min at 0 °C and DCM 
was removed under reduced pressure. The crude product was purified over silica gel 
(hexane/EtOac 15:1) to give (98) as a colourless solid (32 mg, 67%). 
 
Mp: 148-150 °C (from CHCl3); δH (300 MHz, CDCl3) 7.20-7.28 (1 H, m, Ar-
H), 7.12-7.16 (1 H, m, Ar-H), 7.03-7.09 (1 H, m, Ar-H), 6.87-6.94 (1 H, m, Ar-H), 5.94 
(1 H, dd, J=1.8 Hz, J=3.2 Hz, C16H), 5.00-5.04 (1 H, m, C3H), 2.21 (1 H, ddd, 
J=3.3 Hz, J=6.3 Hz, J=15.7 Hz, C15HA), 1.94-2.08 (2 H, m), 2.06 (3 H, s, CH3CO2), 
0.78-1.78 (17 H, m), 1.01 (3 H, s, C18H3), 0.85 (3 H, s, C19H3); δC (75 MHz, CDCl3) 
171.2 (CH3CO2), 163.1 (d, J=244.4 Hz, Ar-F), 154.2 (d, J=1.9 Hz, C17), 140.0 (d, 
J=7.7 Hz, Ar), 129.8 (d, J=8.4 Hz, Ar), 128.9 (C16), 122.7 (d, J=2.6 Hz, Ar), 113.8 (d, 
J=21.5 Hz, Ar), 113.8 (d, J=21.1 Hz, Ar), 70.5 (CH), 58.0 (CH), 54.9 (CH2), 47.8 (C13), 
40.6 (CH), 36.4 (C10), 35.8 (CH2), 34.4 (CH), 33.3 (CH2), 33.1 (CH2), 32.2 (CH2), 31.9 
(CH2), 28.7 (CH2), 26.5 (CH2), 22.0 (CH3CO2), 21.2 (CH2), 17.2 (CH3), 11.7 (CH3);    
δF (282 MHz, CDCl3) -114.3 (1 F, ddd, J=6.1 Hz, J=8.6 Hz, J=10.6 Hz); m/z (+ES), 
found (M+Na+): 433.2516, C27H35O2FNa requires 433.2519 (-0.7 ppm). 
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5.2.8 (3α,5α)-17-(m-Fluorophenyl)androst-16-en-3-ol (99) 
 
 
 
 
 5 N NaOH (0.15 cm3) was added at RT to a solution of (3α,5α)-17-(m-
fluorophenyl)androst-16-en-3-ol acetate (98) (21 mg, 0.05 mmol) in MeOH (2.5 cm3). 
The mixture was heated under reflux for 1 h and cooled to RT. Water (2 cm3) was 
added and the product was extracted into DCM (3 × 10 cm3). The combined organic 
extracts were dried and the solvent removed under reduced pressure. The product was 
purified over silica gel (hexane/EtOAc 9:1) to give (99) as a colourless solid (17 mg, 
90%). 
 
Mp: 179-184 °C (from CHCl3); δH (300 MHz, CDCl3) 7.20-7.27 (1 H, m, Ar-
H), 7.12-7.15 (1 H, m, Ar-H), 7.03-7.08 (1 H, m, Ar-H), 6.87-6.94 (1 H, m, Ar-H), 5.93 
(1 H, J=1.8 Hz, J=3.1 Hz, C16H), 4.04-4.07 (1 H, m, C3H), 2.21 (1 H, ddd, J=3.3 Hz, 
J=6.2 Hz, J=15.6 Hz, C15HA), 1.94-2.01 (2 H, m), 0.75-1.78 (18 H, m), 1.01 (3 H, s, 
C18H3), 0.84 (3 H, s, C19H3); δC (75 MHz, CDCl3) 163.1 (d, J=244.5 Hz, Ar-F), 154.3 
(d, J=2.0 Hz, C17), 140.0 (d, J=7.8 Hz, Ar), 129.8 (d, J=8.5 Hz, Ar), 128.9 (C16), 122.7 
(d, J=2.6 Hz, Ar), 113.8 (d, J=21.5 Hz, Ar), 113.7 (d, J=21.1 Hz, Ar), 67.0 (CH), 58.0 
(CH), 55.0 (CH), 47.8 (C13), 39.7 (CH), 36.7 (C10), 36.3 (CH2), 35.8 (CH2), 34.4 (CH), 
32.4 (CH2), 32.2 (CH2), 31.9 (CH2), 29.4 (CH2), 28.9 (CH2), 21.2 (CH2), 17.2 (CH3), 
11.6 (CH3); δF (282 MHz, CDCl3) -114.3 (1 F, ddd, J=6.2 Hz, J=8.7 Hz, J=10.7 Hz); 
m/z (+CI), found MH+: 369.2599, C25H34OF requires 369.2594 (+1.3 ppm). 
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5.2.9 17α-(m-Fluorophenyl)-17β-methyl-5α-androsten-13-3α-ol (110) 
 
 
 
 
p-Toluenesulfonic acid monohydrate (40 mg, 0.26 mmol) was added at RT to a 
solution of (3α,5α,17β)-17-(m-fluorophenyl)androstane-3,17-diol (96) (50 mg, 
0.13 mmol) in dry DCM (10 cm3). The mixture was heated under reflux for 5 h, cooled 
down to RT, 1 M NaHCO3 (5 cm3) was added and the solution was stirred for 15 min. 
The product was extracted into DCM (2 × 20 cm3), the combined organic extracts were 
dried and the solvent was evaporated under reduced pressure. The product was purified 
over silica gel (hexane/EtOAc 10:1) to give (110) as a colourless oil (25 mg, 52%). 
δH (500 MHz, CDCl3) 7.23 (1 H, ddd, J=6.4 Hz, J=8.0 Hz, J=8.0 Hz, Ar-H), 
7.03 (1 H, ddd, J=2.0 Hz, J=2.0 Hz, J=7.9 Hz, Ar-H), 6.95 (1 H, ddd, J=2.0 Hz, 
J=2.0 Hz, J=11.1 Hz, Ar-H), 6.84 (1 H, ddd, J=2.5 Hz, J=8.3 Hz, J=8.4 Hz, Ar-H), 
4.06-4.08 (1 H, m, C3H), 2.32-2.40 (1 H, m, C15HA), 2.12-2.21 (2 H, m, C15HB + C8H), 
1.80-2.02 (5 H, m), 1.04-1.77 (14 H, m), 1.40 (3 H, C18H3), 0.78 (3 H, C19H3); 
δC (75 MHz, CDCl3) 163.0 (d, J=244.2 Hz, Ar), 152.0 (d, J=6.2 Hz, Ar), 139.9 (C14), 
139.6 (C13), 129.3 (d, J=8.2 Hz, Ar), 121.6 (d, J=2.3 Hz, Ar), 113.0 (d, J=21.4 Hz, Ar), 
112.1 (d, J=21.2 Hz, Ar), 66.6 (C3), 53.1 (C17), 51.8 (C9), 42.2 (C16), 39.1 (C5), 36.9 
(C8), 36.1 (C10), 35.7 (C4), 31.9 (C1), 31.5 (C7), 30.5 (C15), 29.0 (C6+C2), 24.2 (C18), 
22.9 (C12), 22.2 (C11), 10.7 (C19); δF (282 MHz, CDCl3) -114.3 (1 F, ddd, J=6.3 Hz, 
J=8.5 Hz, J=11.2 Hz); m/z (+CI), found MH+: 369.2594, C25H34OF requires 369.2594 
(+0.2 ppm). 
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5.2.10 (3α,5α,17β)-17-(p-Fluorophenyl)androstane-3,17-diol (108) 
 
 
 
n-BuLi (3.8 cm3, 2.5 M in hexane, 9.5 mmol) was added at -78 °C under N2 to a 
solution of 4-fluoro-bromobenzene (1.1 cm3, 10.0 mmol) in dry diethyl ether (10 cm3). 
The mixture was stirred for 3 h at -78 °C and then 3 h at -40 °C. The solution was then 
added dropwise via canula at -40 °C to a solution of androsterone (300 mg, 1.0 mmol) 
in dry THF (15 cm3). The reaction mixture was stirred for 8 h at -40 °C and the 
temperature was allowed to warm to RT over 12 h. A saturated solution of NH4Cl 
(10 cm3) was added and the organic phase was extracted into EtOAc (3 × 50 cm3). The 
combined organic extracts were dried and evaporated and the product was purified over 
silica gel (hexane/EtOAc 6:1) to give (108) as a colourless solid (158 mg, 40%). 
Mp: 173-176 °C (from CHCl3); [α]D20 +18.0 (c 1.5, CHCl3); νmax(KBr 
plate)/cm-1 3464 (br), 2932, 2855, 1603, 1508, 1226, 1162, 1075, 1016, 1005, 832; δH 
(300 MHz, CDCl3) 7.23 (2 H, dd, J=5.6 Hz, J=8.8 Hz, Ar-H), 6.91 (2 H, dd, J=8.8 Hz, 
J=8.8 Hz, Ar-H), 3.94-3.99 (1 H, m, C3H), 2.24 (1 H, ddd, J=5.2 Hz, J=9.7 Hz, J=14.7 
Hz, C16HA), 1.93-2.05 (1 H, m, C16HB), 0.72-1.77 (20 H, m), 0.95 (3 H, s, C18H3), 0.67 
(3 H, s, C19H3); 0.20-0.39 (2 H, m); δC (75 MHz, CDCl3) 162.1 (d, J=245.2 Hz, Ar-F), 
142.1 (d, J=3.1 Hz, Ar), 129.3 (2 × C, d, J=7.8 Hz, Ar), 114.3 (2 × C, d, J=20.9 Hz, Ar), 
86.1 (C17), 66.8 (CH), 54.1 (CH), 49.5 (CH), 47.0 (C13), 39.4 (CH), 39.1 (CH2), 36.6 
(CH), 36.4 (C10), 36.1 (CH2), 33.9 (CH2), 32.4 (CH2), 32.0 (CH2), 29.3 (CH2), 28.8 
(CH2), 24.6 (CH2), 20.7 (CH2), 15.2 (CH3), 11.5 (CH3); δF (282 MHz, CDCl3) -117.0 (1 
F, tt, J=5.4 Hz, J=8.6 Hz); m/z (+ES), found (M+Na+): 409.2517, C25H35O2NaF requires 
409.2519 (-0.4 ppm). 
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5.2.11 (3α,5α)-17-(p-Fluorophenyl)androst-16-en-3-ol (109) 
 
 
 
 
p-Toluenesulfonic acid monohydrate (10 mg, 0.05 mmol) was added at RT to a 
solution of (3α,5α,17β)-17-(p-fluorophenyl)androstane-3,17β-diol (108) (120 mg, 
0.31 mmol) in dry DCM (20 cm3). The reaction solution was heated under reflux for 4 h 
and stirred at RT for 2 h. The reaction solution was washed with a 10% solution of 
NaHCO3 (10 cm3) and the organic phase was extracted into diethyl ether (2 × 40 cm3). 
The combined organic extracts were dried and the solvent was removed under reduced 
pressure. The residue was purified over silica gel (hexane/EtOAc 8:1) to give (109) as a 
colourless solid (65 mg, 57%). 
Mp: 182-187 °C (from CHCl3); [α]D18 +25.6 (c 1.5, CHCl3); νmax(KBr 
plate)/cm-1 3332 (br), 2929, 2858, 1601, 1505, 1442, 1230, 1218, 1034, 1005, 810; 
δH (300 MHz, CDCl3) 7.28-7.33 (2 H, m, Ar-H), 6.94-7.00 (2 H, m, Ar-H), 5.83 (1 H, 
dd, J=1.8 Hz, J=3.2 Hz, C16H), 4.03-4.07 (1 H, m, C3H), 2.19 (1 H, ddd, J=3.3 Hz, 
J=6.2 Hz, J=15.4 Hz, C15HA), 1.92-2.04 (2 H, m), 0.73-1.77 (18 H, m), 0.99 (3 H, s, 
C18H3), 0.83  (3 H, s, C19H3); δC (75 MHz, CDCl3) 162.3 (d, J=245.4 Hz, Ar), 154.3 
(C17), 133.9 (d, J=3.2 Hz, Ar), 128.6 (2 × C, d, J=7.7 Hz, Ar), 127.5 (C16), 115.3 (2 × C, 
d, J=21.1 Hz, Ar), 67.0 (CH), 58.0 (CH), 55.0 (CH), 47.8 (C13), 39.7 (CH), 36.7 (C10), 
36.3 (CH2), 35.9 (CH2), 34.5 (CH), 32.4 (CH2), 32.2 (CH2), 31.9 (CH2), 29.4 (CH2), 
28.9 (CH2), 21.2 (CH2), 17.1(CH3), 11.6 (CH3); δF (282 MHz, CDCl3) -116.7 (1 F, tt, 
J=5.5 Hz, J=8.7 Hz); m/z (+CI), found MH+: 369.2585, C25H34OF requires 369.2594    
(-2.3 ppm). 
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5.2.12 (3α,5α,17β)-(17-p-Toluene)androstane-3,17-diol (111) 
 
 
 
 
n-BuLi (2 cm3, 2.5 M in hexane, 5.0 mmol) was added at RT under N2 to a 
solution of p-bromotoluene (860 mg, 5.0 mmol) in dry diethyl ether (5 cm3). The 
mixture was stirred for 2 h at RT and added dropwise via canula to a solution of 
androsterone (262 mg, 0.9 mmol) in dry THF (10 cm3). The reaction mixture was stirred 
for 15 h at RT and then a 10% solution of NH4Cl (10 cm3) was added. The reaction 
mixture was extracted into EtOAc (3 × 40 cm3) and the combined extracts were washed 
with brine and dried. After evaporation of the solvent under reduced pressure, the 
product was purified over silica gel (hexane/EtOAc 7:1) to give (111) as a colourless 
solid (148 mg, 43%). 
Mp: 173-174 °C (from CHCl3); δH (500 MHz, CDCl3) 7.22 (2 H, d, J=8.0 Hz, 
Ar-H), 7.11 (2 H, d, J=8.0 Hz, Ar-H), 3.94-3.96 (1 H, m, C3H), 2.29-2.35 (1 H, ddd, 
J=5.2 Hz, J=9.8 Hz, J=14.4 Hz, C16HA), 2.33 (3 H, s, PhCH3), 2.03-2.09 (1 H, m, 
C16HB), 0.82-1.92 (20 H, m), 1.02 (3 H, s, C18H3), 0.74 (3 H, s, C19H3), 0.34-0.44 (2 H, 
m); δC (75 MHz, CDCl3) 143.6 (Ar), 136.6 (Ar), 128.3 (2 × C, Ar), 127.6 (2 × C, Ar), 
86.2 (C17), 66.8 (C3), 54.0 (C9), 49.5 (C14), 47.0 (C13), 39.4 (C5), 39.0 (C16), 36.6 (C8), 
36.4 (C10), 36.2 (C4), 34.0 (C12), 32.4 (C1), 32.1 (C7), 29.3 (C2), 28.9 (C6), 24.8 (C15), 
21.4 (C24), 20.7 (C11), 15.3 (C18), 11.6 (C19); m/z (+ES), found (M+Na+): 405.2766, 
C26H38O2Na requires 405.2770 (-0.8 ppm). 
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5.2.13 (3α,5α)-(17-p-Toluene)androst-16-en-3-ol (112) 
 
 
 
 
p-Toluenesulfonic acid monohydrate (10 mg, 0.05 mmol) was added at RT to a 
solution of (3α,5α,17β)-(17-p-toluene)androstane-3,17β-diol (111) (140 mg, 
0.37 mmol) in dry DCM (20 cm3) and the reaction mixture was stirred at RT for 2 days. 
A 10% solution of NaHCO3 (5 cm3) was then added, the organic phase was separated 
and the aqueous phase extracted into DCM (2 × 20 cm3). The combined organic extracts 
were dried and the solvent was removed under reduced pressure. The residue was 
purified over silica gel (hexane/EtOAc 7:1) to give (112) as a colourless solid (95 mg, 
71%). 
Mp: 182-185 °C (from CHCl3); [α]18D +25.1 (c 1.5, CHCl3); (Found: C, 85.41; 
H, 10.38 %, C26H36O requires C, 85.66; H, 9.95 %); νmax (KBr plate)/cm-1 3333 (br), 
3048, 2924, 2846, 1508, 1443, 1368, 1357, 1001, 794; δH (300 MHz, CDCl3) 7.26 (2 H, 
d, J=8.0 Hz), 7.10 (2 H, d, J=8.0 Hz), 5.84 (1 H, dd, J=1.8 Hz, J=3.2 Hz, C16H), 4.03-
4.07 (1 H, m, C3H), 2.33 (3 H, s, PhCH3), 2.18 (1 H, ddd, J=3.3 Hz, J=6.3 Hz, 
J=15.4 Hz, C15HA), 1.92-2.07 (2 H, m), 0.77-1.77 (18 H, m), 1.00 (3 H, s, C18H3), 0.83 
(3 H, s, C19H3); δC (75 MHz, CDCl3) 154.7 (C17), 136.3 (Ar), 134.5 (Ar), 128.9 (2 × C, 
Ar), 126.6 (2 × C, Ar), 126.4 (C16), 66.6 (C3), 57.7 (C14), 54.7 (C9), 47.4 (C13), 39.4 
(C5), 36.3 (C10), 35.9 (C4), 35.6 (C12), 34.1 (C8), 32.1 (C1), 31.9 (C7), 31.5 (C15), 29.1 
(C2), 28.6 (C6), 21.1 (PhCH3), 20.8 (C11), 16.8 (C18), 11.2 (C19); m/z (+CI), found MH+: 
365.2856, C26H37O requires 365.2844 (3.0 ppm). 
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5.2.14 (3α,5α,17β)-17-(p-Methoxyphenyl)androstane-3,17-diol (113) 
 
 
 
 
n-BuLi (2 cm3, 2.5 M in hexane, 5.0 mmol) was added at RT under N2 to a 
solution of 4-bromoanisole (0.63 cm3, 5.0 mmol) in dry diethyl ether (5 cm3). The 
mixture was stirred for 2 h at RT and added dropwise via canula to a solution of 
androsterone (300 mg, 1.0 mmol) in dry THF (10 cm3). The reaction mixture was stirred 
at RT for 15 h. A 10% solution of NH4Cl (10 cm3) was added and the organic phase was 
extracted into Et2O (3 × 40 cm3). The combined organic extracts were dried and after 
evaporation of the solvent under reduced pressure, the product was purified over silica 
gel (hexane/EtOAc 5:1) to give (113) as a white foam (122 mg, 30%). 
Note: (113) was not stable in solution and rapidly dehydrated to (114). 
 
δH (300 MHz, CDCl3) 7.27 (2 H, J=9.0 Hz, Ar-H), 6.86 (2 H, d, J=9.0 Hz, Ar-
H), 3.97-4.01 (1 H, m, C3H), 3.82 (3 H, s, OCH3), 2.33 (1 H, ddd, J=5.2 Hz, J=9.8 Hz, 
J=14.6 Hz, C16HA), 2.02-2.13 (1 H, m, C16HB), 0.81-1.83 (20 H, m), 1.03 (3 H, s, 
C18H3), 0.76 (3 H, s, C19H3); 0.34-0.52 (2 H, m); δC (75 MHz, CDCl3) 158.7 (Ar), 138.5 
(Ar), 128.8 (2 × C, Ar), 112.9 (2 × C, Ar), 86.1 (C17), 66.9 (CH), 55.6 (OCH3), 54.1 
(CH), 49.5 (CH2), 47.1 (C13), 39.5 (CH), 39.1 (CH2), 36.6 (CH), 36.5 (C10), 36.2 (CH2), 
34.0 (CH2), 32.4 (CH2), 32.1 (CH2), 29.4 (CH2), 28.9 (CH2), 24.7 (CH2), 20.7 (CH2), 
15.3 (CH3), 11.6 (CH3); m/z (+ES), found (M+Na+): 421.2730, C26H38O3Na requires 
421.2719 (+2.7 ppm). 
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5.2.15 (3α,5α)-17-(p-Methoxyphenyl)androst-16-en-3-ol (114) 
 
 
 
 
p-Toluenesulfonic acid monohydrate (2 mg) was added at RT to a solution of 
(3α,5α,17β)-17-(p-methoxyphenyl)androstane-3,17-diol (113) (55 mg, 0.14 mmol) in 
dry DCM (5 cm3). The reaction mixture turned pink very rapidly. After 8 h the colour 
had disappeared and DCM was removed under reduced pressure. The residue was 
purified over silica gel (petroleum ether/diethyl ether 3:1) to give (114) as a colourless 
solid (47 mg, 90%). 
 
Mp: 171-176 °C (from CHCl3); [α]20D +27.4 (c 1.5, CHCl3); (Found: C, 81.50; 
H, 9.85 %, C26H36O2 requires C, 82.06; H, 9.53 %); νmax (KBr plate)/cm-1 3322 (br), 
2924, 2846, 1600, 1508, 1443, 1362, 1253, 1242, 1175, 1108, 1035; δH (300 MHz, 
CDCl3) 7.30 (2 H, d, J=8.8 Hz, Ar-H), 6.83 (2 H, d, J=8.8 Hz, Ar-H), 5.79 (1 H, dd, 
J=1.7 Hz, J=3.1 Hz, C16H), 4.02-4.06 (1 H, m, C3H), 3.80 (3 H, s, OCH3), 2.18 (1 H, 
ddd, J=3.2 Hz, J=6.2 Hz, J=15.3 Hz, C15HA), 1.91-2.06 (2 H, m), 0.77-1.76 (18 H, m), 
0.99 (3 H, s, C18H3), 0.83 (3 H, s, C19H3); δC (75 MHz, CDCl3) 158.9 (Ar), 154.7 (C17), 
130.5 (Ar), 128.2 (2 × C, Ar), 126.0 (C16), 113.9 (2 × C, Ar), 67.0 (CH), 58.0 (CH), 55.7 
(OCH3), 55.1 (CH), 47.8 (C13), 39.8 (CH), 36.7 (C10), 36.3 (CH2), 36.0 (CH2), 34.5 
(CH), 32.5 (CH2), 32.3 (CH2), 31.8 (CH2), 29.4 (CH2), 29.0 (CH2), 21.2 (CH2), 17.1 
(CH3), 11.6 (CH3); m/z (+CI), found MH+: 381.2796, C26H37O2 requires 381.2794 (+0.6 
ppm). 
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5.2.16 (3α,5α)-(17β-p-Toluene)androstan-3-ol (115) 
 
 
 
 
Pd/C 5 % (5 mg) was added to a solution of (3α,5α)-(17-p-toluene)androst-16-
en-3-ol (112) (12 mg, 0.03 mmol) in EtOAc (5 cm3). The mixture was stirred at RT 
under a positive atmosphere of H2. After 12 h, the reaction mixture was filtered over 
Celite and the solvent was removed under reduced pressure. The product was purified 
over silica gel (hexane/EtOAc 6:1) to give (115) as a colourless solid (11 mg, 91 %). 
 
Mp: 230-234 °C (from hexane/EtOAc); [α]20D +7.4 (c 0.65, CHCl3); (Found: C, 
84.97; H, 10.82 %, C26H38O requires C, 85.19; H, 10.45 %); νmax (KBr plate)/cm-1 3289 
(br), 2931, 2869, 2842, 1514, 1446, 1262, 1098, 1035, 1002, 807; δH (300 MHz, CDCl3) 
7.00-7.05 (4 H, dd, Ar-H), 4.03-4.06 (1 H, m, C3H), 2.63 (1 H, t, J=9.9 Hz, C17H), 2.32 
(3 H, s, PhCH3), 2.01-2.09 (1 H, m, C16HA), 1.88-1.96 (1 H, m, C16HB), 0.74-1.80 (21 H, 
m), 0.77 (3 H, s, C19H3), 0.45 (3 H, s, C18H3); δC (75 MHz, CDCl3) 138.6 (Ar), 135.7 
(Ar), 129.0 (2 × C, Ar), 128.8 (2 × C, Ar), 67.0 (CH), 57.1 (C17), 56.7 (CH), 55.0 (CH), 
44.6 (C13), 39.7 (CH), 38.2 (CH2), 36.6 (C10), 36.4 (CH), 36.3 (CH2), 32.6 (CH2), 32.5 
(CH2), 29.4 (CH2), 29.0 (CH2), 26.6 (CH2), 24.8 (CH2), 21.4 (PhCH3), 20.9 (CH2), 13.2 
(CH3), 11.7 (CH3); m/z (+CI), found MH+: 367.2992, C26H39O requires 367.3001          
(-2.4 ppm). 
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5.2.17 (3α,5α)-(17β-p-Methoxyphenyl)androstan-3-ol (116) 
 
 
 
 
 
Pd/C 5 % (5 mg) was added to a solution of (3α,5α)-(17-p-
methoxyphenyl)androst-16-en-3-ol (114) (50 mg, 0.13 mmol) in EtOAc (10 cm3). The 
mixture was stirred at RT under a positive atmosphere of H2. After 12 h, the reaction 
mixture was filtered over Celite and the solvent was removed under reduced pressure. 
The product was purified over silica gel (petroleum ether/diethyl ether 2:1) to give (116) 
as a colourless solid (47 mg, 93 %). 
 
Mp: 224-231 °C (from CHCl3); [α]20D +8.0 (c 0.8, CHCl3); (Found: C, 81.76; 
H, 10.29 %, C26H38O2 requires C, 81.63; H, 10.01 %); νmax (KBr plate)/cm-1 3522 (br), 
3457 (br), 2930, 2914, 1609, 1512, 1463, 1249, 1238, 1028; δH (300 MHz, CDCl3) 7.12 
(2 H, d, J=8.6 Hz, Ar-H), 6.82 (2 H, d, J=8.6 Hz, Ar-H),  4.02-4.06 (1 H, m, C3H), 3.79 
(3 H, s, OCH3), 2.61 (1 H, t, J=9.8 Hz, C17H), 1.87-2.08 (2 H, m), 0.80-1.81 (21 H, m), 
0.77 (3 H, s, C19H3), 0.44 (3 H, s, C18H3); δC (75 MHz, CDCl3) 158.2 (Ar), 133.7 (Ar), 
129.9 (2 × C, Ar), 113.4 (2 × C, Ar), 67.0 (C3), 56.6 (C14+C17), 55.6 (OCH3), 55.0 (C9), 
44.5 (C13), 39.7 (C5), 38.2 (C12), 36.6 (C10), 36.4 (C8), 36.3(C4), 32.6 (C1), 32.5 (C7), 
29.4 (C2), 29.0 (C6), 26.8 (C16), 24.8 (C15), 20.9 (C11), 13.2 (C18), 11.7 (C19); 
m/z (+CI), found MH+: 383.2952, C26H39O2 requires 383.2950 (+0.5 ppm). 
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5.2.18 2β-(4-Morpholinyl)-(3α,5α,17β)-(17-p-toluene)androstane-3,17-diol (118) 
 
 
 
p-Bromotoluene (581 mg, 3.4 mmol) was added at RT under N2 to a solution of 
n-BuLi (1.3 cm3, 2.5 M in hexane, 3.3 mmol) in dry diethyl ether (4 cm3). The mixture 
was stirred for 1.5 h at RT and was added dropwise via canula to a solution of 3α-
hydroxy-2β-(4-morpholinyl)-5α-androstan-17-one (117) (257 mg, 0.7 mmol) in dry 
THF (15 cm3). The reaction mixture was stirred for 15 h at RT and then a 10% solution 
of NH4Cl (15 cm3) was added. The reaction mixture was extracted into EtOAc (3 × 
50 cm3) and the combined organic extracts were washed with brine and dried. After 
evaporation of the solvent under reduced pressure, the product was purified over silica 
gel (hexane/EtOAc 5:1) to give (118) as a colourless amorphous solid (160 mg, 50%). 
Mp: 132-135 °C (from hexane/EtOAc); [α]16D +46.2 (c 1.5, CHCl3); νmax (KBr 
plate)/cm-1 3440 (br), 2924, 2852, 1511, 1449, 1382, 1292, 1262, 1116, 1069, 1015, 
814; δH (300 MHz, CDCl3) 7.23 (2 H, d, J=8.1 Hz, Ar-H), 7.12 (2 H, d, J=8.1 Hz, Ar-
H), 3.78 (1 H, ddd, J=5.5 Hz, J=8.1 Hz, J=9.9 Hz, C3H), 3.58-5.71 (4 H, m, 2 × CH2O), 
2.43-2.57 (3 H, m), 2.28-2.38 (3 H, m), 2.34 (3 H, s, PhCH3), 2.02-2.13 (2 H, m), 1.65-
1.83 (3 H, m), 0.73-1.56 (14 H, m), 1.03 (3 H, s, C18H3), 0.82 (3 H, s, C19H3), 0.35-0.45 
(2 H, m); δC (75 MHz, CDCl3) 143.7 (Ar), 136.5 (Ar), 128.3 (2×C, Ar), 127.7 (2×C, Ar), 
86.0 (C17), 67.8 (2×CH2O), 65.3 (C2), 64.0 (C3), 55.7 (CH), 49.3 (CH), 49.2 (2×CH2N), 
47.1 (CH2), 38.9 (CH2), 38.8 (CH), 36.5 (CH), 36.1 (C10), 34.7 (CH2), 34.1 (CH2), 32.7 
(CH2), 31.7 (CH2), 28.6 (CH2), 24.7 (CH2), 21.4 (PhCH3), 21.2 (CH2), 17.2 (C19), 15.4 
(C18); m/z (+ES), found MH+: 468.3473, C30H46NO3 requires 468.3478 (-1.0 ppm).
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5.2.19 2β-(4-Morpholinyl)-(3α,5α)-(17-p-toluene)androst-16-en-3-ol (119) 
 
 
 
 
Chlorotrimethylsilane (0.10 cm3, 0.8 mmol, 5 eq) was added at RT to a solution 
of 2β-(4-morpholinyl)-(3α,5α,17β)-(17-p-toluene)androstane-3,17-diol (118) (78 mg, 
0.16 mmol) in dry acetonitrile (15 cm3) and the mixture was stirred at 50 °C for 3 days. 
After cooling, a 10% solution of K2CO3 (10 cm3) was added and the mixture was stirred 
for a further 5 h at RT. EtOAc (30 cm3) was added and the organic phase was separated. 
The aqueous phase was extracted into EtOAc (2 × 30 cm3) and the combined organic 
extracts were washed with water and dried. After evaporation of the solvent under 
reduced pressure, the residue was purified over silica gel (hexane/EtOAc 6:1) to give 
(119) as a colourless amorphous solid (34 mg, 45%). 
δH (300 MHz, CDCl3) 7.26 (2 H, d, J=8.1 Hz), 7.11 (2 H, d, J=7.9 Hz), 5.84 
(1 H, dd, J=1.7 Hz, J=3.1 Hz, C16H), 3.89 (1 H, ddd, J=5.7 Hz, J=8.0 Hz, J=9.8 Hz, 
C3H), 3.65-3.78 (4 H, m, 2 × CH2O), 2.59-2.70 (3 H, m), 2.44-2.51 (2 H, m), 2.33 (3 H, 
s, PhCH3), 2.13-2.22 (1 H, m, C15HA), 0.81-2.07 (18 H, m), 1.00 (3 H, s, C18H3), 0.91 
(3 H, s, C19H3); δC (75 MHz, CDCl3) 155.0 (C17), 136.8 (Ar), 134.8 (Ar), 129.2 (2 × C, 
Ar), 127.0 (2 × C, Ar), 126.8 (C16), 67.8 (2 × CH2O), 65.5 (C2), 64.1 (C3), 57.8 (CH), 
56.7 (CH), 49.3 (2 × CH2N), 47.8 (C13), 39.1 (CH), 36.4 (C10), 36.0 (CH2), 34.9 (CH2), 
34.4 (CH), 32.9 (CH2), 31.9 (CH2), 31.8 (CH2), 28.7 (CH2), 21.6 (CH2), 21.5 (PhCH3), 
17.3 (CH3), 17.2 (CH3); m/z (+CI), found MH+: 450.3387, C30H44NO2 requires 
450.3372 (+3.2 ppm). 
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5.2.20 2β-(4-Morpholinyl)-(3α,5α,17β)-17-(p-methoxyphenyl)androstane-3,17-
diol (121) 
 
 
p-Bromoanisole (1.05 cm3, 8.4 mmol) was added at RT under N2 to a solution of 
n-BuLi (3.2 cm3, 2.5 M in hexane, 8 mmol) in dry diethyl ether (5 cm3). The mixture 
was stirred for 2 h at RT and was then added dropwise via canula to a solution of 3α-
hydroxy-2β-(4-morpholinyl)-5α-androstan-17-one (117) (380 mg, 1.0 mmol) in dry 
THF (40 cm3). The reaction mixture was stirred for 18 h at RT and then a 10% solution 
of NH4Cl (12 cm3) was added. The reaction mixture was extracted into EtOAc (3 × 
60 cm3) and the combined organic extracts were washed with brine and dried. After 
evaporation of the solvent under reduced pressure, the product was purified over silica 
gel (hexane/EtOAc 3:1) to give (121) as a colourless amorphous solid (180 mg, 37%). 
Mp: 145-148 °C (from hexane/EtOAc); [α]16D +38.2 (c 1.5, CHCl3); (Found: C, 
74.39; H, 9.53; N, 2.89 %, C30H45NO4 requires C, 74.50; H, 9.38; N, 2.90 %); νmax (KBr 
plate)/cm-1 3434 (br), 2924, 2852, 1608, 1510, 1452, 1248, 1178, 1116, 1018, 825, 752; 
δH (300 MHz, CDCl3) 7.25 (2 H, d, J=8.7 Hz), 6.84 (2 H, d, J=8.9 Hz), 3.74-3.82 (1 H, 
m, C3H), 3.80 (3 H, s, OCH3), 3.55-3.71 (4 H, m, 2 × CH2O), 2.43-2.58 (3 H, m), 2.25-
2.39 (3 H, m), 2.02-2.12 (2 H, m), 1.64-1.81 (3 H, m), 0.72-1.55 (14 H, m), 1.02 (3 H, s, 
C18H3), 0.82 (3 H, s, C19H3), 0.35-0.45 (2 H, m); δC (75 MHz, CDCl3) 158.3 (Ar), 138.3 
(Ar), 128.5 (2 × C, Ar), 112.5 (2 × C, Ar), 85.5 (C17), 67.3 (2 × CH2O), 64.9 (C2), 63.7 
(C3), 55.3 (CH), 55.2 (OCH3), 49.0 (CH), 48.8 (2 × CH2N), 46.7 (C13), 38.5 (CH2), 38.5 
(CH), 36.1 (CH), 35.7 (C10), 34.3 (CH2), 33.6 (CH2), 32.4 (CH2), 31.3 (CH2), 28.2 
(CH2), 24.3 (CH2), 20.9 (CH2), 16.9 (C19), 15.0 (C18); m/z (+CI), found MH+: 484.3445, 
C30H46NO4 requires 484.3427 (+3.7 ppm). 
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5.2.21 2β-(4-Morpholinyl)-(3α,5α)-17-(p-methoxyphenyl)androst-16-en-3-ol 
(122) 
 
 
 
Chlorotrimethylsilane (64 µL, 0.5 mmol, 5 eq) was added at RT to a solution of 
2β-(4-morpholinyl)-(3α,5α,17β)-17-(p-methoxyphenyl)androstane-3,17-diol (121) 
(50 mg, 0.1 mmol) in dry DCM (15 cm3) and the mixture was stirred at RT for 24 h. A 
10 % solution of K2CO3 (10 cm3) was added and the mixture was stirred for 6 h at RT. 
The organic phase was separated and the aqueous phase was extracted into EtOAc 
(2 × 30 cm3). The combined organic extracts were washed with water and dried. After 
evaporation of the solvent under reduced pressure, the residue was purified over silica 
gel (hexane/EtOAc 4:1) to give (122) as a colourless amorphous solid (30 mg, 62%). 
 Mp: 193-196 °C (from DCM); [α]17D +71.7 (c 1.5, CHCl3); νmax (KBr plate)/cm-1 3457 
(br), 2920, 1608, 1597, 1507, 1445, 1303, 1256, 1240, 1116, 1033, 807; δH (300 MHz, 
CDCl3) 7.30 (2 H, d, J=8.9 Hz, Ar-H), 6.84 (2 H, d, J=8.9 Hz, Ar-H), 5.79 (1 H, dd, 
J=1.7 Hz, J=3.1 Hz, C16H), 3.85-3.93 (1 H, m, C3H), 3.80 (3 H, s, OCH3), 3.65-3.79 (4 
H, m, 2 × CH2O), 2.58-2.69 (3 H, m), 2.43-2.50 (2 H, m), 2.17 (1 H, ddd, J=3.3 Hz, 
J=5.9 Hz, J=15.4 Hz, C15HA), 0.79-2.06 (18 H, m), 1.00 (3 H, s, C18H3), 0.91 (3 H, s, 
C19H3); δC (75 MHz, CDCl3) 158.9 (Ar), 154.7 (C17), 130.3 (Ar), 128.2 (2 × C, Ar), 
126.0 (C16), 113.9 (2 × C, Ar), 67.8 (2 × CH2O), 65.5 (C2), 64.1 (C3), 57.8 (CH), 56.7 
(CH), 55.6 (OCH3), 49.3 (2 × CH2N), 47.8 (C13), 39.1 (CH), 36.4 (C10), 36.1 (CH2), 
34.9 (CH2), 34.4 (CH), 32.9 (CH2), 31.9 (CH2), 31.8 (CH2), 28.7 (CH2), 21.7 (CH2), 
17.3 (C19), 17.1 (C18); m/z (+ES), found MH+: 466.3313, C30H44NO3 requires 466.3321 
(-1.8 ppm). 
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5.2.22 (2S)-(Dibenzylamino)-3-hydroxypropionic acid benzyl ester (152)2, 3  
 
 
 
 
A solution of L-serine (10.5 g, 100 mmol), K2CO3 (27.6 g, 200 mmol) and 
NaOH (8 g, 200 mmol) in H2O (200 cm3) was heated under reflux and then treated with 
BnBr (38 cm3, 320 mmol). After 1 h, the mixture was cooled to RT and extracted into 
Et2O (3 × 300 cm3). The combined organic extracts were dried and evaporated under 
reduced pressure. The product was purified over silica gel (hexane/EtOAc 6:1) to yield 
benzyl ester (152) as a colourless oil (19.3 g, 51%). 
 
[α]20D -125.1 (c 1.34 CHCl3), lit3 [α]24D -120.1 (c 1.34, CHCl3); νmax(film)/cm-1 
3448 (br), 3063, 3030, 1730, 1602, 1495, 1455, 1174, 1028, 748, 698; δH (300 MHz, 
CDCl3) 7.22-7.43 (15 H, m, Ar-H), 5.28 (1 H, d, J=12.2 Hz, PhCHAHBO), 5.20 (1 H, d, 
J=12.2 Hz, PhCHAHBO), 3.89 (2 H, d, J=13.4 Hz, 2 × PhCHAHBN), 3.77 (1 H, br d, 
J=7.9 Hz, CH2OH), 3.63 (2 H, d, J=13.4 Hz, 2 × PhCHAHBN), 3.59 (2 H, t, J=7.5 Hz, 
CHN), 2.50 (1 H, br s, OH); δC (75 MHz, CDCl3) 171.6 (CO2), 139.0 (2 × C, Ar), 136.1 
(Ar), 129.4 (4 × C, Ar), 129.1 (2 × C, Ar), 129.0 (5 × C, Ar), 128.9 (2 × C, Ar), 127.9 
(2 × C, Ar), 66.9 (PhCH2O), 62.2 (CHN), 59.7 (CH2OH), 55.2 (2 × PhCH2N). 
These data are in accordance with the literature.2, 3
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5.2.23 (2R)-3-(Dibenzylamino)-2-fluoropropanoic acid benzyl ester (153)2 
 
 
 
 
DAST (2.36 cm3, 18 mmol) was added dropwise at 0 °C to a solution of (2S)-
(dibenzylamino)-3-hydroxypropionic acid benzyl ester (152) (5.63 g, 15 mmol) in dry 
THF (30 cm3). The reaction mixture was stirred for 40 min, poured into cold water 
(30 cm3), neutralized by the addition of solid K2CO3 and extracted into Et2O (2 × 
50 cm3). The combined organic fractions were dried over MgSO4 and evaporated under 
reduced pressure. The crude product was purified over silica gel (hexane/EtOAc 16:1) 
to yield (153) as a colourless oil (4.77 g, 85%).  
[α]20D +2.3 (c 1.0, CHCl3), lit2 [α]RTD +2.7 (c 1.0, CHCl3); νmax(film)/cm-1 3063, 
3030, 2807, 2385, 1763, 1495, 1455, 1276, 1197, 1067, 748, 698; δH (300 MHz, 
CDCl3) 7.19-7.36 (15 H, m, Ar-H), 5.22 (1 H, d, J=12.2 Hz, PhCHAHBO), 5.09 (1 H, 
ddd, J=3.3 Hz, J=5.7 Hz, J=49.5 Hz, CHF), 5.05 (1 H, d, J=12.3 Hz, PhCHAHBO), 3.81 
(2 H, d, J=13.7 Hz, 2 × PhCHAHBN), 3.54 (2 H, d, J=13.7 Hz, 2 × PhCHAHBN), 2.95-
3.15 (2 H, m, CH2N); δC (75 MHz, CDCl3) 169.1 (d, J=24.5 Hz, CO2), 139.1 (2 × C, 
Ar), 135.4 (Ar), 129.4 (4 × C, Ar), 129.0 (2 × C, Ar), 128.9 (Ar), 128.8 (2 × C, Ar), 
128.7 (4 × C, Ar), 127.5 (2 × C, Ar), 89.6 (d, J=186.6 Hz, CHF), 67.4 (PhCH2O), 59.1 
(2 × C, PhCH2N), 54.7 (d, J=20.1 Hz, CH2N); δF (282 MHz, CDCl3) -190.6 (dt, 
J=25.8 Hz, J=50.6 Hz); m/z (+CI), found MH+: 378.1880, C24H25NO2F requires 
378.1869 (+2.8 ppm). 
These data are in accordance with the literature.2 
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5.2.24 (2R)-3-(Dibenzylamino)-2-fluoropropanoic (156)4 
 
 
 
 
0.5 N LiOH (12 cm3, 6 mmol) was added at 0 °C to a solution of (2R)-3-
(dibenzylamino)-2-fluoropropanoic acid benzyl ester (153) (2.0 g, 5.3 mmol) in THF 
(30 cm3). The mixture was stirred at RT for 18 h and concentrated under reduced 
pressure to remove THF. The residue was acidified with acetic acid (10 cm3) and 
extracted into EtOAc (2 × 50 cm3). The combined organic extracts were washed with 
brine, dried and evaporated under reduced pressure. The product was purified over 
silica gel (hexane/EtOAc 1:1) to yield (156) as a viscous colourless oil (1.13 g, 74%).  
 
[α]20D -0.8 (c 2.43 CHCl3); νmax(film)/cm-1 3065, 2806, 2360, 2342, 1743 (br), 
1618 (br), 1495, 1456, 1270, 1090, 738, 700; δH (300 MHz, CDCl3) 9.49 (1 H, br s, 
CO2H), 7.28-7.40 (10 H, m, Ar-H), 4.98 (1 H, dt, J=5.6 Hz, J=48.8 Hz, CHF), 4.00 
(2 H, d, J=13.5 Hz, 2 × PhCHAHBN), 3.90 (2 H, d, J=13.5 Hz, 2 × PhCHAHBN), 3.16-
3.26 (2 H, m, CH2N); δC (75 MHz, CDCl3) 171.4 (d, J=21.7 Hz, CO2), 134.2 (2 × C, 
Ar), 130.4 (4 × C, Ar), 129.3 (4 × C, Ar), 129.0 (2 × C, Ar), 86.5 (d, J=186.0 Hz, CHF), 
58.6 (2 × C, PhCH2N), 53.7 (d, J=23.1 Hz, CH2N); δF (282 MHz, CDCl3) -188.5 (dt, 
J=20.3 Hz, J=48.7 Hz); m/z (+EI), found MH+: 288.1399, C17H19NO2F requires 
288.1400 (-0.3 ppm). 
These data are in accordance with the literature.4 
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5.2.25 (3R)-1-Diazo-4-(dibenzylamino)-3-fluorobutan-2-one (157) 
 
 
 
 
 Freshly distilled SOCl2 (0.29 cm3, 3.6 mmol, 6 eq) was added at RT to a 
solution of (2R)-3-(dibenzylamino)-2-fluoropropanoic (156) (189 mg, 0.6 mmol) in dry 
DCM (6 cm3). The solution was heated under reflux for 2 h and the solvent was 
evaporated under reduced pressure. The residue was dissolved in dry THF and 
evaporated again under reduced pressure to remove excess of SOCl2. The resultant 
white foam was dissolved in dry THF (5 cm3) and added dropwise at 0 °C under N2 to a 
stirred solution of diazomethane, prepared from Diazald® (11 mmol).5, 6 The yellow 
reaction mixture was stirred for 14 h at RT under N2. Evaporation of the solvent under 
reduced pressure gave a yellow paste which contained the diazo-ketone (157) and the 
methyl ester (161) in a 70/30 % mixture as determined by NMR analysis. 
 
νmax(KBr plate)/cm-1 2112 (N=N), 1641 (C=O); δH (300 MHz, CDCl3) 7.13-
7.30 (10 H, m, Ar-H), 5.55 (1 H, d, J=3.0 Hz, CHN2), 4.81-5.05 (1 H, dm, J=50.1 Hz, 
CHF), 3.69 (2 H, d, J=13.9 Hz, 2 × PhCHAHBN), 3.56 (2 H, d, J=13.9 Hz, 2 × 
PhCHAHBN), 2.92-3.05 (2 H, m, CH2N); δC (75 MHz, CDCl3) 192.4 (d, J=24.2 Hz, 
CO), 139.2 (2 × C, Ar), 129.3 (4 × C, Ar), 128.7 (4 × C, Ar), 127.6 (2 × C, Ar), 94.7 (d, 
J=189.5 Hz, CHF), 58.9 (2 × C, PhCH2N), 55.4 (d, J=19.3 Hz, CH2N), 54.2 (d, J=9.5 
Hz, CHN2); δF (282 MHz, CDCl3) -191.9 (1 F, m, CHF). 
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5.2.26 β-Methyl-(S)-aspartate hydrochloride (170)7, 8 
 
 
 
 
 SOCl2 (1.55 cm3, 21.2 mmol, 1.4 eq) was added dropwise at 0 °C to a solution 
of L-aspartic acid (2 g, 15 mmol) in dry methanol (10 cm3). The reaction mixture was 
stirred for 30 min while slowly warming up to room temperature. Diethyl ether (50 cm3) 
was then added and the mixture was cooled to -10 °C. The resultant white precipitate 
was filtered, washed with ice cold diethyl ether and dried under vacuum. The solid was 
re-crystallised from methanol/diethyl ether (1:5) to yield β-methyl-(S)-aspartate 
hydrochloride (170) as a colourless amorphous solid (1.7 g, 62%). 
 
 Mp: 190-192 °C (from MeOH/Et2O), lit9 184-186 °C (from MeOH/Et2O); 
[α]20D + 9.8 (c 0.6, H2O),  lit9 [α]25D +9.7 (c 0.6, H2O); δH (300 MHz, D2O) 4.23 (1 H, t, 
J=5.5 Hz, CHN), 4.60 (3 H, s, OCH3), 2.97-3.00 (CH2); δC (75 MHz, D2O) 172.2 
(CO2Me), 171.2 (CO2H), 53.2 (OCH3), 49.6 (CHN), 34.1 (CH2). 
These data are in accordance with the literature.7, 8 
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5.2.27 (S)-N,N-Dibenzylaspartic acid β-methyl ester (172)10 
 
 
 
 
 A solution of β-methyl-(S)-aspartate hydrochloride (170) (500 mg, 2.7 mmol) in 
dry methanol (25 cm3) was treated with Et3N (~0.27 cm3, 2 mmol) to neutralise pH to 
~7. Benzaldehyde (1.66 cm3, 16.3 mmol, 6 eq) was added and the mixture was stirred at 
RT for 2 h. NaCNBH3 (679 mg, 10.8 mmol, 4 eq) was then added portion wise and the 
reaction mixture was stirred for 16 h at RT. The reaction was quenched by the addition 
of acetic acid (25 cm3) and the mixture was concentrated under reduced pressure. Water 
(15 cm3) was added and the aqueous phase was extracted into DCM (2 × 50 cm3). After 
evaporation of the solvent, the resultant oil was purified over silica gel (hexane/EtOAc 
4:1) to give (S)-N,N-dibenzylaspartic acid β-methyl ester (172) as a viscous colourless 
oil (570 mg, 64%).  
 
[α]20D -33.6 (c 0.5, CHCl3), lit11 [α]23D -55 (c 0.5, CHCl3); νmax(film)/cm-1 3029, 
2952, 2850, 1735, 1624, 1495, 1455, 1437, 1174, 700; δH (300 MHz, CDCl3) 10.53 
(1 H, br s, CO2H), 7.20-7.49 (10 H, m, Ar-H), 3.98 (1 H, t, J=7.4 Hz, CHN), 3.83 (2 H, 
AB d, J=13.5 Hz, 2 × PhCHAHB), 3.76 (2 H, AB d, J=13.5 Hz, 2 × PhCHAHB), 3.59 
(3 H, s, OCH3), 2.94 (1 H, dd, J=7.1 Hz, J=15.8 Hz, CHAHB), 2.73 (1 H, dd, J=7.7 Hz, 
J=15.8 Hz, CHAHB); δC (75 MHz, CDCl3) 175.7 (CO2H), 172.2 (CO2Me), 138.3 (2 × C, 
Ar), 129.6 (4 × C, Ar), 128.9 (4 × C, Ar), 128.0 (2 × C, Ar), 58.9 (CHN), 55.2 (2 × 
PhCH2), 52.4 (OCH3), 34.5 (CH2). 
These data are in accordance with the literature.10, 11 
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5.2.28 (2S)-(Dibenzylamino)butane-1,4-diol (173) 
 
 
 
 
 BH3 (1 M solution in THF) (1.6 cm3, 1.6 mmol, 4 eq) was added at RT under N2 
to a solution of (S)-N,N-dibenzylaspartic acid β-methyl ester (172) (130 mg, 0.4 mmol) 
in dry THF (8 cm3). The mixture was heated under reflux for 8 h till TLC analysis 
showed completion of the reaction. After cooling down to RT, the reaction was 
quenched by the addition of water (5 cm3) and acetic acid (5 cm3). The aqueous phase 
was extracted into EtOAc (3 × 20 cm3) and the product was purified over silica gel 
(hexane/EtOAc 2:1) to give (2S)-(dibenzylamino)butane-1,4-diol (173) as a colourless 
oil (86 mg, 75%). 
  
[α]20D +16.5 (c 1, CHCl3), lit12 [α]23D +17 (c 1, CHCl3); νmax(film)/cm-1 3358 
(br), 3028, 2932, 1602, 1495, 1453, 1130, 1028, 749, 699; δH (300 MHz, CDCl3) 7.20-
7.33 (10 H, m, Ar-H), 3.71 (2 H, d, J=13.3 Hz, 2 × PhCHAHB), 3.58 (2 H, d, J=13.3 Hz, 
2 × PhCHAHB), 3.49-3.67 (4 H, m, 2 × CH2OH), 2.93 (1 H, tt, J=5.9 Hz, J=7.8 Hz, 
CHN), 2.70 (2 H, br s, 2 × CH2OH), 1.92-2.02 (1 H, m, CHAHB), 1.46 (1 H, ddt, 
J=5.7 Hz, J=7.3 Hz, J=11.3 Hz, CHAHB); δC (75 MHz, CDCl3) 139.5 (2 × C, Ar), 129.5 
(4 × C, Ar), 128.9 (4 × C, Ar), 127.7 (2 × C, Ar), 61.8 (CH2OH), 61.6 (CH2OH), 57.3 
(CHN), 54.0 (2 × PhCH2), 29.3 (CH2). 
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5.2.29 (2S)-(Dibenzylamino)-3-phenylpropanoic acid benzyl ester (180) 
 
 
 
 
Anhydrous potassium carbonate (13.8 g, 99.9 mmol, 3.3 eq) and benzyl bromide 
(15.8 g, 92.3 mmol, 3.05 eq) were added to a solution of L-phenylalanine (5 g, 
30.26 mmol) in ethanol (100 cm3). The mixture was then stirred at 70 °C for 3 days. 
After cooling, the solids were filtered and washed with EtOAc. The filtrate was 
concentrated under reduced pressure to give (180) as a light yellow oil in nearly 
quantitative yield.  
An analytical sample was obtained after chromatography over silica gel (hexane/EtOAc 
12:1) to give (180) as a colourless oil. 
 [α]18D -83.3 (c 1.8 CHCl3), lit13 [α]20D -72.9 (c 1.8, CHCl3); νmax(film)/cm-1 
3062, 3028, 2935, 2844, 2360, 2341, 1730, 1602, 1585, 1495, 1454, 1212, 1160; 
δH (300 MHz, CDCl3) 6.07-7.39 (20 H, m, Ar-H), 5.22 (1 H, d, J=12.2 Hz, 
PhCHAHBO), 5.11 (1 H, d, J=12.2 Hz, PhCHAHBO), 3.92 (2 H, d, J=14.0 Hz, 2 × 
PhCHAHBN), 3.71 (1 H, t, J=7.7 Hz, CHN), 3.53 (2 H, d, J=14.0 Hz, 2 × PhCHAHBN), 
3.13 (1 H, dd, J=7.3 Hz, J=13.9 Hz, PhCHAHB), 2.99 (1 H, dd, J=8.2 Hz, J=13.9 Hz, 
PhCHAHB); δC (75 MHz, CDCl3) 172.6 (CO2), 139.7 (2 × C, Ar), 138.5 (Ar), 136.4, 
(Ar), 129.9 (2 × C, Ar), 129.1 (4 × C, Ar), 129.0 (2 × C, Ar), 128.9 (2 × C, Ar), 128.7 
(Ar), 128.6 (6 × C, Ar), 127.4 (2 × C, Ar), 126.7 (Ar), 66.5 (PhCH2O), 62.8 (CHN), 54.8 
(2 × PhCH2N), 36.1 (PhCH2). 
These data are in accordance with the literature.13 
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5.2.30 (2R)-(Dibenzylamino)-3-phenylpropanoic acid methyl ester (182) 
 
 
 
 
Anhydrous potassium carbonate (8.0 g, 57.5 mmol, 3.1 eq) and benzyl bromide 
(7.0 g, 40.8 mmol, 2.2 eq) were added to a solution of D-phenylalanine methyl ester 
hydrochloride (181) (4.0 g, 18.5 mmol) in acetonitrile (100 cm3). The mixture was then 
heated under reflux for 16 h. After cooling, the solids were filtered and washed with 
EtOAc. The filtrate was concentrated under reduced pressure and the product was 
purified over silica gel (hexane/EtOAc 12:1) to give (182) as a colourless oil (5.25 g, 
79%). 
 
[α]16D +74.5 (c 1.8, CHCl3), lit14 [α]20D -77.8 (c 2.2, CHCl3, (S)-enantiomer); 
δH (300 MHz, CDCl3) 6.98-7.26 (15 H, m, Ar-H), 3.95 (2 H, d, J=14.0 Hz, 2 × 
PhCHAHBN), 3.72 (3 H, s, OCH3), 3.67 (1 H, dd, J=7.2 Hz, J=8.2 Hz, CHN), 3.54 (2 H, 
d, J=14.0 Hz, 2 × PhCHAHBN), 3.12 (1 H, dd, J=7.2 Hz, J=14.0 Hz, PhCHAHB), 2.98 
(1 H, dd, J=8.2 Hz, J=14.0 Hz, PhCHAHB); δC (75 MHz, CDCl3) 173.2 (CO2), 139.7 
(2 × C, Ar), 138.6 (Ar), 129.9 (2 × C, Ar), 129.2 (4 × C, Ar), 128.6 (6 × C, Ar), 127.4 
(2 × C, Ar), 126.7 (Ar), 62.8 (CHN), 54.9 (2 × PhCH2N), 51.6 (OCH3), 36.2 (PhCH2). 
These data are in accordance with the literature.14 
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5.2.31 (2S)-(Dibenzylamino)-3-phenylpropan-1-ol (178)13 
 
 
 
 
A solution of ester (180) (9 g, 20.7 mmol) in dry THF (50 cm3) was added 
dropwise at 0 °C to a suspension of LiAlH4 (1.96 g, 51.6 mmol, 2.5 eq) in dry THF 
(150 cm3). The reaction mixture was stirred for 2 h at 0 °C and the excess of hydride 
was quenched by the addition of EtOAc and water. Et2O was added and the mixture was 
filtered over Celite. Filtrates were concentrated under reduced pressure and the residue 
was purified over silica gel (hexane/EtOAc 7:1) to give (178) as a colourless solid 
(5.84 g, 85%). 
 
Mp 73-74 °C (from DCM), lit13 69-71 °C from Et2O/hexane; [α]20D +43.0 (c 
1.5, CHCl3), lit13 [α]20D +38.4 (c 1.5, CHCl3), lit15 [α]20D +42.5 (c 1, CHCl3); νmax(KBr 
plate)/cm-1 3393 (br), 3063, 3026, 2924, 1601, 1583, 1494, 1454, 1412, 1259, 1103, 
1042; δH (300 MHz, CDCl3) 7.09-7.36 (15 H, m, Ar-H), 3.93 (2 H, d, J=13.3 Hz, 2 × 
PhCHAHBN), 3.48-3.55 (1 H, m, CHAHBOH), 3.49 (2 H, d, J=13.3 Hz, 2 × PhCHAHBN), 
3.33 (1 H, dd, J=4.4 Hz, J=10.6 Hz, CHAHBOH), 3.04-3.15 (2 H, m, CHN and 
PhCHAHB), 3.02 (1 H, br s, OH), 2.43 (1 H, dd, J=9.4 Hz, J=12.9 Hz, PhCHAHB); 
δC (75 MHz, CDCl3) 139.6 (Ar), 139.5 (2 × C, Ar), 129.5 (6 × C, Ar), 129.0 (6 × C, Ar), 
127.8 (2 × C, Ar), 126.7 (Ar), 61.3 (CHN), 60.8 (CH2OH), 53.7 (2 × PhCH2N), 32.1 
(PhCH2).  
These data are in accordance with the literature.13 
N
OH
178
Chapter 5 
_______________________________ 
 
 225 
 
5.2.32 (2R)-(Dibenzylamino)-3-phenylpropan-1-ol (183) 13 
 
 
 
 
This product was prepared following the procedure for the (S)-enantiomer (178) 
(see 5.2.31), starting with (2R)-(dibenzylamino)-3-phenylpropanoic acid methyl ester 
(182). The product was obtained as a colourless amorphous solid (93%). 
 
Spectroscopic data were identical to the (S)-enantiomer (178); mp 70-72 °C 
(from hexane/EtOAc), [α]20D  -43.6 (c 1.5 CHCl3). 
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5.2.33 (2R)-N,N-Dibenzyl-2-fluoro-3-phenylpropan-1-amine (179)16 
 
 
 
 
A solution of DeoxofluorTM (2.67 g, 12.1 mmol, 1 eq) in dry DCM (20 cm3) was 
added dropwise over 15 min at -10 °C to a stirred solution of amino alcohol (178) 
(4.0 g, 12.1 mmol) in dry DCM (100 cm3). The reaction was allowed to warm to RT, 
stirred for 15 h and was then quenched by the addition of a 10% solution of K2CO3 
(10 cm3). The organic phase was separated and the aqueous phase washed with DCM. 
The combined organic extracts were concentrated under reduced pressure and the 
residue was purified over silica gel (hexane/DCM 5:1). Side product (184) eluted first 
and was obtained as a colourless oil (0.350 g, 9%). The desired and major product (179) 
was then collected as a colourless oil (3.03 g, 75%).  
 
Rf: 0.25 (hexane/DCM 2:1); [α]20D + 1.1 (c 6, CHCl3); νmax(film)/cm-1 3062, 
3028, 2929, 2802, 2360, 1602, 1495, 1455, 1369, 1028, 745, 699; δH (300 MHz, 
CDCl3) 7.07-7.35 (15 H, m, Ar-H), 4.81 (1 H, d m, J=49.3 Hz, CHF), 3.65 (4 H, s, 2 × 
PhCH2N), 2.75-2.87 (2 H, m, PhCH2CF), 2.65-2.78 (2 H, m, CFCH2N); δC (75 MHz, 
CDCl3) 139.8 (2 × C, Ar), 137.8 (d, J=3.9 Hz, Ar), 129.7 (2 × C, Ar), 129.4 (4 × C, Ar), 
128.9 (2 × C, Ar), 128.7 (4 × C, Ar), 127.5 (2 × C, Ar), 126.9 (Ar), 94.0 (d, J=172.7 Hz), 
59.6 (2 × C), 57.1 (d, J=22.0 Hz), 40.2 (d, J=21.1 Hz); δF (280 MHz, CDCl3) -180.4 (m, 
1 F); m/z (+EI), found MH+: 334.1972, C23H25NF requires 334.1971 (+0.1 ppm). 
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5.2.34 (2S)-N,N-Dibenzyl-1-fluoro-3-phenylpropan-2-amine (184)16 
 
 
 
 
Compound (184) was obtained as a side product (9%) from the synthesis of 
(179) (see 5.2.33). 
 
Rf: 0.42 Hexane/DCM (2:1); [α]20D -19.2 (c 1, CHCl3), lit17 [α]Hg 23546 -45 (c 1, 
CH2Cl2); νmax(film)/cm-1 3062, 3027, 2953, 2803, 1602, 1495, 1454, 1365, 1143, 1029, 
743, 698; δH (300 MHz, CDCl3) 7.05-7.29 (15 H, m, Ar-H), 4.57 (1 H, ddd, J=3.2 Hz, 
J=9.8 Hz, J=47.8 Hz, CHAHBF), 4.46 (1 H, ddd, J=5.3 Hz, J=9.8 Hz, J=47.9 Hz, 
CHAHBF), 3.72-3.82 (4 H, dd, 2 × PhCH2N), 3.02-3.19 (1 H, m, CHN), 2.97 (1 H, ddd, 
J=1.6 Hz, J=6.4 Hz, J=13.4 Hz, PhCHAHB), 2.80 (1 H, dd, J=8.5 Hz, J=13.4 Hz, 
PhCHAHB); δC (75 MHz, CDCl3) 140.0 (2 × C, Ar), 139.7 (Ar), 129.4 (2 × C, Ar), 128.6 
(4 × C, Ar), 128.4 (2 × C, Ar), 128.3 (4 × C, Ar), 126.9 (2 × C, Ar), 126.2 (Ar), 83.6 (d, 
J=172.4 Hz, CH2F), 59.3 (d, J=17.4 Hz, CHN), 54.5 (d, J=1.5 Hz, 2 × PhCH2N), 33.1 
(d, J=6.0 Hz, PhCH2); δF (280 MHz, CDCl3) -226.7 (1 F, dt, J=26.1 Hz, J=47.8 Hz); 
m/z (+EI), found MH+: 334.1969, C23H25NF requires 334.1971 (-0.5 ppm). 
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5.2.35 (2S)-N,N-Dibenzyl-2-fluoro-3-phenylpropan-1-amine (186)  
 
 
 
 
This product was prepared following the procedure for the (R)-enantiomer (179) 
(see 5.2.33), starting with (2R)-(dibenzylamino)-3-phenylpropan-1-ol (183). The 
product (186) was obtained as a colourless oil (76%). 
 
Spectroscopic data were identical to the (R)-enantiomer (179); [α]20D -1.0 (c 6, 
CHCl3); m/z (+EI), found MH+: 334.1971, C23H25NF requires 334.1971 (+0.1 ppm) 
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5.2.36 N-((2R)-Fluoro-3-phenylpropyl)-(S)-MTPA amide (188) 
 
 
 
 Et3N (18 µL, 2.5 eq), 4-DMAP (3 mg) and (R)-(-)-α-methoxy-α-
(trifluoromethyl)phenylacetyl chloride (187) (20 mg, 1.5 eq) were added at RT to a 
suspension of (2R)-fluoro-3-phenylpropan-1-amine (190) (10 mg, 5.3 10-2 mmol) in 
DCM (2 cm3). The reaction mixture was stirred for 4 h and was quenched by the 
addition of water. Solvents were removed under reduced pressure and the residue was 
dissolved in CDCl3 and filtered through a glass cotton plug directly into a NMR tub.  
 
δF {1H} (470 MHz, CDCl3) -68.8 (3 F, s, CF3 Mosher amide), -70.7 (s, CF3 
Mosher acid in excess), -184.9 (1 F, s, CHF); m/z (+EI), found (M+Na+): 392.1247, 
C19H19NO2F4Na requires 392.1250 (-0.6 ppm). 
 
5.2.37 N-((2S)-Fluoro-3-phenylpropyl)-(S)-MTPA amide 189 
 
 
 
(189) was prepared in an identical manner to that described above (5.2.36), 
starting with (2S)-fluoro-3-phenylpropan-1-amine hydrochloride. 
 δF {1H} (470 MHz, CDCl3) -68.8 (3 F, s, CF3 Mosher amide), -70.7 (s, CF3 
Mosher acid in excess), -184.7 (1 F, s, CHF). 
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5.2.38 (2R)-Fluoro-3-phenylpropan-1-amine hydrochloride (190) 
 
 
 
 20% Pd(OH)2/C (40 mg) was added to a solution of (2R)-N,N-dibenzyl-2-fluoro-
3-phenylpropan-1-amine (179) (0.125 g, 0.37 mmol) in methanol (10 cm3). The mixture 
was stirred at RT under a positive pressure of H2 for 2 h. The palladium catalyst was 
removed by filtration over Celite and 1 M HCl in diethyl ether (2 cm3) was added to the 
filtrate. The solution was concentrated under reduced pressure and the product was re-
crystallised from EtOH/Et2O. (2R)-Fluoro-3-phenylpropan-1-amine hydrochloride (190) 
was obtained as a colourless crystalline solid (0.053 g, 76%). 
 
Mp 129-132 °C (from EtOH/Et2O), [α]20D +9.81 (c 3.18, MeOH); (Found: C, 
56.86; H, 6.95; N, 7.25 %, C9H13NFCl requires C, 57.00; H, 6.91; N, 7.39 %); νmax(KBr 
plate)/cm-1 2993 (br), 1588, 1486, 1457, 1375, 1148, 1037, 993, 958, 753, 745, 697; 
δH (300 MHz, D2O) 7.19-7.32 (5 H, m, Ar-H), 4.82-5.07 (1 H, m, CHF), 3.07-3.28 
(2 H, m, CH2N), 2.88-2.99 (2 H, m, PhCH2); δC (75 MHz, D2O) 135.9 (d, J=4.0 Hz, 
Ar), 129.8 (2 × C, Ar), 129.2 (2 × C, Ar), 127.6 (Ar), 91.4 (d, J=171.3 Hz, CHF), 42.9 
(d, J=20.4 Hz, CH2N), 38.2 (d, J=19.9 Hz, PhCH2); δF (280 MHz, CDCl3) -188.4 (m, 
1 F); m/z (+EI), found (M-Cl-):154.1033, C9H13NF requires 154.1032 (+0.9 ppm). 
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5.2.39 tert-Butyl-(2R)-fluoro-3-phenylpropylcarbamate (191) 
 
 
 
20% Pd(OH)2/C (200 mg) was added to a solution of (2R)-N,N-dibenzyl-2-
fluoro-3-phenylpropan-1-amine (179) (0.675 g, 2.0 mmol) in methanol (30 cm3). The 
mixture was stirred for 3 h at RT under a positive atmosphere of H2 and then di-tert-
butyl dicarbonate (0.664 g, 3.04 mmol, 1.5 eq) was added. The reaction was then stirred 
for 14 h at RT. The palladium catalyst was removed by filtration over Celite, the filtrate 
was concentrated to dryness and the crude residue was purified over silica gel 
(hexane/DCM 10:1). The product (191) was obtained after re-crystallisation from 
hexane/DCM as a colourless crystalline solid (0.462 g, 90%). 
 
Mp 66-76 °C (from hexane/DCM), [α]20D -11.2 (c 1, CHCl3); νmax(KBr 
plate)/cm-1 3374, 2991, 2970, 1696, 1525, 1248, 1165, 1076, 990, 896, 754, 703; 
(Found: C, 66.59; H, 7.61; N, 5.39 %, C14H20NO2F requires C, 66.38; H, 7.96; N, 5.53 
%); δH (300 MHz, CDCl3) 7.15-7.32 (5 H, m, Ar-H), 4.96 (1 H, br s, N-H), 4.61-4.86 
(1 H, m, CHF),  3.40-3.57 (1 H, m, CHAHBN), 3.11-3.27 (1 H, m, CHAHBN), 2.79-3.01 
(2 H, m, PhCH2), 1.44 (9 H, s, C(CH3)3); δC (75 MHz, CDCl3) 156.3 (NCO), 136.7 (d, 
J=4.3 Hz, Ar), 129.8 (2 × C, Ar), 129.0 (2 × C, Ar), 127.2 (Ar), 93.8 (d, J=172.4 Hz, 
CHF), 80.0 (C(CH3)3), 44.6 (d, J=20.7 Hz, CH2N), 39.3 (d, J=20.8 Hz, PhCH2), 28.8 
(C(CH3)3); δF (280 MHz, CDCl3) -185.4 (1 F, m); m/z (+EI), found (M+Na+): 276.1378, 
C14H20NO2FNa requires 276.1376 (+1.0 ppm). 
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5.2.40 tert-Butyl-(2S)-fluoro-3-phenylpropylcarbamate (192) 
 
 
 
This product was prepared following the procedure for the (R)-enantiomer (191) 
(see 5.2.39), starting with (2S)-N,N-dibenzyl-2-fluoro-3-phenylpropan-1-amine (186). 
The product was obtained as a colourless crystalline solid (85%). 
 
Spectroscopic data were identical to the (R)-enantiomer (191); mp 68-76 °C 
(from hexane/DCM); [α]20D +10.6 (c 1, CHCl3); m/z (+ES), found (M+Na+): 276.1369, 
C14H20NO2FNa requires 276.1376 (-2.6 ppm). 
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5.2.41 Di(tert-butyl)-(2R)-fluoro-3-phenylpropyldicarbamate (197) 
 
 
 
20% Pd(OH)2/C (300 mg) was added to a solution of (179) (1.45 g, 4.3 mmol) in 
methanol (50 cm3). The mixture was stirred for 3 h at RT under a positive atmosphere 
of H2 and then di-tert-butyl dicarbonate (1.90 g, 8.7 mmol, 2 eq) was added. The 
reaction was then stirred for 14 h at RT. The palladium catalyst was removed by 
filtration over Celite and the solution was concentrated to dryness. The residue was 
dissolved in MeCN (50 cm3), then di-tert-butyl dicarbonate (1.90 g, 8.7 mmol, 2 eq) and 
4-DMAP (80 g, 0.65 mmol, 15% mol) were added and the solution was heated under 
reflux for 14 h. After cooling, the solvent was evaporated under reduced pressure, the 
residue dissolved in Et2O and the organic phase washed with water. After evaporation 
of the organic phase under reduced pressure, the product was purified over silica gel 
(hexane/EtOAc 18:1) to give (197) as a colourless oil (1.23 g, 80%). 
 
[α]20D -16.4 (c 2, CHCl3), νmax(film)/cm-1 2980, 2935, 1792, 1749, 1699, 1429, 
1368, 1234, 1146, 1122, 856, 752, 700; δH (300 MHz, CDCl3) 7.20-7.33 (5 H, m, Ar-
H), 4.76-5.01 (1 H, m, CHF), 3.59-4.06 (2 H, m, CFCH2N), 2.81-3.03 (2 H, m, 
PhCH2CF), 1.47 (18 H, s, 6 × CH3); δC (75 MHz, CDCl3) 152.9 (2 × NCO2), 136.8 (d, 
J=3.9 Hz, Ar), 129.7 (2 × C, Ar), 128.9 (2 × C, Ar), 127.15 (Ar), 92.9 (d, J=175.0 Hz, 
CHF), 83.0 (2 × C(CH3)), 49.9 (d, J =22.3 Hz, CH2N), 39.7 (d, J=20.6 Hz, PhCH2), 
29.37 (6 × CH3); δF (280 MHz, CDCl3) -186.8 (1 F, m); m/z (+EI), found  (M+Na+): 
376.1905, C19H28NO4FNa requires 376.1900 (+1.4 ppm). 
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5.2.42 Di(tert-butyl)-(2S)-fluoro-3-phenylpropyldicarbamate (198) 
 
 
 
This product was prepared following the procedure for the (R)-enantiomer (197) 
(see 5.2.41), starting with (2S)-N,N-dibenzyl-2-fluoro-3-phenylpropan-1-amine (186). 
The product was obtained as a colourless oil (78%). 
 
Spectroscopic data were identical to the (R)-enantiomer (197); [α]20D +16.2 (c 2, 
CHCl3); m/z (+EI), found (M+Na+): 376.1906, C19H28NO4FNa requires 376.1900 
(+1.5 ppm). 
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5.2.43 4-(Bis(tert-butoxycarbonyl)amino)-(3R)-fluorobutanoic acid (199) 
 
 
 
NaIO4 (5.584 g, 26 mmol, 18 eq) was added to a stirred solution of (197) 
(512 mg, 1.45 mmol) in the biphasic solvent system CCl4/MeCN/H2O (12 /12 /15 cm3). 
The mixture was treated with RuCl3. xH2O (23 mg, 0.09 mmol, 6% mol) and the 
reaction was stirred vigorously at 25 °C for 3 days. The mixture was then filtered 
through a large Celite pad and the solids were washed with EtOAc. The filtrate was 
concentrated to dryness and the product was purified over silica gel (hexane/EtOAc 
2.5:1). Carboxylic acid (199) was obtained as a colourless oil (356 mg, 76%). 
 
[α]20D -19.1 (c 2, CHCl3), νmax(film)/cm-1 2982, 2936, 1785, 1720, 1429, 1370, 
1125, 1043, 854, 736, δH (300 MHz, CDCl3) 9.51 (1 H, br s, CO2H), 4.99-5.23 (1 H, m, 
CHF), 3.72-4.09 (2 H, m, CFCH2N), 2.60-2.82 (2 H, m, CH2CO2), 1.51 (18 H, s, 6 × 
CH3); δC (75 MHz, CDCl3) 175.4 (d, J=5.0 Hz, CO2H), 152.8 (2 × NCO2), 88.6 (d, 
J=173.9 Hz, CHF), 83.5 (2 × C(CH3)3), 49.1 (d, J=23.5 Hz, CH2N), 38.2 (d, J=23.8 Hz, 
CH2CO2), 28.31 (6 × CH3); δF (280 MHz, CDCl3) -186.9 (1 F, m); m/z (-EI), found (M-
H+): 320.1504, C14H23NO6F requires 320.1509 (-1.6 ppm). 
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5.2.44 4-(Bis(tert-butoxycarbonyl)amino)-(3S)-fluorobutanoic acid (200) 
 
 
 
This product was prepared following the procedure for the (R)-enantiomer (199) 
(see 5.2.43), starting with di(tert-butyl)-(2S)-fluoro-3-phenylpropyl-dicarbamate (198). 
The product was obtained as a colourless oil (75%). 
 
Spectroscopic data were identical to the (R)-enantiomer XX; [α]20D +18.9 (c 2, 
CHCl3); m/z (-EI), found (M-H+): 320.1512, C14H23NO6F requires 320.1509 
(+0.6 ppm). 
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5.2.45 (3R)-Fluoro-4-aminobutyric acid hydrochloride (123) 
 
 
 
HCl gas was bubbled for 20 min into an ice-cooled solution of (199) (350 mg, 
1.1 mmol) in dry DCM (40 cm3). After the formation of a white precipitate, nitrogen 
gas was bubbled through the reaction mixture at RT until evaporation of the solvent was 
complete. The off-white solid was dissolved in ethanol and re-crystallised twice from 
diethyl ether to yield (3R)-fluoro-4-aminobutyric acid hydrochloride (123) as a 
colourless crystalline solid (137 mg, 80%). 
 
Mp 116-118 °C (from EtOH/Et2O); [α]20D -15.5 (c 2.21, MeOH); (Found: C, 
30.28; H, 5.51; N, 8.68 %, C4H9NO2FCl requires C, 30.49; H, 5.76; N, 8.89 %); 
νmax(KBr plate)/cm-1 3027 (br), 1701, 1610, 1572, 1506, 1448, 1394, 1306, 1255, 1222, 
1036, 1005; δH (300 MHz, CD3OD) 5.05-5.31 (1 H, d m, J=49.2 Hz, CHF), 2.24-3.41 
(2 H, m, CH2N), 2.75-2.86 (2 H, m, CH2CO2H); δC (75 MHz, CD3OD) 172.7 (d, 
J=6.0 Hz, CO2), 88.9 (d, J=171.5 Hz, CHF), 44.2 (d, J=20.6 Hz, CH2N), 38.4 (d, 
J=22.4 Hz, CH2CO2); δF (280 MHz, CD3OD) -190.0 (1 F, m); m/z (+EI) found (M-Cl-): 
122.0615, C4H9NO2F requires 122.0617 (-2.3 ppm). 
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5.2.46 (3S)-Fluoro-4-aminobutyric acid hydrochloride (124) 
 
 
 
This product was prepared following the procedure for the (R)-enantiomer (123) 
(see 5.2.45), starting with 4-(bis(tert-butoxycarbonyl)amino)-(3S)-fluorobutanoic acid 
(200). The product was obtained as a colourless crystalline solid (84%). 
 
Spectroscopic data were identical to (R)-enantiomer; mp 116-117 °C (from 
EtOH/Et2O); [α]20D +15.6 (c 2.22, MeOH); (Found: C, 30.63; H, 5.70; N, 8.71 %, 
C4H9NO2FCl requires C, 30.49; H, 5.76; N, 8.89 %); m/z (+EI) found (M-Cl-): 
122.0614, C4H9NO2F requires 122.0617 (-2.6 ppm). 
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5.2.47 (1S, 4R)-2-Azabicyclo[2.2.1]heptan-3-one (212)18, 19 
 
 
 
10% Pd/C (8 mg) was added to a solution of (1S, 4R)-2-azabicyclo[2.2.1]hept-5-
en-3-one (150 mg, 1.4 mmol) in EtOAc (15 cm3). The suspension was stirred at room 
temperature for 18 h under a positive pressure of H2. The reaction solution was then 
filtered through Celite and the stationary phase washed with EtOAc. Evaporation of the 
combined organic phases gave (212) as a colourless hygroscopic solid (145 mg, 95%), 
which liquefied rapidly when exposed to air. 
 
[α]20D -552 (c 1, CHCl3), lit20 [α]D -560 (c 1.1 CHCl3); δH (300 MHz, CDCl3) 
6.36 (1 H, br s, NH), 3.83 (1 H, m, CHN), 2.62 (1 H, m, CHCO), 1.30-1.80 (6 H, m, 3 × 
CH2); m/z (+EI): 111 (M, 100%), 96 (10), 83 (96), 67 (83), 55 (73). 
These data are in accordance with the literature.18, 19 
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5.2.48 (1R, 3S)-3-Aminocyclopentane carboxylic acid (213) 21, 22 
 
 
 
4 N HCl (8 cm3) was added to a solution of (1S, 4R)-2-azabicyclo[2.2.1]heptan-
3-one (212) (120 mg, 1.1 mmol) in acetic acid (8 cm3). The mixture was stirred for 5 h 
at 70 °C and after evaporation of the solvents under reduced pressure, the residue was 
dissolved in water (2 cm3). The solution was passed down an ion-exchange column 
(Dowex AG 50W-X8100), eluting with 2 N NH3. After evaporation of the solvent, the 
resultant solid was re-crystallised from methanol/EtOAc to give (1R, 3S)-3-
aminocyclopentane carboxylic acid (213) as a colourless amorphous solid (128 mg, 
72%).  
 
Mp: 253-255 °C (from MeOH/EtOAc), lit21 250-255 °C, [α]20D -7.5 (c 1, H2O), 
lit21 -7 (c 1, H2O); (Found C, 55.69; H, 8.55; N, 10.79 %, C6H11NO2 requires C, 55.78; 
H, 8.60; N, 10.85 %); δH (300 MHz, D2O) 3.56-3.64 (1 H, m, CHN), 2.62-2.70 (1 H, m, 
CHCO2), 1.64-2.14 (6 H, m, 3 × CH2); δC (75 MHz, D2O) 180.3 (CO2), 51.8 (CHN), 
42.8 (CHCO2), 34.0 (CH2), 30.1 (CH2), 28.0 (CH2). 
These data are in accordance with the literature.21, 22 
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5.2.49 (±)-Cis-3-aminocyclopentane carboxylic acid (215) 
 
 
 
Racemic (±)-cis-3-aminocyclopentane carboxylic acid was obtained following 
the procedure for (1R, 3S)-3-aminocyclopentane carboxylic acid (213), starting with 
(±)-2-aza-bicyclo-[2.2.1]hept-5-en-3-one (see 5.2.47). The product (215) was isolated as 
a colourless amorphous solid (85% over 2 steps). 
Spectroscopic data were identical to (1R, 3S) enantiomer (213); mp. 243-246 °C 
(from H2O/EtOH/Et2O), lit23: 242-244 °C (from H2O/EtOH/Et2O). 
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5.2.50 (1S, 4R)-4-Aminocyclopent-2-ene carboxylic acid hydrochloride (214) 
 
 
 
4 N HCl (8 cm3) was added to a solution of (1S, 4R)-2-azabicyclo[2.2.1]hepten-
3-one (150 mg, 1.38 mmol) in acetic acid (8 cm3). The mixture was stirred for 5 h at 
70 °C. After evaporation of the solvents under reduced pressure, the residue was 
dissolved in water (2 cm3) and was passed down an ion-exchange column (Dowex AG 
50W-X8100), eluting with 2 N NH3. After evaporation of the solvent, the off-white 
solid was dissolved in 0.1 N HCl (1.4 cm3, 1 eq) and freeze-dried.  The amino acid 
hydrochloride was then re-crystallised from acetic acid to give (1S, 4R)-4-
aminocyclopent-2-ene carboxylic acid hydrochloride (214) as a colourless amorphous 
solid (135 mg, 60%). 
 
Mp: 178-180 °C (from AcOH), [α]20D -96.6 (c 1, H2O); (Found C, 44.20; H, 
6.75; N, 8.58 %, C6H10NO2Cl requires C, 44.05; H, 6.16; N, 8.56 %); δH (300 MHz, 
D2O) 6.11 (1 H, ddd, J=1.6 Hz, J=2.4 Hz, J=5.7 Hz, CH=C), 5.85 (1 H, dt, J=2.3 Hz, 
J=5.6 Hz, CH=C), 4.25-4.30 (1 H, m, CHN), 3.59-3.66 (1 H, m, CHCO2), 2.56 (1 H, dt, 
J=8.6 Hz, J=14.5 Hz, CHAHB), 1.96 (1 H, dt, J=4.9 Hz, J=14.4 Hz, CHAHB); δC (75 
MHz, D2O) 177.9 (CO2), 136.6 (CH=C), 129.9 (CH=C), 56.5 (CHN), 50.0 (CHCO2), 
31.6 (CH2). 
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5.2.51 (±)-Cis-4-Aminocyclopent-2-ene carboxylic acid hydrochloride (216)24 
 
 
 
Racemic (±)-cis-4-aminocyclopent-2-ene carboxylic acid hydrochloride was 
obtained following the procedure for the (1S, 4R) enantiomer (214), starting with (±)-2-
aza-bicyclo-[2.2.1]hept-5-en-3-one (see 5.2.50). The product (216) was obtained as a 
colourless amorphous solid (55%). 
 
Spectroscopic data were identical to (1S, 4R) enantiomer (214), mp: 168-172 °C 
(from AcOH), lit24: 167-170 °C (from AcOH). 
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5.2.52 tert-Butyl-N-hydroxycarbamate (220)25, 26  
 
 
 
 A suspension of hydroxylamine hydrochloride (3.2 g, 45 mmol, 1.5 eq) and 
K2CO3·3/2H2O (3.8 g, 23 mmol) in diethyl ether (20 cm3) and water (0.35 cm3) was 
stirred for 1 h at RT with evolution of CO2. A solution of t-butyl dicarbonate (6.33 g, 
29 mmol) in diethyl ether (12 cm3) was then added dropwise at 0 °C and the suspension 
was stirred at RT for 15 h. The organic phase was decanted, the solids washed with 
diethyl ether and the organic fractions evaporated to dryness. tert-Butyl-N-
hydroxycarbamate (220) was obtained as a colourless solid (3.42 g, 89%) which could 
be used directly without further purification. 
 
 Mp: 59-61 °C (from Et2O), lit26:58-59 °C; δH (300 MHz, CDCl3) 7.15-7.40 
(1 H, br s, NH), 1.47 (9 H, s, 3 × CH3). 
These data are in accordance with the literature.26 
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5.2.53 (±)-N-(Carbo-tert-butoxy)-2,3-oxazabicyclo[2.2.1]hept-5-ene (219)27  
 
 
 
Freshly generated cyclopentadiene (7.2 g, 110 mmol) was added at 0 °C to a 
stirred solution of t-butyl-N-hydroxycarbamate (220) (3.25 g, 24.4 mmol) in MeOH 
(240 cm3). A solution of NaIO4 (5.77 g, 27 mmol) in H2O (65 cm3) was then added 
dropwise over 20 min. After stirring at 0 °C for 30 min, the reaction mixture was 
partitioned between brine (325 cm3) and EtOAc (325 cm3). The layers were separated, 
the aqueous layer was saturated with NaCl and extracted into EtOAc (3 × 80 cm3). The 
combined organic layers were washed with saturated NaHCO3, dried and concentrated 
under reduced pressure to give a brown oil which was purified over silica gel 
(hexane/EtOAc 2:1) to give (219) as a brown solid (3.44 g, 72%). 
 
Mp: 41-43 °C (from hexane/EtOAc), lit27 43-45 °C; δH (300 MHz, CDCl3) 5.38-
5.44 (2 H, m, CH=CH), 5.20-5.22 (1 H, m, CHN), 4.97-4.99 (1 H, m, CHO), 1.99 (1 H, 
ddd, J=1.8 Hz, J=1.8 Hz, J=8.6 Hz, CHAHB), 1.71-1.75 (1 H, m, CHAHB), 1.47 (9 H, s, 
3 × CH3); δC (75 MHz, CDCl3) 158.8 (NCO2), 134.5 (CH=C), 133.3 (CH=C) , 83.9 
(CHO), 82.5 (C(CH3)3), 65.4 (CHN), 48.5 (CH2), 28.5 (3 × CH3). 
These data are in accordance with the literature.27 
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5.2.54 (±)-3-Hydroxy-3,3a,4,6a-tetrahydro-2H-cyclopentaoxazol-2-one (222) 
 
 
 
A solution of trimethylsilane cyanide (200 mg, 2 mmol) in DMF (6 cm3) was 
added dropwise over 10 min to a solution of (±)-N-(carbo-tert-butoxy)-2,3-
oxazabicyclo[2.2.1]hept-5-ene (219) (200 mg, 1 mmol) and CuSO4 (360 mg, 1.5 mmol) 
in DMF (10 cm3) stirred at 0 °C under N2 . The reaction mixture was then stirred at 
60 °C for 20 h and the reaction was quenched with a 10% solution of EDTA (35 cm3). 
The mixture was extracted into EtOAc (3 × 60 cm3) and the combined organic phases 
were evaporated under reduced pressure. The residue was purified over silica gel 
(hexane/ EtOAc 1:2) to give the title product (222) as a colourless crystalline solid 
(80 mg, 57%), which was re-crystallised from DCM/hexane. 
 
Mp: 134-138 °C (from DCM/hexane); νmax(KBr plate)/cm-1 3115 (br), 2954 
(br), 1748 (br), 1490, 1365, 1283, 1231, 1161, 1110, 992, 884; δH (300 MHz, CDCl3) 
9.17 (1 H, br s, OH), 6.11-6.14 (1 H, m, CH=C), 5.82 (1 H, ddd, J=2.1 Hz, J=4.2 Hz, 
J=6.0 Hz, CH=C), 5.43-5.46 (1 H, m, CHO), 4.47-4.51 (1 H, m, CHN), 2.82-2.88 (1 H, 
m, CHAHB), 2.53-2.61 (1 H, m, CHAHB); δC (75 MHz, CDCl3) 158.8 (NCO2), 137.5 
(CH=C), 127.7 (CH=C), 83.6 (CHO), 59.9 (CHN), 36.9 (CH2); m/z (+ES), found 
(M+Na+): 164.0319, C6H7NO3Na requires 164.0324 (-3.0 ppm). 
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5.2.55 (S)-Carnitine isobutyl ester (233)28, 29 
 
 
 
A suspension of (S)-carnitine hydrochloride (1.15 g, 5.8 mmol) in isobutyl 
alcohol (8 cm3) was saturated with HCl gas and the resultant solution was heated under 
reflux for 3 h. The solution was then concentrated under reduced pressure and the 
residue was taken up twice into isobutyl alcohol (2 × 8 cm3) and concentrated to 
dryness. The residue was triturated with acetone to give after filtration (233) as a 
colourless solid (1.38 g, 93%).  
 
Mp: 140-142 °C (from isobutyl alcohol), lit29 150 °C (decomp.); [α]20D +14.2 (c 
1, H2O), lit29 [α]25D +15.0 (c 1, H2O) ; δH (300 MHz, D2O); 4.55-4.65 (1 H, m, CHOH), 
3.82-3.93 (2 H, m, OCH2), 3.49-3.42 (2 H, m, CH2N+), 3.15 (9 H, 3 × CH3), 2.53-2.68 
(2 H, m, CH2CO2), 1.78-1.96 (1 H, m, CH(CH3)2), 0.83 (6 H, d, J=6.8 Hz, 2 × CH3); δC 
(75 MHz, D2O); 172.8 (CO2), 72.2 (OCH2), 70.0 (CH2N+), 63.3 (CHOH), 54.5 (3 × 
CH3), 40.6 (CH2CO2), 27.5 (CH(CH3)2), 18.6 (2 × CH3). 
These data are in accordance with the literature.28  
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5.2.56 3-Fluorobutanoic acid (237) 
 
 
 
Triethylamine trihydrofluoride (3.8 cm3, 23.3 mmol, 2 eq) was added at RT to a 
solution of β-butyrolactone (1 g, 11.6 mmol) in dry DCM (10 cm3). The mixture was 
then heated under reflux for 5 days. After cooling, the reaction was quenched by the 
addition of a saturated solution of K2CO3 (10 cm3), stirred for 2 h and acidified with 
HCl 1 N till pH 2. EtOAc (40 cm3) was added and the organic phase was separated. The 
aqueous phase was extracted further with EtOAc (3 × 40 cm3) and the combined organic 
extracts were evaporated under reduced pressure. The residue was purified over silica 
gel (hexane/EtOAc 5/1) to give (237) as a colorless oil (370 mg, 30%). 
 
νmax(film)/cm-1 2989, 2942, 2680, 1718, 1433, 1389, 1311, 1214, 1137, 1065, 
940, 842; δH (300 MHz, CDCl3) 11.51 (1 H, br s, CO2H), 5.10 (1 H, dddq, J=47.6 Hz, 
J=4.6 Hz, J=8.0 Hz, J=6.2 Hz, CHF), 2.77 (1 H, ddd, J=8.0 Hz, J=14.0 Hz, J=16.2 Hz, 
CHAHBCO2H), 2.61 (1 H, ddd, J=4.6 Hz, J=16.2 Hz, J=28.8 Hz, CHAHBCO2H), 1.43 
(3 H, dd, J=6.2 Hz, J=23.8 Hz, CH3); δC (75 MHz, CDCl3); 177.1 (d, J=6.4 Hz, CO2) 
87.1 (d, J=167.3 Hz, CHF), 42.1 (d, J=24.1 Hz, CH2CO2), 21.1 (d, J=22.3 Hz, CH3); 
δF (282 MHz, CDCl3) -173.2 (1 F, dddq, J=47.8 Hz, J=29.5 Hz, J=23.6 Hz, J=13.6 Hz); 
m/z (+ES), found (M+Na+): 129.0322, C4H7FO2Na requires 129.0328 (-4.6 ppm). 
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5.2.57 Benzyl (S)-2,6-bis(dibenzylamino)hexanoate (251)30 
 
 
 
 
Anhydrous K2CO3 (30.25 g, 220 mmol, 8 eq) and benzyl bromide (18 cm3, 
150 mmol, 5.5 eq) were added to a solution of L-lysine (4.0 g, 27.4 mmol) in 
DMF/water (10:1 v/v mixture, 60 cm3). After stirring at 60 °C for 3 days, the resulting 
white slurry was diluted with water (150 cm3) and extracted into diethyl ether. The 
combined organic extracts were washed with 10% NaCl solution and the solvent was 
removed under reduced pressure to give a light yellow oil (16 g) which could be used 
for the next step. An analytical sample was obtained after chromatography over silica 
gel (hexane/EtOAc 10:1) to give the perbenzylated lysine (251) as a colourless oil. 
[α]20D -53.2 (c 2.8, CHCl3), lit30 -52.5 (c 2.8, CHCl3); νmax(film)/cm-1 3029, 
2942, 2798, 1731, 1494, 1454, 1365, 1138, 1028, 969, 745, 698; δH (300 MHz, CDCl3) 
7.17-7.40 (25 H, m, Ar-H), 5.23 (1 H, d, J=12.3 Hz, PhCHAHBO), 5.11 (1 H, d, 
J=12.3 Hz, PhCHAHBO), 3.89 (2 H, d, J=13.9 Hz, 2 × PhCHAHBN), 3.49 (2 H, d, 
J=13.9 Hz, 2 × PhCHAHBN), 3.42-3.52 (4 H, dd, PhCH2N’), 3.32 (1 H, dd, J=6.2 Hz, 
J=8.7 Hz, CHN), 2.33 (2 H, t, J=6.8 Hz, CH2N’), 1.14-1.76 (6 H, m, CH2); δC (75 MHz, 
CDCl3) 173.0 (CO2), 140.1 (2 × C, Ar), 139.7 (2 × C, Ar), 136.2 (Ar), 128.9 (4 × C, Ar), 
128.8 (4 × C, Ar), 128.6 (2 × C, Ar), 128.5 (2 × C, Ar), 128.4 (Ar), 128.3 (4 × C, Ar), 
128.2 (4 × C, Ar), 127.0 (2 × C, Ar), 126.8 (2 × C, Ar), 65.9 (PhCH2O), 60.7 (CHN), 
58.3 (2 × PhCH2N’), 54.5 (2 × PhCH2N), 53.2 (CH2N’), 29.3 (CH2), 26.7 (CH2), 23.8 
(CH2); m/z (+EI), found MH+: 597.3477, C41H45N2O2 requires 597.3481 (-0.6 ppm). 
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5.2.58 (S)-2,6-bis(dibenzylamino)hexan-1-ol (246) 
 
 
 
 
 
A solution of the crude benzyl ester (251) (14 g, 23.4 mmol) in dry THF 
(50 cm3) was added dropwise over 15 min at 0 °C to a suspension of LiAlH4 (1.78 g, 
46.9 mmol, 2 eq) in dry THF (150 cm3). The mixture was stirred for 2 h at 0 °C and the 
excess of hydride was quenched by successive addition of isopropanol (20 cm3) and 
water (300 cm3). The mixture was extracted into diethyl ether (2 × 500 cm3), the organic 
extracts were combined and the solvent removed under reduced pressure. The product 
was purified over silica gel (hexane/EtOAc 3:1) to yield the amino alcohol (246) as a 
viscous colourless oil (7.2 g, 62% yield over 2 steps). 
[α]20D +56.7 (c 2.8, CHCl3), νmax(film)/cm-1 3443, 3027, 2935, 2799, 2360, 
1602, 1494, 1453, 1365, 1129, 1028, 747, 698; δH (300 MHz, CDCl3) 7.19-7.38 (20 H, 
m, Ar-H), 3.75 (2 H, d, J=13.3 Hz, PhCHAHBN), 3.57 (2 H, d, J=13.6 Hz, PhCHAHBN’), 
3.48 (2 H, d, J=13.6 Hz, PhCHAHBN’), 3.31-3.45 (2 H, m, CH2OH), 3.32 (2 H, d, 
J=13.3 Hz, PhCHAHBN), 3.14 (1 H, br s, OH), 2.67-2.77 (1 H, m, CHN), 2.34-2.47 (2 
H, m, CH2N’), 1.40-1.63 (3 H, m), 1.00-1.37 (3 H, m); δC (75 MHz, CDCl3) 139.9 (2 × 
C, Ar), 139.3 (2 × C, Ar), 129.0 (4 × C, Ar), 128.7 (4 × C, Ar), 128.4 (4 × C, Ar), 128.1 
(4 × C, Ar), 127.1 (2 × C, Ar), 126.7 (2 × C, Ar), 60.8 (CH2OH), 58.9 (CHN), 58.4 (2 × 
PhCH2N’), 53.1 (2 × PhCH2N), 52.8 (CH2N’), 27.3 (CH2), 24.7 (CH2), 24.5 (CH2); m/z 
(+EI), found MH+: 493.3236, C34H41N2O requires 493.3219 (+3.4 ppm). 
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5.2.59 N1,N1,N6,N6-Tetrabenzyl-(2R)-fluorohexane-1,6-diamine (247) 
 
 
 
 
DAST (0.4 cm3, 3.3 mmol, 1.15 eq) was added dropwise at 0 °C to a solution of 
(246) (1.4 g, 2.8 mmol) in dry DCM (40 cm3). The reaction mixture was stirred at RT 
for 8 h and the reaction was quenched by the addition of 10% K2CO3 (5 cm3). Solvents 
were evaporated to dryness under reduced pressure and the residue was purified over 
silica gel (hexane/EtOAc 1/1). The early fractions were collected and evaporated to give 
an off-white solid (280 mg) containing the title compound (247) and (S)-N1,N1,N5,N5-
tetrabenzyl-6-fluorohexane-1,5-diamine (252) as a 85/15 mixture. Re-crystallisation 
from Et2O/hexane gave (247) as a colourless crystalline solid (160 mg, 11%). 
Mp: 93-94 °C (from Et2O/hexane); [α]20D 0.0 (c 1.1, CHCl3); (Found: C, 82.15; 
H, 8.17; N, 5.69 %, C34H39N2F requires C, 82.55; H, 7.95; N, 5.66 %);νmax(KBr 
plate)/cm-1 3027, 2920, 2796, 1948, 1494, 1454, 1117, 1029, 972, 746, 668; δH (300 
MHz, CDCl3) 7.17-7.36 (20 H, m, Ar-H), 4.57 (1 H, d m, J=49.6 Hz, CHF), 3.63 (4 H, 
s, 2 × PhCH2N1), 3.51 (4 H, s, 2 × PhCH2N6), 2.45-2.76 (2 H, m, CHFCH2N1), 2.34 (2 
H, t, J=7.1 Hz, CH2N6), 1.10-1.54 (6 H, m, 3 × CH2); δC (75 MHz, CDCl3) 140.0 (2 × 
C, Ar), 139.5 (2 × C, Ar), 128.9 (4 × C, Ar), 128.8 (4 × C, Ar), 128.3 (4 × C, Ar), 128.2 
(4 × C, Ar), 127.0 (2 × C, Ar), 126.8 (2 × C, Ar), 93.4 (d, J=169.2 Hz, CHF), 59.1 (2 × 
PhCH2N1), 58.4 (2 × PhCH2N6),  57.0 (d, J=21.6 Hz, CH2N1), 53.1 (CH2N6), 33.0 (d, 
J=20.6 Hz, CHFCH2), 26.9 (CH2), 22.5 (d, J=4.6 Hz, CH2); δF (376 MHz, CDCl3)         
-181.2 (1 F, ddddd, J=49.6 Hz, J=28.9 Hz, J=17.4 Hz, J=19.3 Hz, J=26.7 Hz); m/z 
(+CI), found MH+: 495.3172 C34H40N2F requires 495.3176. (-0.7 ppm). 
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5.2.60 Methyl-6-(benzyloxycarbonylamino)-(2S)-(dibenzylamino)hexanoate 
(257) 
 
 
 
Anhydrous potassium carbonate (6.265 g, 45.3 mmol, 3 eq) and benzyl bromide 
(4.31 cm3, 36.2 mmol, 2.4 eq) were added to a solution of N(ε)-benzyloxycarbonyl-L-
lysine methyl ester hydrochloride (5 g, 15.1 mmol) in acetonitrile (40 cm3). The mixture 
was heated under reflux for 20 h and after cooling, the solids were filtered and washed 
with EtOAc. Solvents were removed under reduced pressure and the product was 
purified over silica gel (hexane/EtOAc 4:1) to yield compound (257) as a colourless oil 
(6.96 g, 97%). 
 
[α]20D -63.6 (c 2.8 CHCl3); νmax(film)/cm-1 3350, 3030, 2948, 1728, 1524, 1455, 
1246, 1140, 1028, 748, 699; δH (300 MHz, CDCl3) 7.19-7.36 (15 H, m, Ar-H), 5.08 
(2 H, s, PhCH2O), 4.65 (1 H, br s, NH), 3.90 (2 H, d, J=13.8 Hz, PhCHAHBN), 3.75 
(3 H, s, OCH3), 3.50 (2 H, d, J=13.8 Hz, PhCHAHBN), 3.29 (1 H, dd, J=6.5 Hz, 
J=8.4 Hz, CHN), 3.10 (2 H, dd, J=6.5 Hz, J=12.7 Hz, CH2N’), 1.64-1.78 (2 H, m, CH2), 
1.37-1.46 (1 H, m, CHAHB), 1.19-1.32 (3 H, m, CH2 + CHAHB); δC (75 MHz, CDCl3) 
173.8 (CO2), 156.7 (CON), 140.0 (2 × C, Ar), 137.1 (Ar), 129.3 (4 × C, Ar), 128.9 (2 × 
C, Ar), 128.7 (4 × C, v), 128.5 (3 × C, Ar), 127.4 (2 × C, Ar), 67.0 (PhCH2O), 60.7 
(CHN), 54.9 (2 × PhCH2N), 51.5 (OCH3), 41.2 (CH2N’), 29.7 (CH2), 29.5 (CH2), 23.5 
(CH2); m/z (+CI), found MH+: 475.2585, C29H35N2O4 requires 475.2597 (-2.5 ppm). 
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5.2.61 6-(Benzyloxycarbonylamino)-(2S)-(dibenzylamino)hexan-1-ol (258) 
 
 
 
 
A solution of (257) (2.15 g, 4.5 mmol) in dry THF (10 cm3) was added dropwise 
at -10 °C to a suspension of LiAlH4 (0.344 g, 9.1 mmol, 2 eq) in dry THF (30 cm3). The 
reaction mixture was stirred for 50 min at -10 °C until TLC analysis indicated 
completion. The reaction was then quenched by careful addition of water and stirred for 
1 h. The mixture was acidified with 1 N HCl till pH 7 and extracted into EtOAc. The 
combined organic extracts were dried and the solvents were evaporated under reduced 
pressure. The resultant oil was purified over silica gel (hexane/EtOAc 2:1) to yield the 
amino alcohol (258) as a viscous colourless oil (1.90 g, 94%). 
 
[α]20D +62.2 (c 3, CHCl3); νmax(film)/cm-1 3421, 3335, 3029, 2860, 1702, 1534, 
1455, 1252, 1132, 1028, 749, 699; δH (300 MHz, CDCl3) 7.19-7.36 (15 H, m, Ar-H), 
5.10 (2 H, s, PhCH2O), 4.84 (1 H, br s, NH), 3.79 (2 H, d, J=13.3 Hz, 2 × PhCHAHBN), 
3.38-3.50 (2 H, m, CH2OH), 3.40 (2 H, d, J=13.3 Hz, 2 × PhCHAHBN), 3.15-3.21 (3 H, 
m, CH2N’ and OH), 2.71-2.79 (1 H, m, CHN), 1.66-1.77 (1 H, m, CHAHB), 1.40-1.54 
(2 H, m, CH2), 1.14-1.34 (3 H, m, CH2 and C’HAHB); δC (75 MHz, CDCl3) 156.5 
(CO2N), 139.3 (2 × C, Ar), 136.6 (Ar), 129.0 (4 × C, Ar), 128.6 (2 × C, Ar), 128.5 (4 × 
C, Ar), 128.2 (3 × C, Ar), 127.3 (2 × C, Ar), 66.7 (PhCH2O), 60.9 (CH2OH), 58.9 
(CHN), 53.2 (2 × PhCH2N), 40.8 (CH2N’), 30.3 (CH2), 24.8 (CH2), 24.2 (CH2); m/z 
(+CI), found MH+: 447.2652, C28H35N2O3 requires 447.2648 (+1.0 ppm). 
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5.2.62 Benzyl 6-(dibenzylamino)-(5R)-fluorohexylcarbamate (259) 
 
 
 
 
Deoxofluor 50% in THF (3.02 g, 6.8 mmol, 1.2 eq) was added dropwise at          
-10 °C to a solution of (258) (2.54 g, 5.7 mmol) in dry DCM (40 cm3). The mixture was 
stirred for 6 h, slowly warming from -10 °C to 0 °C and the reaction was quenched by 
addition of 10% K2CO3 (10 cm3). The product was extracted into EtOAc and the 
combined organic extracts were evaporated under reduced pressure. The residue was 
purified over silica gel (hexane/EtOAc 5:1) to yield (259) and (260) as a 90/10 mixture 
(1.7 g, 67%) as a colourless oil. Re-crystallisation from Et2O/hexane gave an analytical 
sample of (259) as a colourless crystalline solid. 
Rf: 0.20 Hexane/EtOAc (5:1); mp: 60-62 °C (from Et2O/hexane); [α]20D +3.2 (c 
3.5, CHCl3); (Found: C, 74.75; H, 7.42; N, 6.43 %, C28H33N2O2F requires C, 74.97; H, 
7.42; N, 6.25 %); νmax(KBr plate)/cm-1 3361, 2933, 1685, 1539, 1453, 1370, 1266, 
1144, 1022, 748, 701; δH (300 MHz, CDCl3) 7.19-7.37 (15 H, m, Ar-H), 5.08 (2 H, s, 
PhCH2O), 4.72 (1 H, br s, NH), 4.59 (1 H, d m, J=49.6 Hz, CHF), 3.63 (4 H, s, 2 × 
PhCH2N) 3.12 (2 H, dd, J=6.7 Hz, J=13.1 Hz, CH2N’), 2.50-2.73 (2 H, m, CHFCH2N), 
1.13-1.60 (6 H, m, 3 × CH2); δC (75 MHz, CDCl3) 156.8 (CO2N), 139.8 (2 × C, Ar), 
137.0 (Ar), 129.3 (4 × C, Ar), 129.0 (2 × C, Ar), 128.7 (4 × C, Ar), 128.5 (3 × C, Ar), 
127.4 (2 × C, Ar), 93.6 (d, J=169.3 Hz, CHF), 67.0 (PhCH2O), 59.6 (2 × PhCH2N), 57.2 
(d, J=21.9 Hz, CHFCH2N), 41.3 (CH2N’), 33.1 (d, J=20.7 Hz, CH2CF), 30.1 (CH2), 
22.5 (d, J=4.3 Hz, CH2); δF (282 MHz, CDCl3) -182.1 (1 F, m);  m/z (+CI), found MH+: 
449.2621, C28H34N2O2F requires 449.2604 (+3.6 ppm). 
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5.2.63 (2R)-Fluorohexane-1,6-diamine dihydrochloride (248) 
 
 
 
Pd(OH)2/C (20% dry weight) (350 mg) was added to a solution of the 90/10 
mixture of (259) and (260) (1.45 g, 3.2 mmol) in methanol (60 cm3) (see 5.2.62). The 
mixture was stirred in an autoclave at RT for 2 days under a pressure of H2 (20 bars).  
The reaction mixture was then filtered over Celite, 1 M HCl in diethyl ether (8 cm3) was 
added and the product was re-crystallised 3 times from methanol/ethanol/diethyl ether 
till 19F-NMR spectroscopy indicated only one peak. (2R)-Fluorohexane-1,6-diamine 
dihydrochloride (248) was obtained as a colourless amorphous solid (490 mg, 73%). 
 
Mp: 235-237 °C (from MeOH/Et2O); [α]16D 0.0 (c 4, MeOH); νmax(KBr 
plate)/cm-1 2996 (br), 2058, 1603, 1485, 1474, 1230, 1152, 1108, 1040, 970, 931, 782; 
δH (300 MHz, CD3OD) 4.89 (6 H, s, 6 × NH), 4.71-4.96 (1 H, m, CHF), 3.13-3.34 (2 H, 
m, CHFCH2N), 2.95-3.00 (2 H, m, CH2N’), 1.67-1.85 (4 H, m, 2 × CH2), 1.50-1.70 
(2 H, m, CH2); δC (75 MHz, CD3OD) 91.7 (d, J=170.6 Hz, CHF), 44.3 (d, J=20.9 Hz, 
CHFCH2N), 40.5 (CH2N’), 32.8 (d, J=19.9 Hz, CH2), 28.2 (CH2), 22.84 (d, J=4.1 Hz, 
CH2); δF (282 MHz, CD3OD) -190.9 (1 F, m); m/z (+CI), found (M-HCl2-): 135.1298, 
C6H16N2F requires 135.1298 (+0.4 ppm). 
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5.2.64 N,N-((2R)-Fluorohexane-1,6-diyl)bis((2S)-methoxy-2-trifluoromethyl-
phenylacetamide)  (265) 
 
 
 
 Et3N (27 µL, 4 eq), 4-DMAP (5 mg), DCC (40 mg, 4 eq) and (S)-(-)-α-
methoxy-α-(trifluoromethyl)-phenylacetic acid (37 mg, 3 eq) were added at RT to a 
suspension of (2R)-fluorohexane-1,6-diamine dihydrochloride (248) (10 mg, 4.8 10-2 
mmol) in DCM (1 cm3). The reaction mixture was stirred for 12 h and the solvent was 
removed under reduced pressure. The residue was dissolved in CDCl3 and filtered 
through a glass cotton plug directly into a NMR tub.  
δF {1H} (375 MHz, CDCl3) -68.8 (3 F, s, CF3 Mosher amide), -68.9 (3 F, s, CF3 
Mosher amide), -70.5 (s, CF3 Mosher acid in excess), -186.2 (1 F, s, CHF); m/z (+CI), 
found (MH+): 567.2093, C26H30F7N2O4 requires 567.2094 (-0.1 ppm). 
  
 
5.2.65 N,N-((2R)-Fluorohexane-1,6-diyl)bis((2R)-methoxy-2-trifluoromethyl-
phenylacetamide)  (266) 
 
 
 (266) was prepared in an identical manner to that described above (5.2.64) 
using (R)-(+)-α-methoxy-α-(trifluoromethyl) phenylacetic acid. 
δF {1H} (375 MHz, CDCl3) -68.9 (6 F, s, 2 × CF3 Mosher amide), -70.5 (s, CF3 
Mosher acid in excess), -186.1 (1 F, s, CHF). 
Chapter 5 
_______________________________ 
 
 257 
N
N
O
O
 
5.2.66 (2R)-((dibenzylamino)methyl)piperidine-1-benzoxycarbonate (261) 
 
 
 
 
 
Silica gel (40-63 micron) was added to a solution of (258) (200 mg, 0.45 mmol) 
in dry DCM (10 cm3). The mixture was then cooled to -78 °C and Deoxofluor 50% in 
THF (0.25 cm3, 0.7 mmol, 1.5 eq) was added. The mixture was stirred for 6 h at -78 °C 
and allowed to warm to 0 °C. The reaction was then quenched by the addition of 10% 
K2CO3 (2 cm3). The product was extracted into DCM and the combined organic extracts 
were evaporated under reduced pressure. The residue was purified over silica gel 
(hexane/EtOAc 5:1) to yield (261) as a colourless oil (96 mg, 50%).  
 
Rf: 0.40 Hexane/EtOAc (5:1); [α]20D +93.9 (c 3, CHCl3); νmax(film)/cm-1 3029, 
2936, 2797, 1696, 1495, 1425, 1354, 1256, 1150, 1069, 748, 699; δH (300 MHz, 
CDCl3) 7.20-7.33 (15 H, m, Ar-H), 4.99-5.21 (2 H, m, PhCH2O), 4.48 (1 H, br d, 
J=42.7 Hz, CHN’), 3.89 (1 H, br s, CHAHBN’), 3.54 (4 H, br s, 2 × PhCH2N), 2.44-2.56 
(2 H, m, CH2N), 2.35 (1 H, dt, J=3.0 Hz, J=13.1 Hz, CHAHBN’), 1.77 (1 H, d, 
J=11.1 Hz, CHAHB), 1.24-1.53 (4 H, m, 2 × CH2), 0.85-0.99 (1 H, m, C’HAHB); 
δC (75 MHz, CDCl3) 155.6 (CO2N), 139.6 (2 × C, Ar), 137.0 (Ar), 129.0 (4 × C, Ar), 
128.5 (2 × C, Ar), 128.2 (6 × C, Ar), 127.9 (Ar), 126.9 (2 × C, Ar), 67.0 (PhCH2O), 58.7 
(2 × PhCH2N), 52.2 (CH2N), 48.2 (CHN’), 39.6 (CH2N’), 26.0 (CH2), 25.3 (CH2), 18.7 
(CH2); m/z (+EI), found MH+: 429.2534, C28H33N2O2 requires 429.2542 (-1.8 ppm). 
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5.2.67 Piperidine-(2R)-methylamine dihydrochloride (267) 
 
 
 
 
Pd(OH)2/C (20% dry weight) (150 mg) was added to a solution of benzyl-(2R)-
((dibenzylamino)methyl)piperidine-1-carboxylate (261) (500 mg, 1.2 mmol) in 
methanol (30 cm3). The mixture was stirred for 2 days in an autoclave at room 
temperature under H2 (20 bars). The black suspension was then filtered over Celite and 
1 M HCl in Et2O (4 cm3) was added to the filtrate. Solvents were removed under 
reduced pressure and the crude product was re-crystallised from methanol/diethyl ether 
to yield piperidine-(2R)-methylamine dihydrochloride (267) (164 mg, 75%) as a 
colourless crystalline solid. 
 
Mp: 213-215 °C (from MeOH/Et2O), lit31 240-242 °C (from MeOH/Et2O, (S)-
enantiomer); [α]20D +2.3 (c 1.4, MeOH), lit31 [α]20D -5.7 (c 0.42, MeOH, (S)-
enantiomer); (Found: C, 38.86; H, 8.31; N, 14.66 %, C6H16N2Cl2 requires C, 38.51; H, 
8.62; N, 14.97 %); νmax(KBr plate)/cm-1 3416, 2955 (br), 2842 (br), 1584, 1514, 1484, 
1476, 1440, 1407, 1133, 1022, 1008; δH (300 MHz, CD3OD) 4.77 (5 H, s, 5 × NH), 
3.38-3.48 (1 H, m, CHN), 3.34-3.42 (1 H, m, CHAHBN), 3.28 (1 H, dd, J=5.8 Hz, 
J=13.6 Hz, CHAHBN’), 3.14 (1 H, dd, J=6.5 Hz, J=13.6 Hz, CHAHBN’), 3.00 (1 H, dt, 
J=3.3 Hz, J=12.5 Hz, CHAHBN), 1.46-2.04 (6 H, m, 3 × CH2); δC (75 MHz, CD3OD); 
55.8 (CHN), 46.5 (CH2N), 42.9 (CH2N’), 27.8 (CH2), 23.3 (CH2), 23.0 (CH2); 
m/z (+CI), found (M-HCl2-): 115.1236, C6H15N2 requires 115.1235 (+0.4 ppm). 
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5.4 Crystallographic data 
 
5.4.1 (3α,5α)-17-Phenylandrost-16-en-3-ol (87) 
 
 
 
 
 
 
Table 1. Crystal data and structure refinement for gddh2. 
Identification code  gddh2 
Empirical formula  C25 H34 O 
Formula weight  350.52 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 14.011(3) Å α= 90°. 
 b = 6.6880(9) Å β= 97.499(5)°. 
 c = 21.436(4) Å γ = 90°. 
Volume 1991.5(6) Å3 
Z 4 
Density (calculated) 1.169 Mg/m3 
Absorption coefficient 0.069 mm-1 
F(000) 768 
Crystal size 0.2000 x 0.1000 x 0.0200 mm3 
Theta range for data collection 1.85 to 25.34°. 
Index ranges -16<=h<=15, -6<=k<=7, -25<=l<=19 
Reflections collected 12835 
Independent reflections 6604 [R(int) = 0.0512] 
Completeness to theta = 25.34° 98.7 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.2034 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6604 / 3 / 479 
Goodness-of-fit on F2 0.966 
Final R indices [I>2sigma(I)] R1 = 0.0645, wR2 = 0.1495 
R indices (all data) R1 = 0.0921, wR2 = 0.1694 
Absolute structure parameter 1(2) 
Extinction coefficient 0.012(2) 
Largest diff. peak and hole 0.280 and -0.267 e.Å-3 
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5.4.2 2β-(4-Morpholinyl)-(3α,5α,17β)-17-(p-methoxyphenyl)androstane-3,17-
diol (121) 
 
 
 
 
 
Table 1. Crystal data and structure refinement for gddh3. 
Identification code  gddh3 
Empirical formula  C30 H43 N O3 
Formula weight  465.65 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 6.2862(5) Å α= 90°. 
 b = 12.3500(9) Å β= 90°. 
 c = 32.739(2) Å γ = 90°. 
Volume 2541.7(3) Å3 
Z 4 
Density (calculated) 1.217 Mg/m3 
Absorption coefficient 0.077 mm-1 
F(000) 1016 
Crystal size 0.150 x 0.030 x 0.010 mm3 
Theta range for data collection 2.07 to 25.34°. 
Index ranges -7<=h<=6, -14<=k<=8, -39<=l<=39 
Reflections collected 18475 
Independent reflections 4392 [R(int) = 0.0281] 
Completeness to theta = 25.34° 95.5 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.9310 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4392 / 1 / 314 
Goodness-of-fit on F2 1.112 
Final R indices [I>2sigma(I)] R1 = 0.0356, wR2 = 0.0773 
R indices (all data) R1 = 0.0396, wR2 = 0.0794 
Absolute structure parameter 0.8(11) 
Extinction coefficient 0.0022(13) 
Largest diff. peak and hole 0.173 and -0.155 e.Å-3 
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5.4.3 (2R)-Fluoro-3-phenylpropan-1-amine hydrochloride (190) 
 
 
 
 
Table 1. Crystal data and structure refinement for gddh6. 
Identification code  gddh6 
Empirical formula  C9 H13 Cl F N 
Formula weight  189.65 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 4.522(6) Å α= 90°. 
 b = 5.804(6) Å β= 90°. 
 c = 37.62(2) Å γ = 90°. 
Volume 987.3(18) Å3 
Z 4 
Density (calculated) 1.276 Mg/m3 
Absorption coefficient 3.131 mm-1 
F(000) 400 
Crystal size 0.1500 x 0.1000 x 0.0300 mm3 
Theta range for data collection 4.70 to 68.08°. 
Index ranges -5<=h<=5, -6<=k<=6, -44<=l<=45 
Reflections collected 10441 
Independent reflections 1699 [R(int) = 0.0525] 
Completeness to theta = 68.08° 96.2 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.5730 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1699 / 3 / 122 
Goodness-of-fit on F2 1.097 
Final R indices [I>2sigma(I)] R1 = 0.0333, wR2 = 0.0917 
R indices (all data) R1 = 0.0401, wR2 = 0.1098 
Absolute structure parameter 0.04(2) 
Largest diff. peak and hole 0.255 and -0.409 e.Å-3 
 
 
Table 2. Torsion angles [°] for gddh6. 
________________________________ 
C(6)-C(1)-C(2)-C(3) 0.6(4) 
C(7)-C(1)-C(2)-C(3) -178.1(3) 
C(1)-C(2)-C(3)-C(4) -0.3(4) 
C(2)-C(3)-C(4)-C(5) -0.1(4) 
C(3)-C(4)-C(5)-C(6) 0.2(4) 
C(4)-C(5)-C(6)-C(1) 0.1(4) 
C(2)-C(1)-C(6)-C(5) -0.5(4) 
C(7)-C(1)-C(6)-C(5) 178.2(2) 
C(2)-C(1)-C(7)-C(8) 76.2(3) 
C(6)-C(1)-C(7)-C(8) -102.4(3) 
C(1)-C(7)-C(8)-F(8) 62.0(3) 
C(1)-C(7)-C(8)-C(9) -178.3(2) 
F(8)-C(8)-C(9)-N(9) -62.9(2) 
C(7)-C(8)-C(9)-N(9) 176.4(2) 
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5.4.4 tert-Butyl-(2R)-fluoro-3-phenylpropylcarbamate (191) 
 
 
 
 
Table 1. Crystal data and structure refinement for gddh5. 
Identification code  gddh5 
Empirical formula  C14 H20 F N O2 
Formula weight  253.31 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 5.2329(8) Å α= 90°. 
 b = 8.9769(14) Å β= 90.272(4)°. 
 c = 14.679(2) Å γ = 90°. 
Volume 689.53(18) Å3 
Z 2 
Density (calculated) 1.220 Mg/m3 
Absorption coefficient 0.740 mm-1 
F(000) 272 
Crystal size 0.200 x 0.200 x 0.200 mm3 
Theta range for data collection 3.01 to 44.82°. 
Index ranges -4<=h<=4, -8<=k<=8, -13<=l<=13 
Reflections collected 3099 
Independent reflections 1010 [R(int) = 0.0318] 
Completeness to theta = 25.00° 66.2 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.4133 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1010 / 2 / 169 
Goodness-of-fit on F2 1.091 
Final R indices [I>2sigma(I)] R1 = 0.0262, wR2 = 0.0651 
R indices (all data) R1 = 0.0262, wR2 = 0.0651 
Absolute structure parameter -0.03(17) 
Extinction coefficient 0.053(9) 
Largest diff. peak and hole 0.080 and -0.078 e.Å-3 
 
Table 2. Torsion angles [°] for gddh5. 
_______________________________ 
C(6)-C(1)-C(2)-C(3) 0.6(4) 
C(7)-C(1)-C(2)-C(3) -177.35(19) 
C(1)-C(2)-C(3)-C(4) 0.0(4) 
C(2)-C(3)-C(4)-C(5) -1.2(4) 
C(3)-C(4)-C(5)-C(6) 1.8(4) 
C(2)-C(1)-C(6)-C(5) 0.1(3) 
C(7)-C(1)-C(6)-C(5) 177.9(2) 
C(4)-C(5)-C(6)-C(1) -1.3(4) 
C(6)-C(1)-C(7)-C(8) -99.4(2) 
C(2)-C(1)-C(7)-C(8) 78.4(3) 
C(1)-C(7)-C(8)-F(8) 61.2(2) 
C(1)-C(7)-C(8)-C(9) -178.92(17) 
F(8)-C(8)-C(9)-N(9) -66.8(2) 
C(7)-C(8)-C(9)-N(9) 173.53(18) 
C(8)-C(9)-N(9)-C(10) -130.9(2) 
C(9)-N(9)-C(10)-O(10) 1.0(3) 
C(9)-N(9)-C(10)-O(11) 179.92(17) 
O(10)-C(10)-O(11)-C(11) -1.9(3) 
N(9)-C(10)-O(11)-C(11) 179.20(16) 
C(10)-O(11)-C(11)-C(14) -177.97(16) 
C(10)-O(11)-C(11)-C(12) 64.8(2) 
C(10)-O(11)-C(11)-C(13) -60.0(2) 
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5.4.5 tert-Butyl-(2S)-fluoro-3-phenylpropylcarbamate (192) 
 
 
 
Table 1. Crystal data and structure refinement for gddh4. 
Identification code  gddh4 
Empirical formula  C14 H20 F N O2 
Formula weight  253.31 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 5.2346(9) Å α= 90°. 
 b = 8.9661(15) Å β= 90.445(5)°. 
 c = 14.681(3) Å γ = 90°. 
Volume 689.0(2) Å3 
Z 2 
Density (calculated) 1.221 Mg/m3 
Absorption coefficient 0.740 mm-1 
F(000) 272 
Crystal size 0.300 x 0.300 x 0.030 mm3 
Theta range for data collection 8.47 to 44.70°. 
Index ranges -4<=h<=4, -8<=k<=8, -13<=l<=13 
Reflections collected 3190 
Independent reflections 1041 [R(int) = 0.0464] 
Completeness to theta = 25.00° 84.8 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.2371 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1041 / 2 / 169 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0337, wR2 = 0.0821 
R indices (all data) R1 = 0.0338, wR2 = 0.0822 
Absolute structure parameter 0.0(2) 
Extinction coefficient 0.029(5) 
Largest diff. peak and hole 0.108 and -0.121 e.Å-3 
 
Table 2. Torsion angles [°] for gddh4. 
_______________________________ 
C(6)-C(1)-C(2)-C(3) -0.7(4) 
C(7)-C(1)-C(2)-C(3) 177.5(2) 
C(1)-C(2)-C(3)-C(4) 0.3(5) 
C(2)-C(3)-C(4)-C(5) 0.7(5) 
C(3)-C(4)-C(5)-C(6) -1.1(5) 
C(4)-C(5)-C(6)-C(1) 0.7(5) 
C(2)-C(1)-C(6)-C(5) 0.3(4) 
C(7)-C(1)-C(6)-C(5) -178.0(2) 
C(6)-C(1)-C(7)-C(8) 99.8(3) 
C(2)-C(1)-C(7)-C(8) -78.4(3) 
C(1)-C(7)-C(8)-F(8) -61.0(3) 
C(1)-C(7)-C(8)-C(9) 178.9(2) 
F(8)-C(8)-C(9)-N(9) 66.4(3) 
C(7)-C(8)-C(9)-N(9) -173.9(2) 
C(8)-C(9)-N(9)-C(10) 131.4(3) 
C(9)-N(9)-C(10)-O(10) -1.5(4) 
C(9)-N(9)-C(10)-O(11) -179.8(2) 
O(10)-C(10)-O(11)-C(11) 2.2(4) 
N(9)-C(10)-O(11)-C(11) -179.5(2) 
C(10)-O(11)-C(11)-C(12) -65.0(3) 
C(10)-O(11)-C(11)-C(13) 60.0(3) 
C(10)-O(11)-C(11)-C(14) 177.8(2) 
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5.4.6 (3R)-Fluoro-4-aminobutyric acid hydrochloride (123) 
 
 
 
 
Table 1. Crystal data and structure refinement for gddh8. 
Identification code  gddh8 
Empirical formula  C4 H9 Cl F N O2 
Formula weight  157.57 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 5.3327(5) Å α= 90°. 
 b = 10.1855(10) Å β= 90°. 
 c = 13.0250(13) Å γ = 90°. 
Volume 707.47(12) Å3 
Z 4 
Density (calculated) 1.479 Mg/m3 
Absorption coefficient 4.458 mm-1 
F(000) 328 
Crystal size 0.100 x 0.100 x 0.020 mm3 
Theta range for data collection 6.80 to 44.70°. 
Index ranges -4<=h<=4, -9<=k<=9, -11<=l<=11 
Reflections collected 3269 
Independent reflections 533 [R(int) = 0.0369] 
Completeness to theta = 25.00° 82.8 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.1973 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 533 / 4 / 100 
Goodness-of-fit on F2 1.072 
Final R indices [I>2sigma(I)] R1 = 0.0189, wR2 = 0.0480 
R indices (all data) R1 = 0.0189, wR2 = 0.0480 
Absolute structure parameter 0.009(17) 
Extinction coefficient 0.0121(16) 
Largest diff. peak and hole 0.085 and -0.091 e.Å-3 
 
Table 2. Torsion angles [°] for gddh8. 
_______________________________ 
O(1)-C(1)-C(2)-C(3) 174.3(2) 
O(2)-C(1)-C(2)-C(3) -5.7(3) 
C(1)-C(2)-C(3)-F(3) 172.4(2) 
C(1)-C(2)-C(3)-C(4) -70.3(3) 
F(3)-C(3)-C(4)-N(5) -56.0(3) 
C(2)-C(3)-C(4)-N(5) -173.8(2) 
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5.4.7 (3S)-Fluoro-4-aminobutyric acid hydrochloride (124) 
 
 
 
 
Table 1. Crystal data and structure refinement for gddh15. 
Identification code  gddh15 
Empirical formula  C4 H9 Cl F N O2 
Formula weight  157.57 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 5.4219(6) Å α= 90°. 
 b = 8.5384(10) Å β= 90°. 
 c = 15.4796(19) Å γ = 90°. 
Volume 716.62(15) Å3 
Z 4 
Density (calculated) 1.460 Mg/m3 
Absorption coefficient 0.483 mm-1 
F(000) 328 
Crystal size 0.200 x 0.030 x 0.030 mm3 
Theta range for data collection 3.98 to 25.35°. 
Index ranges -6<=h<=6, -10<=k<=10, -18<=l<=18 
Reflections collected 6233 
Independent reflections 1252 [R(int) = 0.0395] 
Completeness to theta = 25.00° 95.7 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.5768 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1252 / 4 / 99 
Goodness-of-fit on F2 1.048 
Final R indices [I>2sigma(I)] R1 = 0.0198, wR2 = 0.0469 
R indices (all data) R1 = 0.0206, wR2 = 0.0473 
Absolute structure parameter 0.07(6) 
Largest diff. peak and hole 0.157 and -0.157 e.Å-3 
 
 
Table 2. Torsion angles [°] for gddh15. 
________________________________ 
O(1)-C(1)-C(2)-C(3) 142.93(14) 
O(2)-C(1)-C(2)-C(3) -37.65(18) 
C(1)-C(2)-C(3)-F(3) -52.84(16) 
C(1)-C(2)-C(3)-C(4) -170.51(13) 
F(3)-C(3)-C(4)-N(5) 64.81(14) 
C(2)-C(3)-C(4)-N(5) -176.80(12) 
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5.4.8 N1,N1,N6,N6-Tetrabenzyl-(2R)-fluorohexane-1,6-diamine (247) 
 
 
 
 
 
 
Table 1. Crystal data and structure refinement for GDDH12. 
Identification code  gddh12 
Empirical formula  C34 H39 F N2 
Formula weight  494.67 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.6765(11) Å α= 104.607(11)°. 
 b = 9.5940(18) Å β= 90.735(12)°. 
 c = 13.544(2) Å γ = 90.574(13)°. 
Volume 713.6(2) Å3 
Z 1 
Density (calculated) 1.151 Mg/m3 
Absorption coefficient 0.071 mm-1 
F(000) 266 
Crystal size 0.200 x 0.050 x 0.020 mm3 
Theta range for data collection 2.99 to 25.34°. 
Index ranges -6<=h<=6, -11<=k<=11, -16<=l<=13 
Reflections collected 6233 
Independent reflections 2446 [R(int) = 0.0704] 
Completeness to theta = 25.00° 94.8 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.1867 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2446 / 0 / 174 
Goodness-of-fit on F2 2.060 
Final R indices [I>2sigma(I)] R1 = 0.1580, wR2 = 0.4444 
R indices (all data) R1 = 0.1674, wR2 = 0.4495 
Extinction coefficient 0.8(2) 
Largest diff. peak and hole 1.450 and -0.473 e.Å-3 
 
 
Chapter 5 
_______________________________ 
 
 269 
 
5.4.9 Benzyl 6-(dibenzylamino)-(5R)-fluorohexylcarbamate (259) 
 
 
 
 
 
 
Table 1. Crystal data and structure refinement for gddh13. 
Identification code  gddh13 
Empirical formula  C28 H33 F N2 O2 
Formula weight  448.56 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 12.536(4) Å α= 90°. 
 b = 5.0626(13) Å β= 101.254(17)°. 
 c = 19.426(6) Å γ = 90°. 
Volume 1209.2(6) Å3 
Z 2 
Density (calculated) 1.232 Mg/m3 
Absorption coefficient 0.082 mm-1 
F(000) 480 
Crystal size 0.1000 x 0.0300 x 0.0300 mm3 
Theta range for data collection 1.07 to 25.36°. 
Index ranges -15<=h<=12, -6<=k<=5, -21<=l<=23 
Reflections collected 6860 
Independent reflections 3755 [R(int) = 0.0465] 
Completeness to theta = 25.00° 97.1 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.5079 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3755 / 2 / 304 
Goodness-of-fit on F2 1.048 
Final R indices [I>2sigma(I)] R1 = 0.0661, wR2 = 0.1319 
R indices (all data) R1 = 0.1147, wR2 = 0.1626 
Absolute structure parameter 1.3(19) 
Extinction coefficient 0.018(3) 
Largest diff. peak and hole 0.244 and -0.262 e.Å-3 
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5.4.10 (2R)-Fluorohexane-1,6-diamine dihydrochloride (248) 
 
 
 
 
 
Table 1. Crystal data and structure refinement for GDDH14. 
Identification code  gddh14 
Empirical formula  C6 H17 Cl2 F N2 
Formula weight  207.12 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 9.0111(12) Å α= 90°. 
 b = 5.7519(7) Å β= 108.070(6)°. 
 c = 10.1529(13) Å γ = 90°. 
Volume 500.28(11) Å3 
Z 2 
Density (calculated) 1.375 Mg/m3 
Absorption coefficient 0.610 mm-1 
F(000) 220 
Crystal size 0.100 x 0.100 x 0.030 mm3 
Theta range for data collection 2.64 to 25.34°. 
Index ranges -10<=h<=10, -6<=k<=5, -12<=l<=12 
Reflections collected 4502 
Independent reflections 1487 [R(int) = 0.0503] 
Completeness to theta = 25.00° 96.1 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.3506 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1487 / 7 / 119 
Goodness-of-fit on F2 1.062 
Final R indices [I>2sigma(I)] R1 = 0.0472, wR2 = 0.1288 
R indices (all data) R1 = 0.0475, wR2 = 0.1293 
Absolute structure parameter 0.01(14) 
Largest diff. peak and hole 0.805 and -0.439 e.Å-3 
 
Table 2. Torsion angles [°] for GDDH14. 
__________________________________ 
N(1)-C(1)-C(2)-F(2) -62.7(4) 
N(1)-C(1)-C(2)-C(3) 176.0(3) 
F(2)-C(2)-C(3)-C(4) 165.0(2) 
C(1)-C(2)-C(3)-C(4) -75.0(4) 
C(2)-C(3)-C(4)-C(5) -177.1(3) 
C(3)-C(4)-C(5)-C(6) 70.5(5) 
C(4)-C(5)-C(6)-N(7) -169.9(4) 
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5.4.11 Piperidine-(2R)-methylamine dihydrochloride (267) 
 
 
 
 
 
Table 1. Crystal data and structure refinement for gddh11. 
Identification code  gddh11 
Empirical formula  C6 H16 Cl2 N2 
Formula weight  187.11 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 7.036(2) Å α= 90°. 
 b = 9.112(2) Å β= 106.010(7)°. 
 c = 7.702(2) Å γ = 90°. 
Volume 474.6(2) Å3 
Z 2 
Density (calculated) 1.309 Mg/m3 
Absorption coefficient 0.621 mm-1 
F(000) 200 
Crystal size 0.1000 x 0.1000 x 0.0200 mm3 
Theta range for data collection 2.75 to 25.35°. 
Index ranges -8<=h<=8, -10<=k<=10, -9<=l<=6 
Reflections collected 3060 
Independent reflections 1638 [R(int) = 0.0170] 
Completeness to theta = 25.00° 98.4 %  
Absorption correction Multiscan 
Max. and min. transmission 1.0000 and 0.8985 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1638 / 6 / 112 
Goodness-of-fit on F2 1.053 
Final R indices [I>2sigma(I)] R1 = 0.0194, wR2 = 0.0415 
R indices (all data) R1 = 0.0202, wR2 = 0.0418 
Absolute structure parameter 0.00(5) 
Largest diff. peak and hole 0.156 and -0.137 e.Å-3 
 
Table 2.  Torsion angles [°] for gddh11. 
________________________________ 
N(1)-C(1)-C(2)-N(3) 177.21(12) 
N(1)-C(1)-C(2)-C(7) 56.30(19) 
C(7)-C(2)-N(3)-C(4) -59.60(17) 
C(1)-C(2)-N(3)-C(4) 176.26(13) 
C(2)-N(3)-C(4)-C(5) 59.86(16) 
N(3)-C(4)-C(5)-C(6) -56.94(17) 
C(4)-C(5)-C(6)-C(7) 54.74(18) 
N(3)-C(2)-C(7)-C(6) 56.29(19) 
C(1)-C(2)-C(7)-C(6) 175.37(12) 
C(5)-C(6)-C(7)-C(2) -54.60(1
  
